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Abstract 
Non-alcoholic fatty liver disease (NAFLD) ranges from steatosis to the more 
progressive form non-alcoholic steatohepatitis. Genetic factors may be important risk 
determinants for disease progression. This study aimed to assess association of 
polymorphisms in candidate genes with NAFLD severity and to investigate functional 
significance of selected polymorphisms 
Two approaches were used for association studies, case-control analysis on adults 
(n=351) with biopsy-proven NAFLD and transmission disequilibrium on family trios 
(n=71) with an index child with NAFLD. A total of 37 polymorphisms in 14 candidate 
genes selected on the basis of either biological relevance or previous data suggesting a 
role in NAFLD were genotyped. Significant differences were seen for polymorphisms 
in 4 genes between stages of NAFLD or in transmission within families. For SOD2, 
which encodes manganese-dependent superoxide dismutase, the homozygous T 
genotype for rs4880 was more common in severe fibrosis (OR 2.23 (95% CI 1.19-4.17); 
p=0.01) and the T-allele was preferentially transmitted in the family trios (p=0.038). For 
the adiponutrin gene (PNPLA3), carriage of the variant G-allele (rs738409) was 
associated with severe steatosis (OR 1.87 (95% CI 1.15-3.04); p=0.01) and severe 
fibrosis (OR 2.02 (95% CI 1.29-3.1); p=0.002) in adults and preferentially transmitted 
in the family trios (p=0.001). For the claudin-10 gene (CLDN10), carriage of rs4143093 
was associated with severe steatosis (OR 2.82 (95% CI 1.5-5.3); p=0.0009). To further 
assess the relevance of claudin-10 to NAFLD, immunohistochemistry was performed. 
Expression in liver sections was confirmed. The effect of rs4143093 genotype on 
expression was investigated but insufficient samples were available to reach a firm 
conclusion. For the gamma-glutamyl cysteine ligase catalytic subunit gene (GCLC), 
rs17883901 was preferentially transmitted in the family trios (p= 0.046), but did not 
affect disease severity in adults. Studies on functional significance of this 
polymorphism showed that no significant difference in promoter activity between allelic 
variants.  
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Chapter 1 
Introduction
1 
 
1 Introduction 
1.1 NAFLD  
Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic 
syndrome, is the most common cause of chronic liver disease in western countries. It is 
estimated that 1 in 3 Western adults now have NAFLD [Day, 2010]. The term NAFLD 
encompasses a spectrum of liver diseases, ranging from the initiation stage steatosis to 
its more progressive form non-alcoholic steatohepatitis (NASH). NASH can then lead 
to advanced fibrosis, cirrhosis, liver failure and hepatocellular carcinoma (HCC) (Figure 
1.1) [Day, 2006c]. NASH, the progressive form of NAFLD was described more that 30 
years ago when Adler and colleague in 1979 studied 29 cases and found a resemblance 
between patients with fatty liver that were non-alcoholics to alcoholic steatohepatitis. 
The term NASH was then coined by Ludwig in 1980 [Adler and Schaffner, 
1979;Ludwig et al., 1980]. Because of the different diagnostic methods used for 
NAFLD the true population prevalence is unknown. However, prevalence of NAFLD 
and NASH are estimated to be 20-30% and 2-3% respectively in the general population 
[Matteoni et al., 1999;Bellentani et al., 2010;Moore, 2010]. In a meta-analysis study by 
Musso and colleagues, NAFLD was found associated with increased mortality 
compared with the general population. NASH also had a higher liver-related mortality 
compared to steatosis and increased with advance fibrosis [Musso et al., 2010]. The 
national health and nutritional examination survey (NHANES) conducted a study 
between 1988-2008 and results showed an increase in the prevalence of NAFLD 
compared to other chronic liver diseases which remained stable [Younossi et al., 2011]. 
NAFLD is now also considered to be the most common cause of liver disease in 
children due to the increase in childhood obesity. A study between 1974-2003 in the UK 
revealed an increase in prevalence of childhood obesity from 1.8% to 6% in boys and 
1.3% to 6.6% in girls aged 5-10 years [Stamatakis et al., 2005]. NAFLD is found in all 
ethnic groups, however studies have shown Hispanics to have the highest frequency 
compared to Caucasians and Africans (45%, 33%, and 24% respectively) [Browning et 
al., 2004].  
1.2  Diagnosis 
The lack of consistency in diagnostic tests to identify NAFLD and its different stages 
has been a major issue in the world of NAFLD. Liver biopsy is considered to be the 
golden method for diagnosis of NAFLD; however its invasiveness has lead to cases of  
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Figure 1.1: Diagram representing the stages of NAFLD and the factors affecting its progression. Adapted and 
modified from [Cohen et al., 2011] 
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morbidity and mortality [Cadranel et al., 2000;Gilmore et al., 1995]. Other methods 
such as proton magnetic resonance spectroscopy, ultrasound, MRI and computed 
tomography are non-invasive. However these non-invasive methods do have their 
advantages and disadvantages as reviewed by [Schwenzer et al., 2009]. Although 
methods are able to detect steatosis they lack the ability to differentiate between the 
different stages [Angulo, 2007]. Measurements of liver enzymes such as alanine 
transaminase (ALT) have been used quite often and high levels are a sign for further 
diagnostic tests, although sometimes relying on this can be misleading. A study by 
Browning and colleagues revealed that 79% of subjects with hepatic steatosis measured 
by proton magnetic resonance spectroscopy had normal levels of ALT [Browning et al., 
2004]. The combined biochemical and clinical parameters have been used for fibrosis 
prediction [Hossain et al., 2009;Neuschwander-Tetri et al., 2010;Lebovics and Rubin, 
2011]. Other non-invasive tests such as FibroTest and FibroScan have been used in 
NAFLD however this goes outside the scope of this thesis for review [Pais et al., 2009].  
1.3 Stages of NAFLD 
1.3.1 Steatosis  
Steatosis, the hallmark feature and initiation stage of NAFLD, is suggested to occur 
from the excess accumulation (more than 5%) of lipids, mainly triglycerides (TG), 
although other lipids such as cholesterol esters and sphingolipids also exist within 
hepatocytes [Bircher, 1999b] [Kleiner et al., 2005]. Increased fat in the hepatocytes may 
be divided into macrovesicular (large lipid droplets) and microvesicular (small lipid 
droplets) steatosis. Macrovesicular results from imbalance of hepatic TG synthesis 
whereas microvesicular is a result of mitochondrial dysfunction [Bacon and O'Grady, 
2006]. It is thought that fat initiates as small droplets (microvesicular) and eventually 
lead to large droplets (macrovesicular) [Bacon and O'Grady, 2006]. Excess 
accumulation of lipids is a sign of abnormal synthesis and disposal of TG (discussed 
1.7.1). Having steatosis is considered to be benign, however a follow-up clinical study 
on patients with fatty liver by Matteoni and colleagues showed that 4% develop 
cirrhosis and 2% liver related death [Matteoni et al., 1999]. A scoring system has been 
developed by Kleiner and colleagues that defines the stages (0-3) of steatosis. Presence 
of fat between 5-33% is noted as stage one, >33-66% as stage two and above 66% as 
stage three [Kleiner et al., 2005].  
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1.3.2 NASH   
NASH, the progressive form of NAFLD develops on the background of steatosis and 
features inflammation, ballooning, Mallory bodies, lobular necrosis, and pericellular 
and perivenular fibrosis which are changes that differentiate steatosis from NASH 
[Larter et al., 2010] [Sherlock and Dooley, 2002]. It is estimated that only a quarter of 
subjects progress from NAFLD to its more severe stages NASH/fibrosis, advanced 
fibrosis and cirrhosis [Wanless and Lentz, 1990;Dixon et al., 2001]. The progression 
from NASH/fibrosis to advanced fibrosis occurs over time in NASH patients which 
then leads to cirrhosis [Starley et al., 2010] [Angulo, 2007].  
1.3.3 Fibrosis and cirrhosis 
Fibrosis is described as increase in connective tissue in the liver with various patterns 
such as pericellular or perisinusoidal fibrosis and cirrhosis [Bircher, 1999b]. Fibrosis is 
a result of response to wound healing liver injury [Albanis and Friedman, 2001]. 
Excessive accumulation of extracellular matrix (ECM) proteins including collagen 
results in liver fibrosis [Bataller and Brenner, 2005]. The main ECM producing cells are 
hepatic satellite (HCS) [Gabele et al., 2003]. NASH, is a main cause of liver fibrosis 
[Brunt, 2004]. It is estimated that patients with NASH develop fibrosis in over 3.5-5 
years and about 20% will develop advanced fibrosis [Starley et al., 2010;Ong and 
Younossi, 2003;Argo and Caldwell, 2009]. Kleiner and colleagues further scored 
fibrosis into different stages (0-4), zero having no fibrosis and four, development of 
cirrhosis [Kleiner et al., 2005]. Cirrhosis, the result of ongoing fibrosis is the end stage 
of many chronic liver diseases [Bircher, 1999a;Bataller and Brenner, 2005]. Studies 
show that 5 to 20% of NASH patients develop liver cirrhosis [Matteoni et al., 
1999;Adams et al., 2005;Angulo, 2007].  
1.3.4 Hepatocellular carcinoma 
Hepatocellular carcinoma is the third most common cause of cancer death. The 
aetiology of 15-50% of HCC is unclear suggesting other risk factors such as NAFLD 
may be involved [Bugianesi, 2007]. A retrospective study suggested up to 27% of 
NASH cases may develop HCC [Ratziu et al., 2002;Siegel and Zhu, 2009] while other 
studies found that 40-62% of patients with NASH-related cirrhosis develop HCC after 
5-7 years [Hui et al., 2003;Adams et al., 2005]. Up to 70% of cryptogenic cirrhosis is 
caused by NASH and this is also known to lead to HCC [Angulo, 2007;Yoneda, 2010].  
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Identifying NAFLD at an early stage before it progresses to end stage liver disease may 
allow lifestyle modification to prevent further disease progression. Liver transplantation 
is suggested to be the only effective therapy for cirrhosis, including that linked to 
NASH, [Davis et al., 2003] and it has been projected that the leading cause of liver 
transplantation would be NASH in 2020 [Baumeister et al., 2008;Charlton, 2004]. 
1.4 Risk factors in NAFLD  
Obesity, type 2 diabetes and other components of the metabolic syndrome have all been 
found to be risk factors for the development of NAFLD and its progressive stages. 
1.4.1 NAFLD and the metabolic syndrome  
The metabolic syndrome, also known as syndrome X, is a cluster of risk factors that 
once accumulated increases the risk of developing stroke, coronary artery disease, type 
2 diabetes, kidney disease, and NAFLD. The exact definition of the metabolic syndrome 
has been a controversial topic and definitions vary internationally, as reviewed by 
[Eckel et al., 2005]. Central obesity, dyslipidaemia, hypertension, hyperinsulinaemia, 
impaired glucose tolerance and microalbuminuria have all been proposed as risk factors 
relevant to the metabolic syndrome [Eckel et al., 2005]. Whether obesity and diabetes is 
a component of the metabolic syndrome or a consequence is also a continuing 
controversy [Eckel et al., 2005] [Einhorn et al., 2003]. The prevalence of the metabolic 
syndrome increased 12-41% worldwide between 1988 to 2004  [Deepa et al., 2007]. 
Abdominal obesity, hypertension and hyperglycemia are the most common risk factors 
frequently found in individuals with metabolic syndrome [Ervin, 2009]. More than 90% 
of patients with NAFLD have at least one component of the metabolic syndrome 
[Marchesini et al., 2003]. NAFLD prevalence increased in patients from 27% in normal 
fasting blood glucose to 43% in impaired fasting blood glucose to 62% among patients 
with type 2 diabetes [Jimba et al., 2005].  
1.4.2 NAFLD and obesity 
Obesity is a major risk factor in the development of NAFLD. In obese individuals the 
prevalence of NAFLD is increased to 74% and up to 90% in morbidly obese [Angulo, 
2002b;Abrams et al., 2004]. It is estimated that 15-30% of morbidly obese individuals 
will develop NASH [Ratziu et al., 2000;Qureshi and Abrams, 2007]. Farrell and 
colleagues reviewed that central obesity is strongly associated with NASH and not 
overall obesity and that 20% of obese subjects develop NASH [Chitturi et al., 2002;Kral 
et al., 1993;Omagari et al., 2002;Thomas et al., 2005;Farrell and Larter, 2006]. 
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Improvement of NAFLD is seen in obese patients that have undergone bariatric surgery 
[Angulo, 2006].  
1.4.3 NAFLD and diabetes 
Like obesity, type 2 diabetes is a risk factor in the development of NAFLD. NAFLD is 
seen in over 70% in patients with Type 2 diabetes [Cusi, 2009;Targher et al., 2007;Leite 
et al., 2009]. In a study on 458 Italians with NAFLD, diabetes was found to be an 
independent predictor factor for severe fibrosis [Fracanzani et al., 2008]. Obesity is also 
a well documented risk factor for type 2 diabetes [Goran et al., 2003]. NAFLD 
correlates with both obesity and type 2 diabetes in over 70% of patients [Bjornsson and 
Angulo, 2007;Angulo, 2002a].  
This closely related presence of metabolic syndrome, diabetes and obesity with NAFLD 
suggests a shared pathogenesis in the development of these disorders. The combined 
effects of these risk factors increases the risk of developing NAFLD and its progressive 
forms and therefore avoiding these risk factors could help prevent the development of 
NAFLD and its progression. 
1.5 NAFLD in Children  
NAFLD is the leading cause of chronic liver disease in paediatric population as a result 
of the increase in prevalence of overweight and obesity in children in the past decades 
[Matthiessen et al., 2008;Ji, 2008]. It has been suggested by Schwimmer and colleagues 
that NAFLD in children could be represented in two different forms type 1 and type 2 
NASH [Schwimmer et al., 2005]. Type 1 NASH is characterised by steatosis, 
ballooning and perisinusoidal fibrosis which resembles the same pattern seen in adults 
where as type 2 NASH is characterised by steatosis, portal inflammation, and portal 
fibrosis without ballooning [Schwimmer et al., 2005;Nobili et al., 2006]. Whether the 
pattern of initiation of NAFLD in children is distinct or develops into the same pattern 
seen in adults remains unclear [Loomba et al., 2009].     
1.6 Treatments 
Weight reduction in association with exercise and balanced nutrition is the gold method 
treatment for patients with NAFLD. A steady and modest weight lost results in lower 
ALT levels, reduces steatosis and resolves steatohepatitis and reverses hepatic fibrosis 
[Kral et al., 2004;Hickman et al., 2004;Ueno et al., 1997;Dixon et al., 2004] whereas a 
dramatic weight reduction can result in hepatic fibrosis and liver failure [Chitturi et al., 
2002;Powell et al., 1990;Caldwell and Hespenheide, 2002;Capron et al., 1982]. A 
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considerable interest has been towards pharmacological therapies of NASH. 
Rosigalitazone and pioglitazone, PPAR-γ thiazolidinedione agonists, have been shown 
to improve ALT levels and liver histology. Pioglitazone improves insulin sensitivity and 
glucose and lipid metabolism in type 2 diabetics [Miyazaki et al., 2002]. Pioglatizone 
improves hepatic steatosis, ballooning, and inflammation in patients with NASH when 
compared with placebo [Belfort et al., 2006]. Rosiglitazone also improved steatosis and 
level of ALT when compared with placebo. However, weight gain was observed in 
NASH treatment trials for both drugs [Neuschwander-Tetri et al., 2003;Promrat et al., 
2004]. Metformin is another drug involved in improving insulin sensitivity and is used 
for type 2 diabetes treatment [Knowler et al., 2002] [Yoneda, 2010]. Meta-analysis on 
metformin showed improvement of ALT and steatosis [Angelico et al., 2007]. 
Metformin also improved steatosis, liver inflammation and fibrosis in NAFLD patients 
more effectively than vitamin E which has an antioxidant effect [Bugianesi et al., 2005]. 
1.7 Pathogenic mechanisms involved in NAFLD  
The mechanisms involved in the pathogenesis of NAFLD are not fully understood and 
are complex. However due to NAFLD being common and associated with other 
common disorders such as the metabolic syndrome, Type 2 diabetes and obesity, a 
considerable progress has been made in understanding the mechanisms involved. 
Alcoholic liver disease (ALD) and NAFLD share similar pathogenesis but are 
differentiated by the amount of alcohol consumed. Excessive alcohol intake should be 
excluded to diagnose NAFLD ( > 40mg/d in males and  >20mg/d in females)  
[Neuschwander-Tetri and Caldwell, 2003]. 
In the past decade considerable progress has been made in understanding the 
pathogenesis involved in the initiation and progression of NAFLD. A “two-hit” theory 
that spread in the NAFLD world briefly suggested that the initiation of steatosis known 
as the “first-hit” and the progression to its more severe stages (NASH) known as the 
“second hit” are caused by different sets of molecular mechanisms and environmental 
factors [Day and James, 1998;Day, 2002]. Day suggested that some mechanisms may 
be involved in the first hit as well as the second hit [Day, 2006a]. However with 
ongoing studies on NAFLD in recent years the initiation and progression of NAFLD is 
thought to be multi-factorial with combined mechanisms and environmental factors 
participating in disease initiation and progression. Obesity, type 2 diabetes and 
components of the metabolic syndrome are common risk factors causing NAFLD and 
therefore disease-related pathogenesis such as abnormal lipid metabolism, insulin 
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resistance and oxidative stress are thought to play an integral role in the pathogenesis of 
NAFLD. The main focus of this thesis is the involvement of oxidative stress however 
other mechanisms such as lipid metabolism and insulin resistance will be covered 
briefly.  
1.7.1 Oxidative stress in NAFLD 
Oxidative stress is a result of an imbalance of reactive oxygen species (ROS) and the 
production of antioxidants. There have been studies on human and animal models 
suggesting oxidative stress involvement in the pathogenesis of NAFLD. Sanyal and 
colleagues demonstrated the involvement of oxidative stress in NASH [Sanyal et al., 
2001]. The study used 3-nitrotyrosine an immune-histochemical staining marker for 
oxidative stress and the results showed elevated levels of staining in NASH biopsies 
compared to controls and NAFLD. A recent study suggested oxidative stress was higher 
in NAFLD cases compared to controls after demonstrating elevated serum levels of the 
oxidative stress markers thiobarbituric acid reactive substances (TBARS) and protein 
carbonyl (PCC). This study also demonstrated lower levels of serum glutathione in 
NAFLD patients compared to controls [Narasimhan et al., 2010]. Also, increased 
oxidation of lipids due to accumulation of TG results in oxidative stress. A study on 
Sprague-Dawley rats fed with high-fat liquid diet or the standard Lieber-DeCarli diet 
found that the high-fat fed rats demonstrated oxidative stress and lipid peroxidation on 
the basis of an increase in 4-hydroxynonenal, a product of lipid peroxidation [Lieber et 
al., 2004]. 
1.7.1.1 Reactive oxygen species 
Reactive oxygen species are produced from oxygen during normal cell function which 
include superoxide anions (O2
-
), hydrogen peroxide (H2O2), and hydroxyl radicals 
(OH*) [Fridovich, 1978]. ROS in the liver can be generated by the mitochondria, 
peroxisomes, microsomes (including cytochromes P450), reduced nicotinamide adenine 
dinucleotide oxidase, cyclooxygenase, lipoxygenase and xanthine oxidase 
[Malaguarnera et al., 2009;Koek et al., 2011]. Mitochondria are the main ROS-
generating organelle [Poyton et al., 2009]. In NASH patients mitochondrial 
abnormalities are observed [Sanyal et al., 2001;Pessayre et al., 2001]. The majority of 
oxygen (about 95%) during mitochondrial oxygen metabolism is reduced to H2O 
whereas the remaining 5% shifts away from the main pathway and is converted into O2
-
. 
O2
-
 forms when some electrons undergoing transfer along the respiratory chain react 
with molecular oxygen leading to production of ROS. Excessive production of these 
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ROS can interact with and damage macromolecules (DNA and proteins) in the cells 
[Betteridge, 2000]. In animal models, increased production of ROS has been shown to 
be linked to liver diseases including NAFLD [Calvisi et al., 2004;Wei et al., 2008]. 
1.7.1.2 Antioxidants 
Antioxidants are involved in protecting organisms from oxidative stress. The 
availability of antioxidants may arise endogenously or from the diet. Antioxidants can 
be divided into enzymatic and non-enzymatic antioxidants all of which take part in 
scavenging ROS [Koek et al., 2011]. The pro-oxidant O2
-
 can be dismutated into H2O2 
by the antioxidant superoxide dismutase (SOD) and then detoxified by glutathione 
peroxidase (GPx) and catalase into H2O and O2, a pathway when imbalanced leads to 
oxidative stress [Sasaki, 2006]. In this thesis we have been interested in the mechanisms 
involved in reducing excessive production of ROS specially superoxide anions (Figure 
1.2). 
Superoxide dismutase 
Three forms of SOD exists, SOD1 (Cu/ZnSOD) which contains cooper and zinc and is 
located in the cytoplasm, SOD2 (MnSOD) which contains manganese and is located in 
the mitochondrial matrix, and SOD3 (EC-SOD) which is localized extracellularly 
[McCord and Fridovich, 1969;Weisiger and Fridovich, 1973;Marklund, 1982]. SOD2 is 
of particular interest in relation to NAFLD due to it being located in the mitochondria 
(main ROS generator). Previous reports have shown the lack of MnSOD is lethal in 
mice and mice heterozygous for knockout and showing decreased enzyme activity have 
an increased susceptibility to oxidative stress and mitochondrial dysfunction [Melov et 
al., 1998;Macmillan-Crow and Cruthirds, 2001;Li et al., 1995b;Lebovitz et al., 1996].  
Glutathione peroxidase  
Four forms of GPx exist (GPx1-4) as reviewed by [Arthur, 2000]. GPx1 is the main 
glutathione peroxidase in the liver [Arthur, 2000]. It plays a role in reducing the H2O2 
produced by the MnSOD into H2O leaving the iron stores less H2O2 to react with 
[Sutton et al., 2006]. GPx1 is a selenium dependent enzyme. Adequate selenium is 
essential for mRNA stability, translation and GPx1 activity and therefore insufficient 
levels could lead to termination of the protein at the UGA codon by incorporation of  
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Figure 1.2: Mechanisms involved in balancing antioxidants and ROS. O2- is dismutatated by SOD 
into H2O2 which is then detoxified by GPX and its cofactor GSH into H2O+O2. Activity of GSR and 
GCL is essential for GSH. MAT plays an important role in the transmethylation and 
transsulfuration pathways. HMOX1, BR and UGT1A1 play a role in controlling Bilirubin. 
NEF2/KEAP1 complexes and the role of NRF2 in regulating antioxidants.   
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selenocysteine resulting in translation termination [Bermano et al., 1996;Papp et al., 
2007]. In mouse studies over-expression of GPx1 protects from oxidative stress [Lei, 
2001]. 
Glutathione  
Glutathione (GSH) is the most abundant intracellular thiol and is the major antioxidant 
in the liver [Chen et al., 2007]. GSH is a tri-peptide, composed of glutamate, cysteine 
and glycine (Figure 1.3). It exists in two forms GSH (thiol-reduced) and GSSG 
(disulfide oxidized) [DeLeve and Kaplowitz, 1991]. GSH is found in the cell in three 
sites, cytosol, mitochondria and endoplasmic reticulum [Meredith and Reed, 
1982;Hwang et al., 1992]. GSH functions include detoxification of electrophiles, 
antioxidant defence, cysteine storage and DNA synthesis [Kaplowitz et al., 
1985;Meister and Anderson, 1983;Lu, 2009]. However detoxification is the major 
function of GSH [Lu, 2009]. Cysteine storage is an important function of GSH and 
availability of cysteine plays a role in controlling the rate of GSH synthesis [Meister, 
1988]. Cysteine is derived from diet, protein breakdown and the conversion of 
methionine to cysteine in the transsulfuration pathway [Lu, 1999].  
GSH is synthesised by two ATP-dependent reactions, with the first step involving 
glutamate cysteine ligase (GCL), the rate-limiting enzyme, which is a heterodimer 
composed of two subunits that dissociate into a heavy catalytic (GCLC) and a modifier 
(GCLM) subunits (Figure 1.4) [Meister and Anderson, 1983]. The catalytic activity is 
possessed by GCLC whereas GCLM possess the regulatory effect when it is associated 
with GCLC. Glutamate and cysteine are ligated and catalyzed by GCL (ATP dependent) 
to form ỵ-glutamylcysteine (ỵ-GC) (Figure 1.4). The second reaction is catalyzed by 
GSH synthetase (GS) which is a homodimeric protein [Dickinson et al., 2004]. GS 
ligates glycine to ỵ-GC (Figure 1.4). The product of GCL (ỵ-GC) is seen in low 
concentration levels in cells when GS is present. In humans, low levels of GS results in 
ỵ-GC being converted to oxoproline which if it accumulates results in metabolic 
acidosis and GSH deficiency [Dalton et al., 2004]. In Saccharomyces cerevisiae, over 
expression of GCL resulted in an increased GSH level but this was not seen if GS was 
overexpressed [Grant et al., 1997]. These results are consistent with GCL being the rate-
limiting enzyme.  
GSH synthesis is determined by GCL activity which is affected by both the GCLC and 
GCLM subunits [Lu, 2009]. Chen and colleagues disrupted the GCLC gene in 
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hepatocytes which led to GSH depletion resulting in steatosis and mitochondrial injury 
[Chen et al., 2007]. GCLM knockout mice result in 10% to 40% of the normal GSH 
levels [Yang et al., 2002] because GCLM interacts with GCLC to increase its catalytic 
efficiency [Franklin et al., 2009]. GCLC and GCLM are suggested to being co-
ordinately up-regulated however it is still a controversial area where some studies have 
found them independently regulated [Zheng et al., 2007;Gipp et al., 1995]. 
GSH content is usually decreased as part of a cellular response to oxidative stress. Such 
depletion in content must be replaced. Replacement can be achieved by de novo 
synthesis or by reducing GSSG (a product of GPx and GSH to remove peroxides from 
the cell) to generate GSH by the enzyme glutathione reductase (GSR) which is an 
essential enzyme maintaining the level of GSH [Kanzok et al., 2001;Satoh et al., 
2010;Dickinson et al., 2004]. GSH functions in GPx-catalyzed reactions by acting as a 
cofactor to detoxify H2O2 into H2O [Sasaki, 2006]. Depletion of GSH can therefore lead 
to mitochondrial dysfunction and cell death [Fernandez-Checa and Kaplowitz, 2005].  
S-adenosylmethionine (SAMe) 
SAMe is the precursor of GSH and deficiency in SAMe results in deficiency of GSH 
[Mato et al., 2002]. SAMe biosynthesis from methionine is catalyzed by methionine 
adenosyl transferase (MAT) [Mato et al., 2002]. The two genes MAT1A and MAT2A 
encode the two MAT catalytic subunits of MAT (alpha1 and alpha2). MAT1A knockout 
mice are more susceptible to oxidative stress, demonstrated by lower levels of hepatic 
GSH [Martinez-Chantar et al., 2002]. MAT1A is expressed in the liver and the gene 
product forms part of two isoforms MATI and MATIII which are the main enzymes for 
SAMe synthesis in the liver. MATI is a tetramer and MATIII a dimer of the catalytic 
subunit. MATII is encoded by MAT2A which is widely distributed and expressed in 
foetal liver as well as adult tissues [Kotb et al., 1997;Horikawa and Tsukada, 1992]. 
MAT1A knockout studies in mice were consistent with lack of MAT1A predisposing to 
liver injury due to depletion of hepatic SAMe, changes in expression of methionine 
metabolism enzymes and expression of growth-related genes resulting in the 
development of NASH and liver proliferation [Lu et al., 2001]. Depletion of SAMe 
occurred in wild-type mice fed with methionine choline-deficient diet but 
supplementation with SAMe resulted in reduced severity of NASH [Oz et al., 2008;Oz 
et al., 2006]. Depletion of SAMe occurred in db/db mice (a model of type 2 diabetes 
and the metabolic syndrome harbouring a mutation in the leptin receptor) progressing  
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Figure 1.3: The structure of glutathione showing its tri-peptides. adapted from [Lu, 2009] 
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Figure 1.4: The first and second reaction of GSH synthesis demonstrating the role of the GCL subunits GCLC 
and GCLM. Adapted and modified from [Franklin et al., 2009] 
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from hepatic steatosis to NASH [Wortham et al., 2008]. Potential relevance of this work 
to human disease is shown by Mato and colleagues in a study on alcoholic liver 
cirrhosis patients where treatment with SAMe improved survival [Mato et al., 1999]. 
SAMe is required for the transmethylation and transsullfuration pathways leading to the 
formation of cysteine which is required for controlling GSH synthesis.  
Other antioxidants  
Vitamins (C and E) are free radical scavengers [Valko et al., 2004;van Acker et al., 
2000], and bilirubin also function as an antioxidant [Stocker et al., 1987]. Three 
enzymes control bilirubin concentration, UDP-glucuronosyltransferase 1A1 (UGT1A1), 
haem oxygenase 1 (HMOX1) and biliverdin reductase [Schwertner and Vitek, 2008]. 
UGT1A1 modulates levels of serum bilirubin by conjugating glucuronic acid to 
bilirubin facilitating its removal from the human body [Jansen et al., 1992]. HMOX1 
and biliverdin reductase are responsible for the formation of bilirubin [Schwertner and 
Vitek, 2008]. HMOX1 converts haem to biliverdin which is then converted to bilirubin 
via biliverdin reductase (Figure 1.1). HMOX1 is induced by oxidative stress and is the 
rate limiting enzyme for bilirubin synthesis [Vasavda et al., 2007].  
Transcription factors regulating antioxidants 
Many enzymes contribute to cellular defences against oxidative stress (mentioned 
above). Several of the key enzymes have an upstream sequence known as antioxidant 
response element (ARE) which regulates expression of these genes and can increase 
gene expression when ROS levels are high [Cho et al., 2005]. Two transcription factors 
known as Nrf1 (Nuclear respiratory factor 1) and Nrf2 (NF-E2-related factor 2) can 
interact with AREs. Both Nrf1 and Nrf2 are members of the basic leucine zipper CNC 
(cap 'n' collar) family of proteins. However, in knockout mouse experiments, complete 
loss of Nrf1 is lethal while animals lacking Nrf2 show increased susceptibility to liver 
damage when treated with paracetamol and to lung damage with a variety of toxins 
[Leung et al., 2003;Aleksunes and Manautou, 2007]. Conditional mutants for Nrf1 
where Nrf1 is inactivated only in the liver have also been prepared. In these animals, a 
phenotype of NASH followed by hepatoma development is seen [Xu et al., 2005]. Both 
Nrf1 and Nrf2 are involved in activating genes regulated by ARE however studies 
suggest Nrf2 to be the dependent factor for expressing these genes [Biswas and Chan, 
2010]. Nrf2 functions in protecting cells from oxidant injury by inducing antioxidant 
genes at the level of transcription by translocation from cytoplasm to the nucleus and 
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binding to the ARE. Briefly, in the cytoplasm Nrf2 is normally protected from 
activation by the bound Kelch-like ECH associating protein 1 (Keap1) which regulates 
its levels by promoting rapid turnover (Figure 1.5). Once oxidative stress occurs in 
unstressed cells Keap1 is disrupted allowing Nrf2 to translocate to the nucleus to 
dimerize with small Maf or AP-1 family of proteins resulting in it binding to the ARE 
[Itoh et al., 1999;Lee et al., 2005]. 
GPx2 but not GPx1 was found to be regulated by Nrf2 in mice. Expression of GPx2 
mRNA was increased when small interference RNA (siRNA) was used to knockout the 
Nrf2 inhibitor Keap1 and decreased when siRNA was used for Nrf2 [Singh et al., 2006]. 
Sequence analysis has shown GCLC promoter contains many cis-acting elements such 
as several AREs [Dickinson et al., 2004]. Evidence from knockout experiments have 
shown that Nrf2 regulates GCLC expression [Chan and Kan, 1999]. GCLM also has an 
ARE and studies have found both Nrf1 and Nrf2 to be involved in inducing and up-
regulating GCLM [Zhang et al., 2007;Moinova and Mulcahy, 1999;Kwong et al., 1999]. 
Harvey and colleagues described the role of Nrf2 in regulating GSR during oxidative 
stress in Nrf2-defecient mice [Harvey et al., 2009]. UGT1A1 has been found to be 
regulated by Nrf2. A study by Yueh and Tukey demonstrated the over-expression of 
Nrf2 when UGT1A1 was induced in HepG2 cells treated with pro-oxidants. Over-
expression of Keap1 blocked UGT1A1 expression [Yueh and Tukey, 2007]. Increase in 
Nrf2 levels results in up-regulation of HMOX1 in HepG2 cells and is prevented by 
siRNA-Nrf2 [Gong and Cederbaum, 2006]. These studies suggest an important role for 
Nrf1 and particularly Nrf2 in oxidative stress conditions.   
1.7.2 Lipid metabolism involvement in NAFLD  
Excess accumulation of TG in hepatocytes is a sign of abnormality in lipid metabolism. 
There are several pathways involved in lipid metabolism all of which in some way 
overlap and are reviewed by [Nguyen et al., 2008]. Briefly TG are formed by glycerol 
and three fatty acid molecules, a process that is influenced by insulin for both energy 
(ATP) and cell growth [Donnelly et al., 2005]. The liver plays an important role in 
controlling TG metabolism by maintaining the balance between delivery, synthesising 
and secreting of FA into or out of the liver. FA supply can be obtained from the diet via 
lipoproteins, hydrolysis of TG from adipose tissue which releases FFA, hydrolysis of 
circulating TG, de novo lipogenesis, and non-esterified fatty acid (NEFA) [Fabbrini et 
al., 2010;Moore, 2010]. 
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Figure 1.5: Activation of transcription factor Nrf2-Keap1 in the presence of ROS. Adapted and modified from 
[Lee et al., 2005] 
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On the other hand FFA can be removed via very low density lipoproteins (VLDL) and 
mitochondrial beta-oxidation [Hickman et al., 2004;Moore, 2010]. In individuals with 
NAFLD, there may be a disturbance of TG formation, supply, consumption, oxidation 
and disposal resulting in lipid accumulation [Schreuder et al., 2008]. Increased FFA is 
associated with inflammation via production of inflammatory cytokines that lead to 
Kupffer cell activation which is suggested to be involved in progression from steatosis 
to NASH [Day, 2006a]. 
1.7.2.1 FFA supply 
TG stored in adipose tissue or present in the circulation can release FFA by hydrolysis 
via lipoprotein lipase. In obese subjects with NAFLD gene expression of lipoprotein 
lipase is higher compared in subjects without NAFLD [Pardina et al., 2009;Westerbacka 
et al., 2007]. Intracellular cyclic adenosine monophosphate (cAMP) levels control the 
hydrolysis of TG and in the fed state insulin depletes cAMP preventing TG lipolysis 
(hydrolysis of TG into FFA) [Bacon and O'Grady, 2006]. Donnelly and colleagues 
demonstrated that NEFAs are the main contributor to hepatic TG, and the elevation of 
de novo lipogenesis in NAFLD suggests its contribution in accumulation of hepatic TG 
[Adams et al., 2005]. The major regulatory enzymes for de novo lipogenesis are acetyl-
CoA carboxylase (ACC) and fatty acid synthetase (FAS) [Mendez-Sanchez et al., 2007]. 
NAFLD has been found to be associated with up-regulation of ACC and FAS and other 
related genes involved in lipid metabolism [Mitsuyoshi et al., 2009;Kohjima et al., 
2007]. Transcription factor sterol regulatory element-binding protein-1c (SREBP-1c) is 
activated by insulin to regulate de novo lipogenesis [Grefhorst et al., 2002;Shimomura 
et al., 1999]. SREBP-1c over-expression in transgenic mice results in hepatic steatosis 
[Horton et al., 2002]. 
1.7.2.2 FFA removal  
VLDL is the only disposal mechanism of TG and the rate-limiting step in removal of 
TG from liver to peripheral stores [Bacon and O'Grady, 2006]. VLDL requires 
molecules and enzymes for its assembly. The apolipoprotein B-100 (apoB-100) is 
required for assembly and microsomal triglyceride transfer protein (MTP) is required to 
incorporate TG [Bacon and O'Grady, 2006;Fabbrini et al., 2010]. Peroxisome 
proliferators –activated receptors (PPAR-α and γ) are necessary for VLDL secretion 
[Yoneda, 2010]. Phosphatidylethanolamine methyltransferase (PEMT) involved in the 
synthesis of phosphatidylcholine which is also needed for VLDL synthesis [Yao and 
Vance, 1988]. 
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FFA oxidation occurs mainly in mitochondria (β-oxidation), but also by peroxisomes 
and microsomes to prevent fat accumulation [Hickman et al.;Malaguarnera et al.]. 
Excessive oxidation can result in reduction in antioxidant defences and therefore result 
in oxidative stress [Sanyal et al., 2001]. Lipid peroxidation is correlated with FA, 
therefore an increase in FA results in oxidative stress [Benzie, 1996;Koek et al., 2011]. 
Malondialdehyde (MDA) and 4-hydroxytransnonenal (4-HNE), both products of lipid 
peroxidation are seen in 90% of NASH patients serum suggesting oxidative stress has 
occurred [Loguercio et al., 2001].  
1.7.3 Insulin resistance in NAFLD 
Insulin resistance is now considered a universal finding in NAFLD. There is 
accumulating evidence associating insulin resistance with NAFLD/NASH. Sanyal and 
colleagues demonstrated that non-diabetic patients with hepatic steatosis and NASH had 
decreased insulin sensitivity while Cortez-Pinto and colleagues showed association of 
insulin resistance and NASH [Sanyal et al., 2001;Cortez-Pinto et al., 1999]. Pagano and 
colleagues noted that insulin resistance was seen more in patients with NASH when 
compared to control subjects matched with age, gender and BMI [Pagano et al., 2002]. 
Day suggested that insulin resistance may be involved in both the initiation and 
progression of NAFLD [Day, 2006a]. Insulin resistance is suggested to be involved in 
hepatic lipid accumulation. However it is still not known whether NAFLD is caused by 
insulin resistance or whether it is a consequence of it.  
Insulin resistance is the inability of a cell to perform its normal cellular function in 
response to insulin. Insulin plays a major role in glucose and lipid metabolism 
[Schreuder et al., 2008]. Briefly there are two important insulin receptor substrates 
(IRS) proteins (IRS-1 and IRS-2) which are tyrosine-phosphorylated when insulin 
bonds to its receptor [Schreuder et al., 2008]. IRS-1 initiates glucose metabolism and 
recruits glucose transporters (GLUT) whereas IRS-2 plays a role in lipid metabolism 
working as a regulator of the  de novo lipogenesis via SREBP-1c [Schreuder et al., 
2008]. SREBP-1c is over-expressed and de novo lipogenesis is up-regulated in hepatic 
insulin resistant states resulting in lipogenesis, caused by down-regulation of the IRS-2 
receptor [Schultz et al., 2000]. Larter and colleagues demonstrated the development of 
steatosis was associated with increase insulin levels and FAS activity (involved in 
lipogenesis) [Larter et al., 2009]. FFA in hepatocytes may cause insulin resistance 
through defects in the insulin signalling pathway by activating serine kinases 
[Hotamisligil, 2005;Perseghin et al., 2003;Shoelson et al., 2006]. This will change the 
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tyrosine-phosphorylation in IRS-1 to serine-phosphorylation instead resulting in 
impairment of GLUT transporters [Liu et al., 2010;Schreuder et al., 2008]. Lack of 
ability to cease hepatic glucose production is a common feature of insulin resistance. 
Insulin works on inhibiting glycogenolysis and gluconeogenesis resulting in lower 
glucose production [Rector et al., 2008]. Both insulin and glucose are involved in 
lipogenesis [Browning and Horton, 2004]. Insulin plays a role in restraining the 
production of VLDL and in hepatic insulin resistance states in NAFLD patients. TG-
rich VLDL are over produced suggesting a role of insulin resistance in lipid metabolism 
[Vanni et al., 2010]. Insulin resistance therefore results in FFA accumulation in the liver 
which requires the increase in oxidation that could result in oxidative stress [Cave et al., 
2007]. 
Adiponectin an adipose derived-cytokine, considered as an anti-inflammatory adipokine 
is found to be in low levels in patients with NAFLD [Targher et al., 2004;Pagano et al., 
2005;Pajvani et al., 2003]. Adeponectin is thought to play a role in regulating insulin 
resistance and lipid metabolism [Tsochatzis et al., 2006;Beltowski, 2003]. It plays a role 
in reducing TG accumulation in hepatocytes and increasing fatty acid oxidation by 
down-regulating SREBP-1c and stimulating mitochondrial beta-oxidation by the 
transport of fatty acids respectively [Rector et al., 2008].  
Tumour necrosis factor alpha (TNF-α), an inflammatory mediator which is a candidate 
in transition from hepatic steatosis to NASH, has been shown to have increased serum 
levels in obese and insulin resistance subject and elevated levels in NASH when 
compared with hepatic steatosis [Palmentieri et al., 2006]. TNF-α plays a role in 
activating inflammatory cells and Kupffer cells causing hepatocyte injury and oxidative 
stress [Day, 2006b]. Adiponectin and TNF-α are antagonists. Adiponectin has anti-TNF 
affect which can be a possible therapeutic target for NASH [Cave et al., 2007;Farrell 
and Larter, 2006]. 
1.8 Genetics of NAFLD 
Genetic factors involvement in NAFLD has recently been reviewed in depth by [Daly et 
al., 2011]. Identification of genetic factors involved in susceptibility to NAFLD and its 
progressive stages would allow a non-invasive strategy that could help prevent and 
control disease initiation and progression.   
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1.8.1 Genetic component in NAFLD   
Family and interethnic studies have suggested a genetic component in NAFLD. 
Schwimmer and colleagues performed a familial aggregation study to demonstrate the 
heritability of NAFLD. Two groupshere studied; the first were family members with 
obese children that had biopsy-proven NAFLD and the second group were family 
members of obese children without NAFLD. Measures of fat fraction using magnetic 
resonance imaging were performed on family members. The study found a significant 
increase in fatty liver in the group with NAFLD children and their family members 
(59% and 78% respectively) compared to the group with children without NAFLD 
(17% and 37% respectively) suggesting a familial factor in determining risk of NAFLD 
[Schwimmer et al., 2009]. A recent study evaluated the correlation between liver fat and 
levels of ALT between monozygotic and dizygotic twins. The study found that 
correlation of liver fat and ALT levels were significantly higher in monozygotic twins 
(p<0.001) than dizygotic twins (p=0.37) suggesting the involvement of genetic factors 
[Makkonen et al., 2009]. A study on 8 kindreds (2 with cryptogenic cirrhosis, 4 
NASH/cirrhosis and 2 NASH without cirrhosis) and 10 relatives showed the co-
existence of NASH with or without cirrhosis and with or without cryptogenic cirrhosis 
in kindreds suggests a genetic risk  [Struben et al., 2000]. Willner and colleagues 
studied 90 patients with NASH and found that 18% had a first degree relative that is 
also affected [Willner et al., 2001]. Prevalence of NAFLD is suggested to be different 
between different ethnic backgrounds. African Americans are suggested to be at lower 
risk compared with European Americans and Hispanic Americans which are regarded to 
be at highest risk [Romeo et al., 2008]. Difference between ethnicity is an important 
factor that could help understand genetic susceptibility to NAFLD. 
1.8.2  Genomic approaches to determining novel candidate genes 
Before the completion of the human genome project (HGP) in 2004 [HGP, 2004] and 
the establishment of organisations such as the HapMap project [Gibbs, 2003] and 
recently the 1000 genome project [Durbin et al., 2010], identifying susceptibility genes 
was achieved using linkage analysis also known as positional cloning. Linkage analysis 
used to be a major technique in identifying candidate genes however it did require large 
families to be studied [Kwon and Goate, 2000]. Linkage analysis was successful in 
identifying genes involved in single gene disorders but of more limited value for 
complex genetic disorders [Risch, 2000].   
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The candidate gene approach however does not require large families and can be used 
on unrelated cases and controls or small families [Kwon and Goate, 2000]. However it 
requires the biological knowledge of the complex disease being studied which in some 
cases is difficult when the aetiology of the disease is unknown. Once a candidate gene 
has been selected to study, selecting a polymorphism with functional variation that 
influences susceptibility to the complex disease can be challenging. In the past, this was 
frequently based on arbitrary knowledge concerning a very limited number of 
polymorphisms. However more recently, the SNP and HapMap projects have provided 
comprehensive information on common polymorphisms genome-wide, including the 
provision of detailed information on linkage disequilibrium within the human genome.  
This has facilitated more detailed candidate gene studies where, as discussed in more 
detail below, once a particular gene is chosen for study on the basis of biological 
relevance, a range of polymorphisms that tag the main haplotypes can be studied, 
together with possibly rarer SNPs of established functional significance.  
The HapMap project, together with improvements in genotyping technology, has 
particularly facilitated the increasing use of genome-wide association studies (GWAS) 
to identify disease genes without prior knowledge of disease aetiology. 
1.8.2.1  HapMap project and its relevance to genetic studies on disease susceptibility 
Though the existence of many polymorphisms in human genes was known from the 
1980s when cloning and sequencing of human genes was initiated, following the human 
genome project larger numbers of polymorphisms were identified systematically by the 
SNP consortium (TSC). The aim of TSC was to produce a public resource of SNPs in 
the human genome in 1999 when it was first established and the goal was to reach 
300,000 SNPs. However results exceeded the goal and 1.4 million SNPs was recorded 
and released to the public in 2001 [Sachidanandam et al., 2001;Thorisson and Stein, 
2003]. The HapMap project was then initiated to investigate the relationships between 
these SNPs, characterising linkage disequilibrium (LD) patterns and identifying 
haplotype-tagging SNPs, and to examine haplotypes in a range of different ethnic 
groups.  [Gibbs, 2003;Seng and Seng, 2008]. HapMap started with 270 DNA samples 
(Phase I and Phase II) and now includes 1,301 samples (Phase III) from 11 different 
populations and covers around 10 million SNPs showing their frequencies and LD 
between nearby SNPs. 
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SNPs, haplotype blocks and tag SNPs 
SNPs are the most common types of genetic variations found on average every 300 base 
pairs (Figure 1.6a) [Gibbs, 2003]. LD as defined by Cardon is “the non-random 
association of alleles at tightly linked markers” [Cardon and Abecasis, 2003]. The 
measure of LD is r
2
 which ranges from zero (no LD) to one (complete LD) [Wall and 
Pritchard, 2003]. The stronger the LD between two alleles the more likely they will be 
co-inherited together and therefore studying one will result in knowing the other. Co-
inherited alleles on the same chromosome where little recombination occurs between 
allele are called haplotype (Figure 1.6b) [Gibbs, 2003]. Gabriel and colleagues 
demonstrated that the human genome is divided into haplotype blocks where each block 
has little recombination [Gabriel et al., 2002]. The study suggested only three to five 
haplotypes within each block are needed to capture around 90% of all chromosomes in 
the population [Gibbs, 2003]. LD allows the selection of a few tag SNPs that are able to 
predict the remainder of the SNPs in the genomic region and determine the common 
haplotypes (Figure 1.6c) [Gibbs, 2003]. It is suggested that in order to construct a 
haplotype map for the human genome 300,000 to 1,000,000 chosen tag SNPs are 
required [Gibbs, 2003]. Gabriel also pointed out the LD between adjacent blocks could 
also lower the number of tag SNPs needed to be studied [Gabriel et al., 2002]. The LD 
between SNPs and the availability to select tag SNPs for identifying common 
haplotypes in selected genes for association studies is the hallmark of the HapMap 
project today.   
1.8.2.2  Genome wide association approach 
Following the completion of the human genome project and advances in technology that 
allowed genotyping (Illumina and Affymetrix), HapMap project (LD), statistical 
analysis (PLINK) and collection of samples has lead to the feasibility of GWAS for 
review see [Seng and Seng, 2008]. After the success of GWAS of age-related macular 
degeneration (AMD) in 2005 [Klein et al., 2005], several GWAS were published in 
2006 [Seng and Seng, 2008]. Among those were studied of type 2 diabetes [Altshuler et 
al., 2000;Grant et al., 2006]. The success of GWAS in type 2 diabetes came from the 
convincing evidence of TCF7L2 association found in more than 20 studies from 
different populations [Cauchi et al., 2007].Three loci were found associated with type 2 
diabetes risk in 
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Figure 1.6: representation of SNPs, and assembly of haplotypes from tag SNP [Gibbs, 2003]  
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three GWASs [Zeggini et al., 2007;Saxena et al., 2007;Scott et al., 2007]. The sample 
size of these three studies reached 32 000 allowing the detection of modest size effects 
(OR 1.1)  [Seng and Seng, 2008]. A recent GWAS on a multi-ethnic cohort from 
southeast Asia (3781 cases and 4354 controls) reported 17 genes to be associated with 
type 2 diabetes (p<9x10
-6
) [Sim et al., 2011]. A GWAS on extremely obese children 
from France and German study groups identified FTO gene to be associated with 
obesity (p=7x10
-13
) [Scherag et al., 2010]. The same gene was also found associated to 
obesity in a recent GWAS on non-Hispanics Caucasians (p=2x10
-12
) [Wang et al., 2011].         
1.9 Candidate gene association studies in NAFLD 
A relatively large number of candidate gene association studies in relation to both 
NAFLD susceptibility and progression have now appeared. An overview of all such 
studies to date is provided in table 1.1. Many of these studies have been on single SNPs 
in candidate genes though a few recent studies have involved more comprehensive 
studies on a range of SNPs in particular candidates. There are a number of general 
issues that need to be considered when performing genetic studies on NAFLD. One 
important issue concerns controls. Since NAFLD is a very common disease, finding 
unaffected controls requires use of diagnostic tests with the most accurate being liver 
biopsy. This is not an appropriate investigation for controls but some studies have used 
alternatives such as ultrasound scanning. An alternative approach is to study genes 
concerned with disease progression rather than susceptibility and not include a healthy 
control group. Other important issues for studies on NAFLD genetics include the need 
for consistency in determining histological stages of NAFLD between studies using the 
same technique and for ethnicity to be taken into consideration.  
In this section, candidate gene association studies in relation to NAFLD susceptibility 
and severity will be considered with particular focus on genes relevant to oxidative 
stress and lipid metabolism, the main subjects of this thesis. 
 
 
 
 
 
 
26 
 
Table 1.1: Genetic predictors of NAFLD susceptibly and severity 
Gene SNP Suggested 
Effect 
MVA 
performed 
Replication 
and result 
 References 
      
 
PNPLA3 
 
rs738409; I148M 
 
Both NAFLD only 
and NAFLD cases 
and healthy controls 
studied. NAFLD 
cases show carrying 
the variant allele 
show higher steatosis 
and fibrosis levels 
than homozygous 
wild-type cases.  
 
Yes 
 
Yes, Positive 
 
[Romeo et al., 
2008;Kotronen et al., 
2009b;Speliotes et al., 
2010;Sookoian et al., 
2010;Valenti et al., 
2010b;Romeo et al., 
2010a;Rotman et al., 
2010;Santoro et al., 
2010] 
 
FDFT1 
 
rs2645424 
 
Higher NAFLD 
activity score in 
NAFLD cohort for 
carriers of variant 
allele compared with 
wild-type cases. 
 
Yes 
 
Yes but negative 
 
[Chalasani et al., 
2010;Ballestri et al., 
2011] 
 
COL13A1 
 
rs1227756 
 
Higher lobular 
inflammation in 
NAFLD cohort for 
carriers of variant 
allele compared with 
wild-type cases. 
 
Yes 
 
No 
 
[Chalasani et al., 2010] 
 
TNF-α 
 
Various 
 
Increased frequency 
of carriage of variant 
alleles in NAFLD 
and NASH compared 
with healthy controls 
  
Yes but negative 
 
[Valenti et al., 
2002;Tokushige et al., 
2007;Hu et al., 2009] 
 
IL-6 
 
rs1800795 (G-174C) 
 
Increased frequency 
of carriage of variant 
allele in NAFLD and 
NASH compared 
with healthy controls 
  
No 
 
[Carulli et al., 2009] 
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CD14 
 
rs2569190 (C-159T) 
 
Increased frequency 
of carriage of variant 
allele in NASH 
compared with 
simple steatosis 
  
No 
 
[Day CP, 2006] 
 
GCLC 
 
rs4140528 (C-129T) 
 
Increased carriage of 
variant allele in 
NASH compared 
with simple steatosis 
  
No 
 
[Oliveira et al., 2010] 
 
SOD2 
 
rs4880 (A16V) 
 
Carriage of variant 
(T) allele associated 
with higher fibrosis 
score in NAFLD 
cases and families 
  
Yes, Positive 
 
[Namikawa et al., 
2004;Nobili V, 2007] 
 
PEMT 
 
rs7946 (V175M) 
 
Frequency of carriage 
of variant allele more 
common in (i) NASH 
cases compared with 
healthy controls (ii) 
NAFLD cases 
compared with 
healthy controls 
  
Yes but negative 
 
[Dong et al., 2007;Song 
et al., 2005;Jun et al., 
2009] 
 
MTP 
 
rs1800591  
 
"Wild-type" GG (i) 
more common in  
NASH compared 
with healthy controls 
(ii) associated with 
higher ALT in type II 
diabetics 
  
Yes but negative 
 
[Namikawa et al., 
2004;Bernard et al., 
2000;Oliveira et al., 
2010] 
 
APOC 
 
rs2854116/2854117 
 
Carriage of variant 
alleles more common 
in subjects with 
NAFLD compared 
with those without 
NAFLD  
  
Yes but negative 
 
[Petersen et al., 
2010;Kozlitina et al., 
2011][Valenti et al., 
2011] 
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HFE rs1800562 (C282Y) (i) Increased 
incidence of NASH 
compared with 
simple steatosis in 
those with the variant 
allele, (ii) increased 
incidence of fibrosis 
in NASH patients 
with the variant allele 
Yes, negative and 
positive 
[George et al., 
1998;Nelson et al., 
2007;Valenti et al., 
2010c;Bugianesi et al., 
2004] 
 
ATGR1 
 
rs3772622 
 
Carriage of variant 
associated with 
NAFLD 
susceptibility 
compared with 
healthy controls. 
Fibrosis severity also 
higher 
  
No 
 
[Yoneda et al., 2009] 
 
KLF6 
 
rs3750861 
 
Homozygous wild-
type associated with 
increased fibrosis risk 
in NAFLD cohort. 
 
Yes 
 
No 
 
[Miele et al., 2008] 
 
ENPP1 
 
rs1044498(L121Q) 
 
Carriage of variant 
associated with 
increased fibrosis risk 
in NAFLD cohort 
 
Yes 
 
Yes but negative 
 
[Dongiovanni et al., 
2010;Carulli et al., 
2009] 
 
IRS1 
 
rs1801278(G972R) 
 
Carriage of variant 
associated with 
increased fibrosis risk 
in NAFLD cohort 
 
Yes 
 
No 
 
[Dongiovanni et al., 
2010] 
 
ADIPOQ 
 
rs2241766 
 
Increased frequency 
of homozygous 
variant genotype in 
NAFLD cases 
compared with 
healthy controls. This 
genotype also 
associated with  
increased NASH 
severity 
  
No 
 
[Musso et al., 2008] 
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PXR 
 
rs7643645 
 
Carriage of variant 
shows "higher 
disease severity" in 
NAFLD cohort and 
more frequent in 
NAFLD cohort 
compared with 
healthy controls 
  
No 
 
[Sookoian et al., 2010] 
 
UGT1A1 
 
Upstream TA repeat 
 
Extra TA repeat more 
common in paediatric 
NAFLD cases 
compared with obese 
controls without 
NAFLD 
  
No 
 
[Lin et al., 2009] 
Table adapted from [Daly et al., 2011] and slightly modified.  
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1.9.1 Candidate gene association related to oxidative stress in NAFLD 
Only a few candidate genes related to oxidative stress in NAFLD have been 
investigated to date. 
1.9.1.1 SOD2 
The gene SOD2 encodes for the mitochondrial enzyme MnSOD (see also section 
1.7.1.2). Following translation, an N-terminal mitochondrial targeting sequence (MTS) 
of 24 amino acids is cleaved in the mitochondrial matrix and the enzyme is then 
assembled into an active tetramer [Sutton et al., 2005]. A cytosine to thymine 
polymorphism at position 47 which is associated with an alanine to valine amino acid 
substitution occurs in the targeting sequence [Degoul et al., 2001]. The presence of ala-
SOD2 is predicted to result in an α-helix in this region of the protein and val-SOD2 in a 
β-sheet structure [Shimoda-Matsubayashi et al., 1996]. The ala-SOD2 variant appears to 
achieve high mitochondrial activity due to its structure favouring import to the 
mitochondria whereas the val-SOD2 variant may be stuck in the narrow translocase of 
the inner mitochondria resulting in lower total activity (approximately 40% lower 
compared with the Ala-SOD2 variant) [Sutton et al., 2005]. In one of the earliest studies 
on NAFLD genetic susceptibility, the Ala16Val SOD2 polymorphism was found to be 
more common in 63 Japanese NASH patients compared with 150 controls [Namikawa 
et al., 2004]. However, paradoxically, the ala-SOD2 variant has been suggested to be 
associated with severe alcoholic liver disease though not all studies confirm this 
[Degoul et al., 2001;Nahon et al., 2005;Stewart et al., 2002]. The val-SOD2 was also 
found to be associated with other oxidative stress related conditions including type I 
diabetic nephropathy in a Swedish [Mollsten et al., 2007] and Denmark [Mollsten et al., 
2009] populations. The val-SOD2 was also found to be associated with pancreatic 
adenocarcinoma in a US-based population [Wheatley-Price et al., 2008]. 
1.9.1.2 GCLC 
A promoter region polymorphism C-129T in GCLC suggested to influence promoter 
activity has been investigated in NAFLD subjects. The C-129T GCLC has recently been 
studied in 131 biopsy-proven NAFLD patients from Brazil with heterozygous being 
more common in NASH patients compared with those with steatosis only [Oliveira et 
al., 2010]. The association result is consistent with the T-allele being associated with 
lower promoter activity compared to the C-allele [Nakamura et al., 2002]. However no 
replication studies have been available to confirm these findings. 
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1.9.1.3 UGT1A1 
A common TA repeat polymorphism located 41 nucleotides upstream of the TATA box 
reduces levels of transcription of UGT1A1 [Ritter et al., 1992]. Normally 6 TA repeats 
occur but some individuals may show either 7 repeats or occasionally 5or 8 repeats. The 
7 repeat allelic variant is referred to as UGT1A1*28.  Individuals with Gilbert's 
syndrome who show higher than normal plasma bilirubin levels are usually 
homozygous for this *28 variant allele. This is because the lower UGT1A1 expression 
associated with this genotype results in higher levels of serum bilirubin [Lampe et al., 
1999]. Because bilirubin can act as an antioxidant, the possible relevance of UGT1A1 
genotype to diseases concerned with oxidative stress has been investigated. For example, 
possession of UGT1A1*28 was associated with lower risk of cardiovascular disease 
[Lin et al., 2006]. UGT1A*6 but not the UGT1A1*28 variants have been found to be 
protective against NAFLD in 234 Taiwanese children [Lin et al., 2009].  
1.9.1.4 HFE 
Increase in hepatic iron is associated to severity of fibrosis [George et al., 1998]. The 
common HFE gene mutation has been found to be associated with NAFLD and severity 
of fibrosis [Nelson et al., 2007] however the results have been conflicting [Valenti et al., 
2010c].   
1.9.2 Candidate gene association studies related to lipid metabolism in NAFLD 
1.9.2.1 PEMT 
A non-synonymous polymorphism Val175Met in the PEMT gene was found to be 
associated with biopsy-proven NAFLD in 28 cases (67.9% Mut/Mut) compared to 59 
controls (40.7% Mut/Mut) (p=0.03) without fatty liver in a US-based study [Song et al., 
2005]. The Val175Met was found to be associated with NASH (107 biopsy-proven 
Japanese NASH patients) compared to controls (150 healthy volunteers) (p < 0.001) 
[Dong et al., 2007]. A recent Korean study on 588 ALD and NAFLD patients did not 
find an association with fatty liver disease on PEMT Val175Met [Jun et al., 2009]. The 
inconsistency between the studies could be due to sample size differences.  
1.9.2.2 MTP 
A promoter region polymorphism G-493T in the MTP gene, previously described to be 
involved in TG-VLDL assembly was found to be associated to NASH cases in 63 
Japanese biopsy-proven NASH patients compared to 150 healthy controls. The G-allele 
is associated to decreased transcription of MTP and therefore leads to less exports of TG 
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[Namikawa et al., 2004]. However, this was not confirmed in a recent study on 131 
biopsy-proven NAFLD and 141 healthy volunteers from Brazil [Oliveira et al., 2010]. 
The inconsistency of association could be due to the different populations being studied. 
An association of MTP with ALT was found suggesting an indirect association with 
NASH [Bernard et al., 2000].  
1.9.2.3 APOC3 
Apolipoproteins are components of lipoproteins and are involved in regulating 
lipoproteins metabolism [Mahley et al., 1984]. Two promoter region polymorphisms C-
482T and T-455C in the APOC3 gene have been found to be associated with NAFLD in 
95% healthy Asian Indian men [Petersen et al., 2010]. However, dissociation of the 
polymorphisms were found in a separate study on Americans [Kozlitina et al., 2011]. 
The inconsistency could be due to the differences in ethnicity.  
1.9.2.4 PXR 
PXR (pregnane X receptor) is suggested to be involved in lipid homeostasis. Activation 
of PXR in mice is suggested to cause hepatic steatosis by increased TG deposition in the 
liver [Zhou et al., 2006]. Recently polymorphisms in PXR have been found to be 
associated to progression of NAFLD and to its more severe stages [Sookoian et al., 
2010].  
1.9.3 Candidate gene association related to insulin resistance in NAFLD 
1.9.3.1 ENPP1 and IRS-1 
Polymorphisms in ENPP1 (ectoenzyme nucleotide pyrophosphate phosphodiesterase 1) 
and IRS-1 (insulin receptor substrate-1) genes affecting insulin receptor activity have 
been investigated in 702 biopsy-proven NAFLD patients from Europe (Italy and UK) 
[Dongiovanni et al., 2010]. The variant-alleles were found to be associated with 
increased prevalence of fibrosis scores above 1. However the ENPP1 polymorphism 
was not found to be associated to fibrosis in a smaller (n=114) study based in Italy 
[Carulli et al., 2009]. The inconsistency could be due to the lack of availability of 
biopsies in the [Carulli et al., 2009] study (59 out 114 were biopsied) which might have 
limited the recognition of association.  
1.9.3.2 TNF-α 
TNF-α -238 SNP located in the promoter region was found to be significantly prevalent 
in NAFLD patients (n=99) compared to controls (n=172) (31% vs 15% p<0.0001) in an 
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Italian-based study [Valenti et al., 2002]. Recently the -238 polymorphism was found to 
be significant in NAFLD patients (n=189) compared to controls (n=138) in a Chinese 
population [Hu et al., 2009]. However a Japanese study on 102 NAFLD patients (36 
with steatosis and 66 with NASH) compared against 100 controls showed -1031 and -
863 but not the -238 of TNF-α was found to be associated with NASH [Tokushige et al., 
2007]. The inconsistency between studies could be due to the differences in the stages 
of NAFLD being studied.  
1.9.3.3  ADIPOQ 
Musso and colleagues described two common SNPs in the adiponectin gene (ADIPOQ) 
exon/intron 2 (45GT and 276GT) which showed an association with NAFLD and 
severity of disease [Musso et al., 2008]. 
1.9.4 Other candidate gene association related to NAFLD  
1.9.4.1 KLF6 
The Kruppel-like factor (KLF) belongs to a family of transcription factors suggested to 
be involved in liver fibrogenesis. A functional polymorphism in KLF6 is associated to 
severity of fibrosis in a European (UK and Italy) cohort [Miele et al., 2008].  
1.9.4.2 AGTRI 
Angiotensin II type 1 receptor (AGTRI) is found expressed on HSC which are involved 
in fibrosis progression in NASH [Togashi et al., 2000]. Recently, AGTRI polymorphism 
was found to be associated with severity of fibrosis [Yoneda et al., 2009]. The same 
study also found five other SNPs to be associated with NAFLD [Yoneda et al., 2009].  
1.9.4.3 IL-6 
IL-6 acts as a pro-inflammatory cytokine, has been found to be associated to NAFLD in 
a relatively small study (n=114 of which 59 undergone liver biopsy) [Carulli et al., 
2009]. The IL-6 C-174 was found to be prevalent in NAFLD subjects compared to 
controls, and higher in NASH compared to NAFLD [Carulli et al., 2009].  
1.10 GWAS in NAFLD 
Up to the present date, three GWAS on NAFLD patients have been reported. In a 
limited GWAS involving only nonsynonymous polymorphisms, 383 Hispanics, 1032 
African-Americans and 696 European-Americans all were assessed for hepatic fat 
content by magnetic resonance imaging [Romeo et al., 2008]. The study found a non-
synonymous variant in the patatin-like phospholipase domain-containing protein 3 
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(PNPLA3, rs738409 I148M) to be associated with hepatic fat accumulation. The variant 
allele (G-allele) was most commonly found in Hispanics which are known to be most 
susceptible to NAFLD compared to African-Americans and Europeans [Browning et al., 
2004]. The I148M PNPLA3 variant was also associated with ALT levels, which is 
consistent with population-based GWAS carried by Yuan and colleagues on plasma 
liver enzyme where variants in PNPLA3 predicted plasma ALT levels [Yuan et al., 
2008]. Recently a GWAS on 236 female patients with well-characterized NAFLD has 
been reported [Chalasani et al., 2010]. A SNP (rs343062) in the gene FDFT1 encode for 
the enzyme farnesyl diphosphate farnesyl transferase 1 (FDFT1) is associated with 
NAFLD activity score. FDFT1 is involved in cholesterol biosynthesis [Schechter et al., 
1994]. The collagen gene COL3A1 SNP (rs1227756), EFCAB4B SNP (rs887304) and 
LTBP3 SNP (rs6591182) was associated with lobular inflammation. However no 
association was found with PNPLA3 rs738409 which was not captured by GWAS. 
However the PNPLA3 variant was in complete LD with five other PNPLA3 genotyped 
SNPs. A reason for this dissociation is the modest sample size and that only females 
were selected. Recently a genome wide association study on 7176 individuals from four 
studies was carried out in a meta-analysis study [Speliotes et al., 2011]. Measures of 
hepatic steatosis were carried out using computed tomography. Five SNPs were found 
to be associated with increased hepatic steatosis, the common PNPLA3 rs738409 and 
three novel SNPs rs4240624 near PPP1R3B, rs2228603 near NCAN, rs12137855 near 
LYPLAL1 and rs780094 near GCKR.  In a separate cohort of 592 subjects with biopsy 
proven NAFLD and 1405 healthy controls, PNPLA3, NCAN, GCKR and LYPLAL1 
variants were all found associated with NASH.   
The associations found in GWAS are interesting but need to be replicated in 
independent cohorts. To date, the association with the PNPLA3 variant I148M has been 
replicated in a number of studies [Kotronen et al., 2009b;Sookoian et al., 2009;Valenti 
et al., 2010a;Romeo et al., 2010a;Speliotes et al., 2010;Valenti et al., 2010b;Rotman et 
al., 2010;Santoro et al., 2010], as discussed in more detail in Chapter 6. Only one 
replication study to date on the reported FDFT1 association has been performed. This 
was on 340 biopsy proven NAFLD cases from the UK but no association to severity of 
fibrosis could be demonstrated [Ballestri et al., 2011]. The strong association with 
NCAN, GCKR and LYPLAL1 detected recently also require replication [Speliotes et al., 
2011].  
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1.11 Aim 
Although some progress has been achieved in identifying genetic risk factors for 
NAFLD, there are still considerable gaps to be filled. As a result the genes involved in 
the initiation and progression of NAFLD are still unclear. The aim of this study was to 
identify candidate genes that confer progression of NAFLD to its progressive stages. 
The SNPs to be studied in candidate genes were selected based on both the published 
literature and bioinformatic databases but were consisted of both tag SNPs and non-
synonymous and promoter region SNPs. Their relevance was assessed by single 
association studies, haplotype analysis, and gene-gene interaction analysis. Two 
complementary approaches will be used to assess the relationship of the selected SNPs 
and severity of disease in association studies.  Firstly, case-control studies assessing 
patients with mild NAFLD against severe NAFLD were carried out and secondly, intra-
familial association will be studied in “trios” by assessing the transmission of alleles 
from parents to the affected child. As increased oxidative stress due to lipid 
accumulation appears to be an important contributor to NAFLD severity though 
information on genetic associations is limited, the study of candidate genes relevant to 
oxidative stress such as SOD2 were emphasised with follow up studies on assessment of 
functional significance being performed if appropriate. In addition, studies on the 
relevance to NAFLD severity of genes already reported as risk factors in association 
studies on other NAFLD cohorts were performed. Studies by others on differences in 
gene expression between normal liver biopsies and biopsies from NAFLD patients 
provided additional candidate genes for genotyping analyses and for functional studies. 
This combination of genetic approaches enabled multiple regression models to be 
applied to get a better understanding of overall risk of NAFLD development from 
several genetic risk factors. 
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2 Materials and Methods  
2.1 Patient samples 
Samples from 351 unrelated patients from Newcastle with biopsy-proven NAFLD and 
71 Italian family „trios‟ (213 individuals) from Rome, Italy, each comprising two living 
parents and an index child with biopsy-proven fibrotic NAFLD were collected. The 
study had ethical approval from the Newcastle upon Tyne Local Research Ethics 
committee and from the relevant Italian committee and all participants (or their parents) 
gave informed consent. Other causes of liver disease were excluded such as chronic 
viral hepatitis, autoimmune hepatitis, hereditary hemochromatosis, Wilson‟s disease and 
drug induced liver disease, including increased alcoholic intake (>30/>20 g/day for 
males/females, respectively), as confirmed by at least one family member or friend.  
Clinical and laboratory data were collected on the date a diagnostic liver biopsy was 
performed for the adult NAFLD Newcastle samples (Table 2.1). Liver histology scoring 
was performed according to [Kleiner et al., 2005]. Kleiner and colleagues assigned 
score 0 to livers without fibrosis, score 1 was divided further into scores 1A, 1B and 1C 
characterised with perisinusoidal or periportal fibrosis (score 1), mild zone 3, 
perisinusoidal (1A), moderate zone 3 perisinusoidal (1B) and portal/periportal (1C). 
Score 2 was assigned for livers with both perisinusoidal and periportal fibrosis, score 3 
with those showing fibrosis bridges and score 4 with those showing cirrhosis. Due to the 
existence of sampling error in biopsy and the differences between 0 and 1 being subtle, 
stages 0 and all scores of 1 (mild disease) were grouped together and compared with 
stages 2-4 (severe disease). Body mass index (BMI was calculated using the formula: 
weight (kilograms)/height (m
2) and presence of diabetes mellitus (fasting glucose ≥7.1 
mmol/L mg/dl or treatment with anti-diabetic drugs) was recorded. Laboratory 
evaluation included routine liver biochemistry such as alanine aminotransferase IU/L 
(ALT), total cholesterol mmol/L, triglycerides (TG) mmol/L and homeostasis model 
assessment of insulin resistance (HOMA-IR). For the Italian children, 61 of the 71 
children had fibrosing steatohepatitis (59 patients with stage 1 fibrosis and 2 patients 
with stage 2 fibrosis). Detailed clinical data concerning these children has been 
presented previously [Nobili et al., 2006].   
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2.2 Laboratory methods 
2.2.1 Materials  
The name of suppliers of all chemical and enzymes used in this work is listed (Table 
2.2). 
2.2.1.1 Preparation of solutions and stock solutions   
Reverse osmosis distilled water was used to prepare solutions. Sterilisation via 
autoclave for solutions was applied were appropriate at 120
 o
C, 15 pounds per inch 
(PSI) pressure for 20 min. Plastic ware was autoclaved unless purchased sterilised. 
Tissue culture solutions were filter-sterilised using 0.2mm filters (Millipore, MA, USA).  
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Table 2.1: Clinical characteristics of Newcastle NAFLD patients 
 Newcastle samples 
Number 351 
Sex (Male) 218 (62.1%) 
Age, years 49.7 ± 12.7 
BMI, kg/m2 34.05 ± 5.3 
DM (Yes) 131 (37.3%) 
HOMA-IR 6.3 ± 6.2 
ALT, IU/L 80.6 ± 64.05 
Total Cholesterol, mmol/L 5.6  ± 1.3 
TG, mmol/L 2.81 ± 2.0 
Steatosis Score  
1  99 (29%) 
2 151 (44%) 
3 93 (27%) 
NASH (yes) 194 (56%) 
Fibrosis Score  
0 134 (38%) 
1 65 (19%) 
2 57 (16.5%) 
3 55 (15.5%) 
4 40 (11%) 
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Table 2.2: List of suppliers and addresses  
Supplier  Address 
Bioline London, UK 
Bio-Rad Hemel Hempstead, UK 
Eurofins MWG Operon London, UK 
Fisher Scientific Loughborough, UK 
Invitrogen Paisley, UK 
New England Biolabs Hitchin, UK 
Promega Southampton, UK 
Qiagen Crawley, UK 
Sigma Aldrich Gillingham, UK 
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Table 2.3: components of frequently used stock solutions  
Solution  Constituents  
10x TBE 0.9 M Tris-base 
0.9 M boric Acid 
20 mM EDTA PH 7.0 
DNA gel loading buffer 0.25% (w/v) bromophenol blue 
0.25% (w/v) xylene cyanol 
30 % glycerol 
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Purchased sterile water was used for PCR (Fresenius Kabi Limited, Chesire, UK). 
Frequently used stock solution and their compositions are listed in Table 2.3 
2.2.2 DNA extraction 
DNA extraction  from peripheral blood leukocytes was performed by Julian Leathart 
and Julia Patch using a perchlorate-chloroform extraction method as described 
previously [Daly et al., 1996]. 
2.2.3 Polymerase Chain Reaction (PCR) 
Lyophilised primers were purchased. Primers were resuspended to 200 µM using sterile 
water (Fresenius Kabi Limited, Chesshire, UK). Working dilutions (25 µM) were made 
and stored at 4
o
C with the main stock stored at -20
o
C. Genomic DNA (0.2 ug) was 
amplified in a total reaction volume 20 µl, containing 0.1 mM dNTPs (Bioline, London, 
UK), 0.25 µM forward primer, 0.25 µM reverse primer (Eurofins MWG, London, UK), 
1 X supplied buffer and 0.025 units Taq DNA polymerase (New England Biolabs 
(NEB), Hitchin, UK). Reactions were performed in 0.2 ml sterile tubes (Fisher 
Scientific, Loughborough, UK). An Applied Biosystems 2720 Thermal cycler was used 
for PCR. Cycling conditions were standard, with only the annealing temperature 
varying depending on primer set. Quality of PCR was checked on agarose gel (see 
section 2.1.5.1).  
2.2.4 Restriction enzyme digestion 
Restriction enzymes were purchased from Fermentas and NEB.  Digestion was 
achieved in a reaction volume of 25 µl with 2 U of digestion enzyme, digestion buffer 
provided and 5 µl of PCR product. Samples were incubated overnight at the temperature 
specified by the manufacturer. Digestion products were then run on either 2% agarose 
or polyacrylamide gels depending on the product sizes.   
2.2.5  Electrophoresis and visualisation of DNA  
2.2.5.1 Agarose gel electrophoresis 
DNase and RNase free agarose powder (Bioline, UK) was dissolved by heating in 1 X 
TBE buffer. Normally 2% gels containing 0.5 µg/ml ethidium bromide (Sigma-Aldrich, 
Gillingham, UK) were used.  DNA gel loading buffer (1 µl) was added to 5 µl of PCR 
product. A 100 - 1000bp size marker ladder (NEB) was included on the gel. 
Electrophoresis was carried out for 15-30 minutes at ~80V in 1 x TBE buffer.  
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2.2.5.2 Polyacrylamide gel electrophoresis (PAGE) and ethidium bromide staining  
Polyacrylamide gels (10%) were made up from 30% (29:1) acrylamide solution (Fisher 
Scientific) in 10 X TBE buffer, 0.1% (v/v) TEMED (Fisher Scientific) and 0.4 mg/ml 
ammonium persulphate (Bio-Rad, Hemel Hempstead, UK) in a final volume of 50 ml. 
The solution was poured between two sealed glasses plates and left for 20-30 minutes to 
set. Loading buffer (2 µl) was added to the 25 µl DNA digest products. Gels were run at 
150V for 4-5 hours in 1 X TBE buffer, followed by gel staining in 1 X TBE and 0.5 
µg/ml ethidium bromide for 30 minutes.    
2.2.5.3 Gel visualisation 
Agarose and polyacylamide gels were visualised and photographed initially on BioRad 
gel documentation system and photographed using Fluro S-multi imager Quantity One 
software and on an AlphaImager 2200 documentation and analysis system.  
2.2.6 KBiosciences genotyping  
Genotyping was also carried out by KBiosciences, Essex where appropriate. The 
KBiosciences competitive allele-specific PCR (KASP) genotyping system is a 
homogenous, fluorescent, endpoint genotyping system that uses three unlabelled 
primers and a universal reaction mix. KBiosciences achieves a >99.5% success rate and 
an error rate of <0.03% in genotyping. 96-well plates were set up with DNA according 
to the manufacturer‟s guidelines. Quality control was performed by including negative 
(water only) controls and genotyping replicate DNA samples (in every 96 well plate 
sent).  
2.3 Statistical analysis  
The chi-square test was used to ensure genotypes were in Hardy-Weinberg Equilibrium 
(HWE) using web-based calculator available at www.tufts.edu/. Pearson‟s chi-square 
test was performed with odds ratio (OR) and 95% confidence intervals (CI) and chi-
square test for trend were calculated for the Newcastle NAFLD samples using PRISM 
version 5.0a software.  
Where appropriate statistical analysis was performed using various packages of the R 
program including „gtools‟, „gdata‟, „MASS‟, „mvtnorm‟, „genetics‟, „combinat‟ and 
„dgc.genetics‟ running in the R software environment version 2.7.1 [Team, 2008]. 
Multivariate analysis by logistic regression to evaluate the factors associated with 
progressive NAFLD was performed using R statistical package. The results of 
multivariate analysis were expressed as OR with 95% CI. The transmission 
43 
 
disequilibrium test (TDT) was performed on the Italian trio families using the R 
statistical package.  
Haplotypes and their frequencies were determined using PHASE version 2.1 [Stephens 
et al., 2001]. Frequencies between Newcastle NAFLD samples and HapMap Caucasian 
samples were then compared by Pearson‟s chi-square analysis.    
SPSS version 17.0 was used for calculations on clinical parameters such as means and 
standard deviations.   
2.3.1 Power calculation 
EpiInfo version 6 was used to calculate the number of samples required to show 
statistical significance.  To detect a difference between mild and severe cases at an odds 
ratio of 2.0 with p<0.05 and a power of 80%, 165 controls and 165 cases would be 
required if the variant genotype frequency in controls is 25%.  
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3 Superoxide dismutase 2 (SOD2) genotype and its association with 
NAFLD severity 
3.1 Introduction 
Oxidative stress results from an imbalance between ROS and antioxidants as discussed 
in section 1.7.1.1. The gene SOD2 encodes the mitochondrial antioxidant enzyme 
manganese-dependent superoxide dismutase (MnSOD). MnSOD dismutates superoxide 
anions (O2
-
) into hydrogen peroxide (H2O2). An N-terminal mitochondrial targeting 
sequence (MTS) of 24 amino acids is cleaved in the mitochondrial matrix and the 
enzyme is then assembled into an active tetramer [Sutton et al., 2005]. A common non-
synonymous cytosine to thymine polymorphism at position 47 (C47T) in the SOD2 
gene is associated with alanine to valine amino acid substitution at codon 16 (Ala16Val) 
in the mitochondrial targeting sequence [Sutton et al., 2003]. The presence of the ala-
SOD2 (C-allele) is predicted to result in an α-helix structure favouring import to the 
mitochondria and therefore achieving high enzyme activity. However, the val-SOD2 (T-
allele) is predicted to result in a β-sheet structure which may get stuck in the narrow 
translocase of the inner mitochondrial membrane resulting in lower enzyme activity 
(approximately 40% lower compared with the ala-SOD2 variant) [Shimoda-
Matsubayashi et al., 1996;Sutton et al., 2005;Sutton et al., 2003]. In one of the earliest 
studies on NAFLD genetic susceptibility, homozygosity for the val-SOD2 was found to 
be more common in 63 biopsy-proven Japanese NASH patients compared with 150 
controls (p=0.016) [Namikawa et al., 2004]. In oxidative stress related diseases 
homozygotes for the val-SOD2 were also found in two studies [Mollsten et al., 2007] 
[Mollsten et al., 2009] from Sweden and Denmark respectively on type 1 diabetes to be 
associated with increased risk of diabetic nephropathy (p=0.049 and p=0.008 
respectively). The val-SOD2 was also found to be associated with pancreatic 
adenocarcinoma in a US-based population (p=0.04) [Wheatley-Price et al., 2008]. 
The aim of the studies described in this chapter is to assess the relationship between the 
Ala16Val polymorphism and susceptibility to severity of NAFLD by two 
complementary approaches using Newcastle NAFLD patients with biopsy proven 
disease and secondly Italian family trios. 
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3.2 Methods 
3.2.1 SOD2 rs4880 genotyping assay  
PCR-RFLP was used to genotype for rs4880. Primers for PCR were previously 
published by [Shimoda-Matsubayashi et al., 1996] but slightly modified for both 
forward and reverse primers (5`-CAGCCCAGCCTGCGTAGACGG-3` and 5`-
GCGTTGATGTGAGGTTCCAG-3`). PCR amplification (35 cycles of denaturation at 
95
o
C for 1 minute, annealing at 63
o
C for 1 minute and extension at 72
o
C for 1 minute) 
was then performed in a GeneAmp PCR system 9700 thermal cycler. PCR product was 
then digested with BsaWI restriction enzyme. The PCR digest products were viewed on 
a 10% acrylamide gel. PCR-RFLP analysis on the Newcastle NAFLD patients was 
performed previously by Julian Leathart who supplied the genotyping data but the 
genotyping of the Italian families was performed as part of the present study. 
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3.3 Results  
3.3.1 SOD2 genotype analysis 
The non-synonymous rs4880 polymorphism in SOD2 at position 47 on exon 2, results 
in an alanine to valine substitution (C to T). The SOD2 rs4880 polymorphism was 
genotyped by PCR-RFLP with a typical result shown in Figure 3.1. Genotypes were in 
Hardy-Weinberg equilibrium (X
2
=0.74, p=0.38). The relationship between genotype 
and severity of fibrosis was analysed (Table 3.1). Incidence of advance fibrosis (stage 2-
4) increased with the number of T (Val) alleles (p=0.01 chi-square for trend) (Table 3.1). 
65% of CC individuals had fibrosis scores 0 or 1 compared with 35% of homozygous T 
patients. Homozygosity for the T-allele vs. C-allele was associated with an odds ratio of 
2.23 (95% CI 1.19-4.17; p=0.01) for the development of fibrosis of grade 2 and above 
(Table 3.1). There was no significant difference between CT vs. CC genotype (odds 
ratio 1.38 (95% CI 0.8-2.3); p=0.23) or CC vs. CT+TT (odds ratio 1.6 (95% CI 0.96-
2.7); p=0.06).  
The TDT showed 55 of the 71 families to be informative in that one or both parents 
were heterozygous. In these families the T-allele was found to be transmitted on 47/76 
(62%) possible occasions and the C-allele was transmitted only 29/76 (38%) occasions, 
p=0.038 (Table 3.2). 
A multivariate analysis using logistic regression was performed on the Newcastle 
NAFLD samples to control for the effect of factors such as age, sex, BMI, diabetes, 
steatosis and NASH that are relevant to disease severity. The multivariate results 
demonstrate that SOD2 genotype, age, BMI, diabetes and NASH were all important 
predictors for advance fibrosis (Table 3.3). Carrying the T-allele was a significant and 
independent predictor of fibrosis with odds ratio 1.68 (95% CI 1.09 – 2.64; p=0.019). 
NASH appeared to be the strongest predictor of fibrosis (odds ratio 29.1 (95% CI 13.8 – 
67.9); p=2x10
-16
).  
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Figure 3.1: 10% acrylamide gel showing SOD2 rs4880 digested with BsaWI. Lane 2 shows heterozygous (CT), 
lane 3 wild-type (CC) and lane 4 mutant (TT).  
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Table 3.1: SOD2 genotyping distribution in Newcastle NAFLD patients – mild fibrosis vs. severe fibrosis 
SOD2 
 
Genotype Fibrosis 0+1 
(n=197) 
Fibrosis 
2+3+4 
(n=151) 
Rs4880 CC 53 (0.27) 28 (0.19) 
CT 105 (0.53) 77 (0.51) 
TT 39 (0.20) 46 (0.30) 
Population Hardy-Weinberg calculation (X
2
=0.74, p=0.38) 
Chi-square for trend p=0.01 
Odds ratio for TT against CC= 2.23 (1.19 – 4.17); p=0.01  
Odds ratio for CC against CT+TT= 1.6 (95% CI 0.96-2.7); p=0.06 
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Table 3.2: SOD2 transmission disequilibrium test, comparing the distribution of the transmitted and 
untransmitted allele from heterozygous parents to affected child 
Gene and SNP number Allele Transmitted Untransmitted p-value 
SOD2 rs4880 T 47 (62%) 29 (38%) 0.038 
C 29 (38%) 47 (62%)  
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Table 3.3: Multivariate analysis using logistic regression for mild fibrosis vs. severe fibrosis to control for the 
effect of predictor factors which are relevant to fibrosis severity  
Variables OR (95% CI) p-value 
SOD2 1.68 (1.09 – 2.64) 0.019 
Age 1.03 (1.00 – 1.06) 0.011 
Sex 1.4 (0.72 – 2.74) 0.32 
BMI 1.07 (1.01 – 1.14) 0.017 
Diabetes 2.07 (1.13 – 3.86) 0.019 
SOD2, Age, BMI and diabetes appear to be predictor factors   
Calculations assume a co-dominant model for SOD2 genotype.  
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3.4 Discussion 
We have shown a consistent association between a functional SNP in the mitochondrial 
targeting sequence of SOD2 and severity of fibrosis in both case-control and intra-
familial association methodologies. These results provide genetic evidence for the 
importance of mitochondria-derived oxidative stress and pathogenesis of NAFLD. The 
TDT analysis on the Italian family samples, 61 of the 71 children had fibrosing 
steatohepatitis (59 patients with stage 1 fibrosis and 2 patients with stage 2 fibrosis) is a 
novel feature which is significantly more powerful at detecting true associations 
compared to case-control approach and therefore inclusion of TDT analysis in an 
association study adds strength to any positive findings [Spielman and Ewens, 1996]. 
Nevertheless, our case-control approach on the adult NAFLD patients demonstrated an 
association with SOD2 genotype and severity of fibrosis. The role of MnSOD in 
protection against oxidative stress is well demonstrated and discussed earlier in section 
1.7.1.2. Previous reports have shown the lack of MnSOD is lethal in mice and mice 
heterozygous for knockout and showing decreased enzyme activity have an increased 
susceptibility to oxidative stress and mitochondrial dysfunction [Melov et al., 
1998;Macmillan-Crow and Cruthirds, 2001;Li et al., 1995b;Lebovitz et al., 1996].    
Our finding is consistent with the idea that the ala-allele (C-allele) resulting in an α-
helix structure favours import to the mitochondria. This means this allele codes for a 
gene product which has greater enzyme activity compared with the val-allele (T-allele) 
where the β-sheet structure is suggested to be less efficiently imported resulting in 
lower enzyme activity (approximately 40% lower compared to C-allele) [Shimoda-
Matsubayashi et al., 1996;Sutton et al., 2005]. Carrying the Val-allele is likely to result 
in more accumulation of the toxic radical (O2
-
) and less production of less toxic radical 
(H2O2) [Naganuma et al., 2008]. Our association of the T-allele with NAFLD was found 
consistent with the previous small study (n=63) on Japanese population with biopsy-
proven NAFLD [Namikawa et al., 2004] and also with studies on other diseases where 
oxidative stress is likely to be relevant to disease pathogenesis such as diabetic 
nephropathy [Mollsten et al., 2007] [Mollsten et al., 2009] and pancreatic 
adenocarcinoma [Wheatley-Price et al., 2008]. SOD2 is a relatively small gene of 14 kb 
and consists of one haplotype block. From HapMap data on European subjects, four 
SNPs (rs2855116, rs8031, rs2758331 and rs2842964) are in strong LD with rs4880. The 
intronic polymorphism rs2855116 has been previously studied [Tomkins et al., 2001] 
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and found not to be a risk factor for amyotrophic lateral sclerosis, however rs4880 is the 
only common non-synonymous polymorphism described in SOD2.  
FA oxidation occurs mainly in the mitochondria (β-oxidation) but also by peroxisome 
and microsomes. Excessive oxidation can result in reduction of antioxidant defences 
and therefore result in oxidative stress [Sanyal et al., 2001]. The synthesis of ROS by 
FA metabolism and the mitochondrial respiratory chain is increased in NAFLD patients 
[Pessayre and Fromenty, 2005]. There is evidence in both humans and rodents of an 
association between an increase in ROS and mitochondrial abnormalities in fibrotic 
NAFLD [Pessayre, 2007]. Therefore the high activity of the ala-allele (C-allele) is likely 
to protect the mitochondria from the high toxicity of superoxide anion (O2
-
) better than 
the val-allele (T-allele).   
In conclusion the rs4880 SOD2 polymorphism represents a biologically plausible 
candidate gene with a well established significant function. The study highlights the role 
of defence mechanisms involved in oxidative stress. However there still remains a need 
for validation in independent large cohorts by either candidate gene studies or genome 
wide association studies.   
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4 Oxidative stress related genes and NAFLD severity 
4.1 Introduction 
The association of a non-synonymous polymorphism in SOD2 gene discussed earlier 
(see chapter 3) suggested that investigation of variants in additional genes encoding 
proteins involved in protection against oxidative stress would be appropriate (Figure 
1.1). I have therefore assessed a number of common SNPs in selected genes to 
determine a possible relationship of these genes to NAFLD severity. A number of SNPs 
in these genes have already been studied by others either in NAFLD or in other diseases 
where oxidative stress may be important. 
Following the dismutation of O2
-
 into H2O2 by SOD2, GPX1 is involved in detoxifying 
H2O2 into H2O. A cytosine to thymine nucleotide substitution at position 537 on exon 2, 
results in a proline (pro) to leucine (leu) change at codon 198 (Pro198Leu) of GPX1. 
This non-synonymous SNP is suggested to affect the levels of activity of GPX1, with 
the Leu-GPX1 being the less active form [Hu and Diamond, 2003].  
As discussed in section 1.7.1.2, GSH is the major antioxidant molecule within the cell. 
The rate limiting step of GSH synthesis is catalyzed by GCL which has two subunits 
(GCLC and GCLM) encoded by different genes. A common promoter region SNP C-
129T in GCLC has previously been suggested to be involved in GCLC promoter activity 
with the C-allele reported to be associated with higher promoter activity [Koide et al., 
2003]. A common promoter region SNP C-588T has also been suggested to be involved 
in GCLM promoter activity with the C-allele reported to be associated with higher 
promoter activity [Nakamura et al., 2002].  Two additional SNPs in GCLM which "tag" 
common haplotypes have been investigated as susceptibility factors for 
methamphetamine-induced disorder and schizophrenia though with negative findings 
[Kishi et al., 2008]. GSR regenerates GSH from GSSG and is encoded by GSR. There 
have been few previous studies on disease susceptibility in relation to this gene but a 
promoter region SNP and six SNPs which tag common haplotypes have been 
investigated as risk factors for breast cancer survival though with negative results [Udler 
et al., 2007]. MAT1A encodes a subunit of MAT which catalyzes formation of SAMe, a 
precursor of GSH, making it an additional good candidate for relevance to oxidative 
stress. A recent study on hypertension and stroke investigated 8 polymorphisms in the 
MAT1A gene.  No association was observed with 8 polymorphisms however haplotype 
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analysis using three tag SNPs was associated to hypertension, stroke and CVD [Lai et 
al., 2010]. Bilirubin is a metabolite of haem. Though this compound is toxic at high 
concentrations, it has been demonstrated to have antioxidant properties and to be of 
potential benefit in a range of diseases [Schwertner and Vitek, 2008]. Genes encoding 
two enzymes that regulate levels of bilirubin are of interest. First of all, haem oxygenase 
1 is the main enzyme which converts haem to bilirubin encoded by HMOX1. Three 
SNPS which tag common haplotypes in HMOX1 which encodes haem oxygenase 1 
have been previously investigated in oxidative stress related disorders [Sheu et al., 
2009]. The study found a common haplotype in HMOX1 to be associated with increased 
risk of acute respiratory distress syndrome (ADRS). UGT1A1 encodes the enzyme 
which conjugates bilirubin by glucuronidation increasing its solubility and therefore 
promoting excretion. A common TA repeat in UGT1A1 (UGT1A1*28) is associated 
with reduced UGT1A1 activity and higher than normal levels of bilirubin in plasma 
(Gilbert's syndrome). Variants of UGT1A1 are found associated with NAFLD. 
UGT1A1*6 but not UGT1A1*28 has been previously suggested to be a protective factor 
against NAFLD in children [Lin et al., 2009]. 
Finally, the NRF1 and NRF2-KEAP1 transcription factors are important in regulating 
enzymes with ARE such as SOD2 and GCLC and GCLM. Two NRF1 SNPs have been 
previously investigated in diabetes patients, however the results did not reach its 
significance after correcting for multiple-testing [Gaulton et al., 2008]. Yamamoto and 
colleagues previously identified promoter region polymorphisms in NRF2 [Yamamoto 
et al., 2004]. Fukushima-Uesaka and colleagues investigated variations in both NRF1 
and KEAP1 and inferred haplotypes for both genes [Fukushima-Uesaka et al., 2007]. 
However recently there has been an explosion of interest mainly in NRF2 
polymorphisms and haplotypes [von Otter et al., 2010;Cordova et al., 2010]. Von Otter 
and colleagues identified a protective haplotype against Parkinson disease. Cordova and 
colleagues found a promoter region SNP in NRF1 to be associated with nephritis.   
Of the genes discussed above, only UGT1A1 has been previously studied in relation to 
NAFLD susceptibility and that study was confined to children. The aim of the 
experimental work described in this chapter was to determine whether there was an 
association between selected polymorphisms in the genes described above (see 
summary list in Table 4.1) and severity of NAFLD in both our Newcastle NAFLD 
patients and our Italian family trios. An additional aim was to test for epistatic effects 
between genes which are biologically suggested to interact with one another.  
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Table 4.1: Candidate genes relating to oxidative stress chosen for study 
Genes 
GPX1 
GCLC 
GCLM 
GSR 
MAT1A 
HMOX1 
UGT1A1 
NRF1 
NRF2 
KEAP1 
 
 
 
 
 
 
 
 
 
55 
 
4.2 Methods 
4.2.1 SNP selection 
Selection of SNPs for the candidate genes listed in Table 4.1 was based on (i) their 
importance from published literature, (ii) their position within the gene (promoter 
region, exon/intron boundary),  (iii) whether synonymous or non-synonymous) and (iv) 
whether they were SNPs that tag common (>10% frequency) haplotypes based on 
Caucasian (CEU) genotypes from the HapMap. The precise approach to SNP selection 
was gene-dependent. A summary of all SNPs studied is shown in Table 4.1.  
4.2.2 Genotyping assays  
Most SNPs were genotyped by either PCR-RFLP or allelic discrimination described in 
detail in chapter 2. The primers, PCR conditions and restriction enzymes used for PCR-
RFLP assays are shown in Table 4.2. Assays were all developed in the laboratory 
except for GPX1 rs1050450 [Forsberg et al., 1999] and UGT1A1*28 [Lin et al., 2009] 
which involved slight modification of the published methods. The PCR-RFLP assays 
were viewed on acrylamide and agarose gels where appropriate. Genotyping by 
fluorescent allelic discrimination was performed by K-Biosciences (described section 
2.1.6).  
4.2.2.1 UGT1A1*28 assay 
The primers selected and PCR conditions were obtained from [Lin et al., 2009]. The 
standard PCR method described in section 2.1.2 was used but 5% DMSO was added to 
the master mix. Cycling conditions were 30 cycles of 1 min at 95 
o
C, 1 min 55
 o
C 
annealing and 72
 o
C extension for 1 min, terminated by 7 min at 72
 o
C resulting in 77 or 
75 bp products. PCR products of 77 and 75 were viewed on 13% acrylamide gels to 
resolve products within 2 bp.   
56 
 
Table 4.2: Primers, PCR conditions and restriction enzymes of PCR-RFLP assays   
Assay Primers (Forward and Reverse) PCR conditions Restriction enzyme 
GPX1 rs1050450 
5‟-GCCTGGTGGTGGGTTCGAGCC-3‟ 
5‟-GACAGCAGCACTGCAACTGCC-3‟ 
Annealing 64 oC for 1min  ApaI 
GCLC rs17883901 
5‟ GGTGAGTTCGTCATTGATTC -3‟ 
5‟- ACTTGTGACCAAAACCTGCG -3‟ 
Annealing 55 oC for 1min TaaI 
MAT1A rs17677908 
5‟- GAAAAGCGAAAGTGCCTGAA-3‟ 
5‟- CTCTGAGAAAGAGTTTCTTG-3‟ 
Annealing 53 oC for 1min HpyCH-4V 
MAT1A rs4934027 
5‟- ACTGCCCCCTCTCTTGTACT -3‟ 
5‟- CACCAGTCAATAGTGATGTC -3‟ 
Annealing 55 oC for 1min MspI 
MAT1A rs10788546 
5‟ CAGGACATCCTTCCTGAGTT -3‟ 
5‟- TCCTCCACTGCAACAGGAC -3‟ 
Annealing 57 oC for 1min AccI 
MAT1A rs2993763 
5‟- ACCAGGTGCCTCCAGGGTGAGA-3‟ 
5‟- GTGGGGAGGCGTAGTGCCATG-3‟ 
Annealing 65 oC for 1min MscI 
NRF2 rs6721961 
5‟-GGCTAAAGATTTGGACCCAGAC-3‟ 
5‟-TTCCCGTTTTTCTCCCAGCT-3‟ 
Annealing 57 oC for 1min HaeII 
NRF2 rs2364722 
5‟-GCAATTGAATAAATCTTGGCCTGT-3‟ 
5‟-GGAGGACAAGTTTACTAGATGTC-3‟ 
Annealing 57 oC for 1min RsaI 
NRF2 rs1806649 
5`- CTCCAGGATATCCTCTCTGA-3` 
5`-AGGTATCTACACACCCTAGG-3` 
Annealing 57 oC for 1min Bpu10I 
NRF2 rs4243387 
5‟-CTCAGACCTACACCTTGGCA-3` 
5`-ATATCCTGGAGGAACTGCCA-3` 
Annealing 57 oC for 1min BstEII 
NRF2 rs10183914 
5‟-GCTGGTCTGTTTCAGCTTAAGC-3‟ 
5‟-CTTGTCAAGGAAACCTTAGCC-3‟ 
Annealing 57 oC for 1min HphI 
UGT1A1*28 
5`-TAACTTGGTGTATCGATTGGT-3`           
5`-CTTTGCTCCTGCCAGAGGT-3` 
Annealing 55 oC for 1min                   * 
All PCRs were carried out using 35 cycles of 94
o
C denaturation for 1 min and 72
o
C 
extension for 1 min and all PCRs ended with 7 min at 72
o
C to ensure elongation.  
*PCR conditions 30 cycles assay obtained from [Lin et al., 2009] described 4.2.2.1  
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4.2.3 Statistical analysis 
27 SNPs and 1 repeat from 12 genes (including SOD2 and PNPLA3) were genotyped in 
both Newcastle NAFLD and the Italian family cohorts and the level of significance was 
therefore set at 0.002 to correct for the number of SNPs studied (Bonferroni correction). 
For the Newcastle adult NAFLD cases, the frequency of carriage of the minor allele 
between cases of mild fibrosis (score 0 or 1) and severe fibrosis (score 2 or higher) were 
compared. For the Italian families with children suffering from NAFLD, transmission 
rates between alleles were compared. Logistic regression analysis using the R statistical 
package was used for analysis of gene-gene interaction.     
4.2.4 Haplotype assignments 
SNP genotype data for Caucasians for each gene was downloaded from HapMap.org 
and uploaded onto Haploview version 4.1 [Barrett et al., 2005] to determine the tag 
SNPs that identify the common (>10%) haplotypes. An input file was created for the 
Newcastle genotyped data which was then run in PHASE to generate all the possible 
haplotypes and their frequencies. Frequencies between Newcastle and HapMap 
Caucasians were then compared as described in section 2.1.7. 
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4.3 Results: 
4.3.1 Candidate gene SNP selection 
For GPX1, UGT1A1 and GCLC single SNPs which had been reported to be of clear 
functional significance were investigated only on the grounds that these genes had 
already been well studied by others. For GCLM, GSR, MAT1A, HMOX1, NRF1, 
NRF2 and KEAP1 a tag SNP approach was adopted due, at the time of initiation of 
these studies, to the limited information on the existence of functionally significant 
polymorphisms in these genes. The studies on genes involving single SNPs are covered 
in the first section below with the studies involving tag SNPs described later. For all 
genes, a description of the assay and genotyping results obtained is provided. In 
addition, where tag SNPs were genotyped, the frequency of overall haplotypes 
compared with those reported previously [Gibbs, 2003] is described. 
4.3.2 Candidate gene association studies 
The overall results obtained for the Newcastle adult NAFLD patients are summarised in 
Table 4.3 with the results of the TDT analysis on the Italian families shown in Table 4.4. 
Results for each gene are discussed individually below.  
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Table 4.3: Candidate genes genotyping distribution in Newcastle NAFLD patients for severity of fibrosis 
Gene and SNP 
 
Genotype Fibrosis 0+1 
Fibrosis 
2+3+4 
Odd ratio for 
carriage of 
minor allele 
(95% CI) 
P value 
for 
carriage of 
minor 
allele 
GPX1 
rs1050450 
 
CC 91 (0.48) 75 (0.53) 
0.85 (0.55 – 
1.31) 
0.88  CT 88 (0.46) 61 (0.42) 
TT 11 (0.06) 8 (0.05) 
GCLC 
rs17883901 
CC 145 (0.77) 110 (0.78) 
0.95 (0.56 – 
1.6) 
 0.85 CT 42 (0.22) 31 (0.22) 
TT 1 (0.01) 0 
GCLM 
rs41303970 
CC 136 (0.73) 104 (0.72) 
1.03 (0.63 - 
1.67) 
0.92 CT 40 (0.21) 39 (0.27) 
TT 11 (0.06) 1 (0.01) 
GCLM 
rs12140446 
AA 89 (0.48) 66 (0.46) 
1.1 (0.71 – 
1.7) 
0.67 AT 78 (0.42) 67 (0.46) 
TT 19 (0.1) 12 (0.08) 
GCLM 
rs7549683 
CC 80 (0.43) 57 (0.41) 
1.1 (0.7 – 
1.7) 
0.67 CA 83 (0.45) 66 (0.47) 
AA 23 (0.12) 17 (0.12) 
 GG 129 (0.68) 112 (0.75) 0.69 (0.42 –  
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GSR rs1002149 GT 52 (0.28) 33 (0.22) 1.12) 0.13 
TT 8 (0.04) 3 (0.03) 
GSR rs3779647 
TT 54 (0.28) 50 (0.34) 
0.77 (0.48 – 
1.23) 
0.28 TC 95 (0.49) 74 (0.49) 
CC 43 (0.23) 25 (0.17) 
GSR rs8190996 
GG 61 (0.32) 50 (0.33) 
0.93 (0.59 – 
1.47) 
0.77 GA 99 (0.52) 68 (0.46) 
AA 30 (0.16) 31 (0.21) 
GSR rs2911678 
TT 102 (0.53) 94 (0.63) 
0.68 (0.44 – 
1.05) 
0.09 TA 80 (0.42) 50 (0.33) 
AA 9 (0.05) 6 (0.04) 
MAT1A 
rs17677908 
AA 147 (0.81)  115 ( 0.78) 
1.2 (0.7 – 
2.05) 
0.49 AG 31 (0.17) 31 (0.21) 
GG 4 (0.02) 2 (0.01) 
MAT1A 
rs4934027 
CC 109 (0.59) 71 (0.52) 
1.3 (0.85 – 
2.05) 
0.22 CT 68 (0.37) 57 (0.42) 
TT 9 (0.04) 9 (0.06) 
MAT1A 
rs10788546 
CC 86 (0.47) 63 (0.43) 
1.2 (0.76 – 
1.82) 
0.46 CT 76 (0.42) 72 (0.49) 
TT 20 (0.11) 11 (0.08) 
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MAT1A 
rs2993763 
GG 54 (0.30) 40 (0.28) 
1.1 (0.67-
1.79) 
0.69 GA 90 (0.49) 68 (0.48) 
AA 38 (0.21) 34 (0.24) 
HMOX1 
rs2071748 
AA 57 (0.3) 52 (0.36) 
0.78 (0.49 -
1.24) 
0.3 AG 102 (0.55) 73 (0.5) 
GG 28 (0.15) 20 (0.14) 
HMOX1 
rs2071749 
GG 58 (0.32) 55 (0.38) 
0.75 (0.48 – 
1.2) 
0.24 GA 93 (0.51) 61 (0.42) 
AA 32 (0.17) 29 (0.2) 
UGT1A1*28 
WT (6/6) 72 (0.39) 60 (0.42) 
0.89 (0.57-
1.39) 
0.61 HET (6/7) 98 (0.53) 69 (0.48) 
MT (7/7) 15 (0.08) 15 (0.10) 
NRF1 rs1882095 
CC 83 (0.45) 49 (0.35) 
1.52 (0.96 – 
2.4) 
0.067 CT 81 (0.44) 70 (0.5) 
TT 19 (0.11) 20 (0.15) 
NRF1 rs4731608 
GG 147 (0.77)  118 (0.81) 
0.79 (0.46 – 
1.35) 
0.4 GA 40 (0.21) 27 (0.18) 
AA 4 (0.02) 1 (0.01) 
NRF1 rs7796553 
TT 145 (0.76) 92 (0.63) 
1.85 (1.15 – 
2.96) 
 
 TC 42 (0.22) 46 (0.32) 
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CC 4 (0.02) 8 (0.05) 0.01 
NRF1 
rs10245818 
AA 138 (0.75) 93 (0.64) 
1.64 (1.02 – 
2.68) 
0.04 AG 42 (0.23) 49 (0.34) 
GG 5 (0.02) 3 (0.02) 
NRF2 rs6721961 
CC 145 (0.78) 114 (0.77) 
1.08 (0.64 – 
1.87) 
0.76 CA 36 (0.2) 32 (0.22) 
AA 4 (0.02) 2 (0.01) 
NRF2 rs2364722 
AA 84 (0.45) 69 (0.49) 
0.85 (0.55 – 
1.32) 
0.48 AG 96 (0.51) 66 (0.46) 
GG 8 (0.04) 7 (0.05) 
NRF2 rs1806649 
CC 95 (0.51) 70 (0.47) 
1.17 (0.76 – 
1.81) 
0.46 CT 77 (0.42) 68 (0.46) 
TT 13 (0.07) 10 (0.07) 
NRF2 rs4243387 
TT 147 (0.78) 113 (0.76) 
1.1 (0.67 – 
1.85) 
0.67 TC 39 (0.21) 32 (0.21) 
CC 3 (0.01) 4 (0.03) 
NRF2 
rs10183914 
CC 78 (0.4) 60 (0.4) 
1 (0.65 – 
1.55) 
0.97 CT 94 (0.49) 73 (0.49) 
TT 21 (0.11) 16 (0.11) 
KEAP1 
CC 69 ( 0.37) 53 (0.38) 
0.96 (0.61 – 0.88 
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rs1048290 CG 88 (0.47) 69 (0.49) 1.53) 
GG 29 (0.16) 18 (0.13)   
All variations were in Hardy-Weinberg equilibrium except for NRF2 rs2364722 
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Table 4.4:  TDT in the trio Italian families comparing the distribution of the transmitted and untransmitted 
allele from heterozygous parentsto affected child 
Gene and SNP number Allele Transmitted Untransmitted p-value 
GPX1 rs1050450 C 31 (48.5%) 33 (51.5%) 0.9 
T 33 (51.5%) 31 (48.5%)  
GCLC rs17883901 C 3 (23%) 10 (77%) 0.046 
T 10 (77%) 3 (23%)  
GCLM rs41303970 C 12 (41%) 17 (59%) 0.45 
T 17 (59%) 12 (41%)  
GCLM rs12140446 A 37 (57%) 28 (43%) 0.32 
T 28 (43%) 37 (57%)  
GCLM rs7549683 C 26 (45%) 32 (55%) 0.51 
A 32 (55%) 26 (45%)  
GSR rs1002149 G 20 (55%) 16 (45%) 0.61 
T 16 (45%) 20 (55%)  
GSR rs3779647 T 36 (55%) 30 (45%) 0.54 
C 30 (45%) 36 (55%)  
GSR rs8190996 C 35 (48%) 38 (52%) 0.81 
T 38 (52%) 35 (48%)  
GSR rs2911678 A 27 (64%) 15 (36%) 0.08 
T 15 (36%) 27 (64%)  
MAT1A rs17677908 A 13 (46%) 15 (54%) 0.14 
65 
 
G 15 (54%) 13 (46%)  
MAT1A rs4934027 C 30 (57%) 23 (43%) 0.41 
T 23 (43%) 30 (57%)  
MAT1A rs10788546 C 29 (54%) 25 (46%) 0.68 
T 25 (46%) 29 (54%)  
MAT1A rs2993763 G 30 (55%) 25 (45%) 0.66 
A 35 (45%) 30 (55%)  
HMOX1 rs2071748 G 33 (51%) 32 (49%) 1 
A 32 (49%) 33 (51%)  
HMOX1 rs2071749 G 29 (46%) 36 (54%) 0.45 
A 36 (54%) 29 (46%)  
UGT1A1*28 -TA 25 (44%) 32 (56%) 0.42 
+TA 32 (56%) 25 (44%)  
NRF1 rs1882095 C 28 (60%) 19 (40%) 0.24 
T 19 (40%) 28 (60%)  
NRF1 rs7796553 T 15 (65%) 8 (35%) 0.21 
C 8 (35%) 15 (65%)  
NRF1 rs4731608 G 11(44%) 14 (46%) 0.69 
A 14 (46%) 11 (44%)  
NRF1 rs10245818 A 15 (65%) 8 (35%) 0.21 
G 8 (35%) 15 (65%)  
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NRF2 rs10183914 C 43 (59%) 30 (41%) 0.12 
T 30 (41%) 43 (59%)  
NRF2 rs2364722 A 26 (46%) 30 (54%) 0.59 
G 30 (54%) 26 (46%)  
NRF2 rs6721961 G 21 (60%) 14 (40%) 0.23 
T 14 (40%) 21 (60%)  
NRF2 rs1806649 C 38 (59%) 26 (41%) 0.16 
T 26 (41%) 38 (59%)  
NRF2 rs4243387 T 20 (51%) 19 (49%) 1 
C 19 (49%) 20 (51%)  
KEAP1 rs1048290 C 31 (56%) 24 (44%) 0.42 
G 24 (44%) 31 (56%)  
Percentage of the alleles being transmitted and untransmitted from parents to the 
affected child 
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4.3.3 Studies on SNPs of known functional significance 
4.3.3.1 GPX1  
The non-synonymous rs1050450 polymorphism in GPX1 at position 537 on exon 2, 
results in a Proline to Leucine substitution at codon 198 (Pro198Leu). The GPX1 
rs1050450 polymorphism was genotyped by PCR-RFLP with a typical result shown in 
Figure 4.1. The relationship between genotype and severity of fibrosis was analysed 
(Table 4.3). There was no difference in genotype frequency between mild fibrosis and 
severe fibrosis (p=0.85). TDT analysis on the Italian families did not show any 
preferential transmission of either allele to the affected child (p=0.9) (Table 4.4).  
4.3.3.2 GCLC 
The GCLC polymorphism rs17883901 is a C to T substitution located in the promoter 
region at position -129. The polymorphism was genotyped by PCR-RFLP (see Figure 
4.2 for a typical result) and the relationship between genotype and severity of fibrosis 
was analysed (Table 4.3). There was no difference in carriage of the variant allele 
between mild fibrosis and severe fibrosis (p=0.85). The TDT on the Italian families 
showed a borderline significance prior to Bonferroni correction (Table 4.4). The T-
allele was found to be transmitted on 10/13 (77%) occasions compared with the C-allele 
which was transmitted on 3/13 (23%) occasions from both or at least one heterozygous 
parent (p=0.046).  
4.3.3.3 UGT1A1 
The TA repeat polymorphism UGT1A1*28 is located in the promoter region of 
UGT1A1. Repeat was differentiated by length of PCR product (see Figure 4.3). The 
relationship between genotype and severity of fibrosis was analysed (Table 4.3). There 
was no significant differences in carriage of the 7-TA repeat allele between the mild 
fibrosis and severe fibrosis groups (p=0.61). TDT was performed on the Italian families 
(Table 4.4). There was no preferential transmission of the 7-TA repeat allele to the 
affected child (p=0.42).  
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Figure 4.1:  10% acrylamide gel showing GPX1 rs1050450 digested with ApaI. Lane 2 shows mutant (TT), lane 
3 shows wild type (CC), and lane 4 a heterozygote (CT) 
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Figure 4.2: 2% agarose gel showing GCLC rs17883901 digested with TaaI. Lane 2 shows mutant (TT), lane 3 
wild type (CC) and lane 4 heterozygous (CT).   
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Figure 4.3: 13% acrylamide gel, UGT1A1*28 TA repeat PCR product. Lane 2, shows wild type TA 6/6, lane 3, 
heterozygous TA 6/7, and lane 4 TA 7/7.    
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4.3.3.4 GCLM 
Three GCLM polymorphisms were selected for study. A promoter region SNP 
(rs41303970), an intronic SNP (rs12140446) and 3`-UTR SNP rs7549683 were selected. 
Using Haploview and genotype data on Europeans from the HapMap, GCLM showed 
only one haplotype block. The two tag SNPs (rs12140446 and rs7549683) selected were 
in LD (r
2
>0.8) with four SNPs that were predicted to represent the common (>10%) 
haplotypes of GCLM (Figure 4.4). These SNPs were genotyped by allelic discrimination 
and the relationship between genotype and severity of fibrosis was analysed (Table 4.3). 
None of these polymorphisms showed any significant differences in carriage of the 
variant allele between the mild fibrosis and severe fibrosis groups (p=0.92, p=0.67, and 
p=0.67 respectively). TDT was performed on the Italian families (Table 4.4). There was 
no preferential transmission of any allele to the affected child for any of the 3 SNPs 
studied (p=0.45, p=0.32, and p=0.51 respectively). There was no HapMap data available 
on the upstream promoter region SNP and therefore LD between the upstream SNP and 
the tag SNPs selected was not available. Frequencies of common haplotypes were 
generated using the two tag SNPs (Table 4.5). There were no differences between 
frequencies of haplotypes generated compared against frequencies from HapMap CEU 
(p=0.24). 
4.3.3.5 GSR 
Four GSR polymorphisms were selected for genotyping. A promoter region SNP 
rs1002149, and three intronic region SNPs rs3779647, rs8190996 and rs2911678 were 
selected (Figure 4.5). Using Haploview, GSR consisted of three haplotype blocks. Each 
block represented a region of the GSR gene (Figure 4.5). The three tag SNPs 
(rs3779647, rs8190996 and rs2911678) selected were in LD (r
2
>0.8) with six SNPs that 
were predicted to represent the common (>10%) haplotypes (Figure 4.4). These SNPs 
were genotyped by allelic discrimination and the relationship between genotype and 
severity of fibrosis was analysed (Table 4.3). None of these polymorphisms showed any 
significant differences in carriage of the variant allele between the mild fibrosis and 
severe fibrosis groups (p=0.13, p=0.28, p=0.77 and p=0.09 respectively). TDT was 
performed on the Italian families (Table 4.4). There was no preferential transmission of 
any allele to the affected child for any of the 4 SNPs studied (p=0.61, p=0.54, p=0.81 
and p=0.08 respectively). Frequencies of common haplotypes were generated using the 
three tag SNPs (Table 4.6). There were no differences between frequencies of 
haplotypes generated compared against frequencies from HapMap CEU (p=0.95). 
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Figure 4.4: Location of rs41303970, rs12140446 (intron region) and rs7549683 (3’ UTR) SNPs in the GCLM 
gene. Haplotypes were obtained from Haploview based on European data from the HapMap. Four haplotypes 
with their frequencies are shown. Three were common (>10%) haplotypes. Two SNPs indicated with arrows 
were sufficient to tag these common haplotypes.  
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Table 4.5: GCLM Haplotype frequencies compared in both Newcastle and HapMap  
 
 
 
 
 
 
Chi-square test analysing the differences between frequencies of the Newcastle and 
HapMap populations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Newcastle 
frequency 
HapMap 
frequency 
P-value 
GCLM    
TT 0.349 0.242 
0.24 
GT 0.337 0.375 
GA 0.309 0.383 
TA 0.002 NA 
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Figure 4.5: Four polymorphisms were selected and their position in the GSR gene is illustrated. Three 
haplotype blocks were identified using Haploview. Each haplotype block covers a region of the GSR gene 
represented by dotted lines. The dark lines between blocks indicate the strength of LD between haplotypes. 
The r2 numbers (1.0) between blocks indicates LD between alleles from different blocks. Three tag SNPs 
illustrated with red arrows were selected to identify the common (>10%) haplotypes. Rs2911678 (018) was in 
complete LD (r2=1) with rs2253409 (041).  
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Table 4.6: GSR Haplotype frequencies comparing both Newcastle and HapMap 
 
 
 
 
 
 
 
Chi-square test analysing the differences between frequencies of the Newcastle and 
HapMap populations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Newcastle 
frequency 
HapMap 
frequency 
P-value 
GSR    
ATT 0.4 0.43 
0.95 
TCC 0.23 0.25 
ACC 0.19 0.183 
ACT 0.14 0.12 
ACT 0.02 NA 
TTT 0.003 NA 
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4.3.3.6 MAT1A 
Four polymorphisms were selected for MAT1A. A promoter region SNP rs17677908, an 
intronic SNP rs4934027, and two non-synonymous SNPs rs10788546 and rs2993763 
were selected (Figure 4.6). Using Haploview, MAT1A consisted on three haplotype 
blocks, each block representing a region of the MAT1A gene (Figure 4.6). Three tag 
SNPs (rs4934027, rs10788549 and rs2993763) selected were in LD (r
2
> 0.8) with 16 
SNPs across the haplotype blocks that were predicted to represent the common (>10%) 
haplotypes (Figure 4.6). These SNPs were genotyped by PCR-RFLP (see Figures 4.7 
for typical results). The relationship between genotype and severity of fibrosis was 
analysed (Table 4.3). None of these polymorphisms showed any significant differences 
in carriage of the variant allele between the mild fibrosis and severe fibrosis groups 
(p=0.49, p=0.22, p=0.46 and p=0.69 respectively). TDT was performed on the Italian 
families (Table 4.4). There was no preferential transmission of any allele to the affected 
child for any of the 4 SNPs studied (p=0.14, p=0.41, p=0.68 and p=0.69 respectively). 
The upstream promoter region SNP was not among the HapMap data SNPs available 
and therefore no LD was available with the selected tag SNPs. Frequencies of common 
haplotypes were generated using the three tag SNPs (Table 4.7). There were no 
differences between frequencies of haplotypes generated compared against frequencies 
from HapMap CEU (p=0.47). 
4.3.3.7 HMOX1 
Two SNPs rs2071748 and rs2071749 in the intron region were selected for HMOX1 
(Figure 4.8). Using Haploview, HMOX1 consisted of one haplotype block. The two tag 
SNPs (rs2071748 and rs2071749) selected were in LD (r
2
>0.8) with three SNPs across 
the haplotype block and were predicted to represent the common (>10%) haplotypes 
(Figure 4.8). These SNPs were genotyped by allelic discrimination and the relationship 
between genotype and severity of fibrosis was analysed (Table 4.3). None of these 
polymorphisms showed any significant differences in carriage of the variant allele 
between the mild fibrosis and severe fibrosis groups (p=0.3, and p=0.24 respectively). 
TDT was performed on the Italian families (Table 4.4). There was no preferential 
transmission of any allele to the affected child for any of the two SNPs studied (p=1 and 
p=0.45 respectively). Frequencies of common haplotypes were generated using the two 
tag SNPs (Table 4.8). There were no differences between frequencies of haplotypes 
generated compared against frequencies from HapMap CEU (p=0.27). 
77 
 
 
Figure 4.6: Four polymorphisms were selected and their position on the MAT1A gene is illustrated. Three 
MAT1A haplotype blocks identified, each block covers a region of the MAT1A gene represented with the 
dotted lines. The dark lines between blocks indicate the strength of LD between haplotypes. The r2 numbers 
(0.95 and 1.0) between blocks indicates LD between alleles from different blocks. Three tag SNPs illustrated 
with red arrows were selected to identify the common (>10%) haplotypes.   
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Figure 4.7: 2% agarose gel showing MAT1A selected SNPs A) rs2993763 digested with MscI. Lane 2 shows 
heterozygous (GA), lane 3 Wild type (GG), and lane 4 mutant (AA). B) 10% acrylamide rs17677908 digested 
with HpyCH-4V. Lane 2 shows heterozygous (AG), lane 3 wild type (AA), and lane 4 mutant (GG). C) 2% 
agarose gel showing MAT1A rs4934027 digested with MspI. Lane 2 shows, heterozygous (GA), lane 3 mutant 
(AA), and lane 4 wild type (GG). D) 2% agarose gel showing MAT1A rs10788546 digested with AccI. Lane 2 
shows heterozygous (CT), lane 2 mutant (TT) and lane 4, wild type (CC). 
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Table 4.7: MAT1A Haplotype frequencies comparing both Newcastle and HapMap 
 
 
 
 
 
 
 
 
Chi-square test analysing the differences between frequencies of the Newcastle and 
HapMap populations 
 
 
 
 
 
 
 
 
 
 
Newcastle 
frequency 
HapMap 
frequency 
P-value 
MAT1A    
GTC 0.309 0.374 
0.47 
ACT 0.24 0.192 
ACC 0.232 0.149 
GCC 0.206 0.167 
GCT 0.008 NA 
GTT 0.003 NA 
ATT 0.002 NA 
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Figure 4.8: Location of the two tag SNPs rs2071749 (intronic) and rs2071748 (intronic) in the HMOX1 gene 
structure. Haplotypes obtained from Haploview showing 4 haplotypes with their frequencies, only 3 were 
common (>10%) haplotypes. Two tag SNPs indicated with arrows were sufficient to determine these common 
haplotypes.  
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Table 4.8: HMOX1 Haplotype frequencies comparing both Newcastle and HapMap 
 
 
 
 
 
 
Chi-square test analysing the differences between frequencies of the Newcastle and 
HapMap populations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Newcastle 
frequency 
HapMap 
frequency 
P-value 
HMOX1    
AA 0.418 0.492 
0.27 
GG 0.408 0.3 
GA 0.165 0.117 
GG 0.009 0.083 
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4.3.3.8 NRF1 
Four polymorphisms were selected for NRF1. One promoter region SNP rs1882095 and 
three intron region SNPs rs7796553, rs4731608 and rs10245818 were selected (Figure 
4.9). Using Haploview, NRF1 consisted of 8 haplotype blocks. Each block representing 
a region of NRF1 gene (Figure 4.9). The two tag SNPs (rs4731608 and rs10245818) 
selected were in LD (r
2
>0.8) with 20 SNPs across the haplotype blocks which were 
predicted to determine the common (>10%) haplotypes (Figure 4.9). These SNPs were 
genotyped by allelic discrimination and the relationship between genotype and severity 
of fibrosis was analysed (Table 4.3). Two SNPs (rs7796553 and rs10245818) were 
associated with severity of fibrosis. Carriage of the C-allele of rs7796553 (OR 1.85 
(1.15-2.96), p=0.01) was found associated with severity of fibrosis. Carriage of G-allele 
of rs10245818 (OR 1.64 (1.02-2.68), p=0.04) was found associated with severity of 
fibrosis. Both results were prior to Bonferroni correction. None of the remaining SNPs 
(rs4731608 and rs1882092) showed any significant differences in carriage of the variant 
allele between the mild fibrosis and severe fibrosis groups (p=0.4 and p=0.067 
respectively). TDT was performed on the Italian families (Table 4.4). There was no 
preferential transmission of any allele to the affected child for any of the 4 SNPs studied 
(p=0.24, p=0.21, p=0.69 and p=0.21 respectively). The upstream promoter region SNP 
was not found in HapMap SNP data and therefore no LD with the other selected SNPs 
was available. However rs7796553 was selected from the literature and was found to be 
in LD (r
2
= 0.86) with rs10245818. Frequencies of common haplotypes were generated 
using the two tag SNPs (Table 4.9). There were no differences between frequencies of 
haplotypes generated compared against frequencies from HapMap CEU (p=0.65). 
4.3.3.9 NRF2 
Five polymorphisms were selected for NRF2. A promoter region SNP rs6721961 and 4 
intron region SNPs rs2364722, rs1806649, rs4243387 and rs10183914 were selected 
(Figure 4.10). Using Haploview, NRF2 consisted of one haplotype block. Four tag 
SNPs (rs2364722, rs1806649, rs4243387 and rs10183914) selected were in LD (r
2
>0.8) 
with 10 SNPs found across the haplotype block that were able to determine the common 
(>10%) haplotypes (Figure 4.10).  These SNPs were genotyped by PCR-RFLP (see 
Figure 4.11 for typical results) and rs4243387 by allelic discrimination. The relationship 
between genotype and severity of fibrosis was analysed (Table 4.3). None of these 
polymorphisms showed any significant differences in carriage of the variant allele 
between the mild fibrosis and severe fibrosis groups (p=0.76, p=0.48, p=0.46 p=0.67 
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and p=0.97 respectively). TDT was performed on the Italian families (Table 4.4). There 
was no preferential transmission of any allele to the affected child for any of the 4 SNPs 
studied (p=0.23, p=0.59, p=0.16, p=1 and p=0.12 respectively). The upstream promoter 
region SNP was not found in HapMap SNP data and therefore no LD with the other 
selected SNPs was available. Frequencies of common haplotypes were generated using 
the three tag SNPs (Table 4.10). There were no differences between frequencies of 
haplotypes generated compared against frequencies from HapMap CEU (p=0.32). 
4.3.3.10 KEAP1 
One polymorphism was selected for KEAP1. A synonymous SNP rs1048290 was 
selected (Figure 4.12). Using Haploview, KEAP1 consisted of two haplotype blocks. 
Each block represented a region of the KEAP1 gene. One tag SNP (rs1048290) selected 
was in LD (r
2
>0.9) with one SNP that was able to determine the common (>10%) 
haplotype (Figure 4.12). The polymorphism was genotyped by allelic discrimination. 
There was no differences in carriage of the variant allele between the mild fibrosis and 
severe fibrosis groups (p=0.88) (Figure 4.3). TDT was performed on the Italian families 
(Table 4.4). There was no preferential transmission of any allele to the affected child 
(p=0.42). There were no differences between frequencies of haplotypes generated 
compared against frequencies from HapMap CEU (p=0.8). 
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Figure 4.9: Four polymorphisms were selected and their positions are illustrated in the NRF1 gene. Haploview 
identified 8 haplotype blocks in NRF1. Each block covers a region of the NRF1 gene represented with dotted 
lines. The dark lines between the blocks indicate strength of the LD between haplotypes from different blocks. 
The r2 number (1.0) between blocks indicates complete LD between alleles across different blocks. Two tag 
SNPs illustrated with red arrows in block one were selected to identify the common (>10%) haplotypes.  
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Table 4.9: NRF1Haplotype frequencies comparing both Newcastle and HapMap 
 
 
 
 
 
 
Chi-square test analysing the differences between frequencies of the Newcastle and 
HapMap populations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Newcastle 
frequency 
HapMap 
frequency 
P-value 
NRF1    
AG 0.73 0.465 
0.65 
GG 0.145 0.225 
AA 0.097 0.133 
GA 0.018 NA 
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Figure 4.10: Five polymorphisms were selected for NRF2 and their positions in the NRF2 gene are illustrated. 
Haplotypes obtained from Haploview showing 5 Haplotypes with their frequencies, all 5 were common (>10%) 
haplotypes. Four tag SNPs indicated with arrows were sufficient to determine these common haplotypes.  
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Figure 4.11: A) 2% agarose gel showing NRF2 rs10183914 digested with HphI. Lane 2 showing heterozygous 
(CT), and lane 3 wild type (CC) and lane 4 mutant (TT). B) 10% acrylamide gel showing NRF2 rs2364722 
digested with RsaI. Lane 2 shows heterozygous (AG), lane 3 mutant (GG) and lane 4 wild type (AA). C) 2% 
agarose gel showing NRF2 rs6721961 digested with HaeII. Lane 2 shows heterozygous (CT), lane 3 wild type 
(CC) and lane 4 mutant (TT). D) 2% agarose gel showing NRF2 rs1806649 digested with Bpu10I. Lane 2 
shows heterozygous (CT), lane 3 wild type (CC) and lane 4 mutant (TT). 
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Table 4.10: NRF2 Haplotype frequencies comparing both Newcastle and HapMap 
 
 
 
 
 
 
Chi-square test analysing the differences between frequencies of the Newcastle and 
HapMap populations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Newcastle 
frequency 
HapMap 
frequency 
P-value 
NRF2    
TTTA 0.235 0.292 
0.32 
CTCG 0.265 0.275 
CTCA 0.227 0.183 
TTCA 0.087 0.117 
CCCA 0.117 0.100 
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Figure 4.12: One SNP was selected for KEAP1 and its position in KEAP1 Gene is illustrated. Haplotypes 
obtained from Haploview showing 3 haplotypes with their frequencies, only 2 were common (>10%) 
haplotypes. One tag SNP indicated with arrow was sufficient to determine these common haplotypes.  
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4.3.4 Gene-Gene interaction 
SNPs were selected based on their apparently significant functional effects in published 
studies and were analysed for gene-gene interaction. SOD2, GPX1, GCLC and GCLM 
SNPs were analysed. Interaction was examined between two SNPs at one time (SOD2 
and GPX1), (SOD2 and GCLC), (SOD2 and GCLM), (GPX1 and GCLC), (GPX1 and 
GCLM) and (GCLC and GCLM). Of the six interactions performed only SOD2 with 
GCLC and SOD2 with GCLM were significant (Table 4.11).  
The results for SOD2 and GCLC showed a significant interaction (P for interaction = 
0.0008) (Table 4.4). In table 4.11 the GCLC CC and the SOD2 Ala/Ala were set as the 
base (OR = 1) for comparison with the other genotype combinations. The highest risk 
for having the disease is seen in individuals with the SOD2 Ala/Ala and GCLC CT/TT 
with an OR of 5.5 (95% CI 1.62-18.5).  Individuals with SOD2 Ala/Val or Val/Val and 
GCLC CC also have a higher risk (OR = 2.565 (95% CI 1.36-4.9)). Individuals with low 
enzyme activity SOD2 Ala/Val or Val/Val and low promoter activity GCLC CT or TT 
appeared to show a slightly lower risk but this may not be different to the overall risk 
for possession of the val-SOD2 (OR = 1.5 (95% CI 0.7- 3.3)). 
The results for SOD2 and GCLM showed a significant interaction (p for interaction 
0.003) (Table 4.11). In table 4.11 SOD2 Ala/Ala and GCLM CC were set as the base 
(OR=1) to compare with the other combined groups. The SOD2 (Ala/Ala) GCLM 
(CT+TT) combination appeared to be protective against disease (OR=0.1(95% CI 0.03-
0.78)) with the highest risk found in the SOD2 (Ala/Val) and GCLM (CT+TT) group 
(OR=1.5 (95% CI 0.8-3.2)). 
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Table 4.11: Interaction between variants in SOD2 gene and GCLC and GCLM genes in relation to severity of 
fibrosis (Mild vs. Severe) 
Genotype 
SOD2 rs4880 
Ala/Ala (CC) 
SOD2 rs4880 Ala/Val + 
Val/Ala (CT+TT) 
P for 
interaction 
 OR 95% CI OR 95% CI  
GCLC rs17883901    
CC 1 5.5 (1.6-18.5) 
0.0008 
CT+TT 2.5 (1.3-4.9) 1.5 (0.7-3.3) 
GCLM rs41303970    
CC 1 0.1 (0.03-0.8) 
0.003 
CT+TT 1.1 (0.6-2.04) 1.5 (0.8-3.2) 
P-value for overall interaction of the different groups compared to the base group (OR 
=1)   
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4.4 Discussion  
We examined the association of 25 SNPs and one TA repeat in 10 genes involved in 
defence against ROS. Between the 26 polymorphisms none appeared to be associated 
with severity of NAFLD in the Newcastle and Italian family samples after Bonferroni 
correction. Prior to the Bonferroni correction three SNPs, GCLC C-129T (rs17883901) 
and NRF1 rs7796553 and rs10245818 appeared to show a borderline significance.  
A non-synonymous Pro198Leu polymorphism was investigated in the GPX1 gene that 
encodes for the enzyme GPX1 involved in detoxifying the product (H2O2) of SOD2 into 
H2O. Results showed no significance in both the Newcastle and Italian family samples. 
In contrast, Kuzuya and colleagues study on 2233 randomly selected, community-
dwelling, middle-aged and older Japanese people found the CT and TT genotypes of the 
Pro198Leu polymorphism associated with anthropometric and metabolic variables such 
as the waist-hip ratio (WHR), triacylglycerol concentrations, immunoreactive insulin 
(IRA), homeostasis model assessment of insulin resistance (HOMA-IR) and body fat 
mass. The study also found men with high WHR and waist circumference without any 
difference in BMI or body fat mass suggests that CT and TT to be associated with 
central obesity [Kuzuya et al., 2008]. Such a  suggestion agrees with the hypothesis 
from Farrell and Larter which suggests that many individuals that are not obese based 
on BMI have central obesity which had a stronger association with NASH than overall 
obesity [Farrell and Larter, 2006]. [Kuzuya et al., 2008] found an association with 
higher prevalence of metabolic syndrome (defined according to International Diabetes 
Federation and National Education Cholesterol Program criteria) in men. The study was 
done on Japanese population and on 2233 samples which may be the reason for such 
difference with our study [Kuzuya et al., 2008]. Sutton and colleagues used 
combinations of SOD2 and GPX1 genotypes and found that ALD patients with two val-
SOD2 alleles and two pro-GPX1 alleles had a lower risk for developing HCC [Sutton et 
al., 2006]. However such a result can be a chance observation due to the small sample 
size (n=162) in this study [Sutton et al., 2006]. Our gene-gene study did not show an 
interaction between both the SOD2 and GPX1 variants which may be due to the sample 
size studied for gene-gene interaction was relatively small (n=330) for such type of 
analysis. However, though some patients with severe NAFLD may develop HCC in the 
future, it was not possible to do a comparable study in the present patient cohort. 
We investigated two common variations in the genes encoding for the subunits (GCLC 
and GCLM) of GCL, the rate limiting enzyme of GSH. There was no association found 
93 
 
between the GCLC C-129T and severity of NAFLD in the Newcastle samples. However 
a borderline association was found in the Italian family samples. The T-allele was found 
to be preferentially transmitted from the parents to the effected children. Such 
conflicting results between the two cohorts could be a spurious result due to chance. 
Spurious results are commonly found in genetic association studies which require the 
need of replication studies [Hong et al., 2004]. A possible reason could also be due to 
the difference in the region between the two cohorts (UK and Italy) and therefore 
differences in environmental factors could mean that all factors affecting disease are not 
the same. In addition, NAFLD in children may have some differences to NAFLD in 
adults [Schwimmer et al., 2005]. Ideally, we would have performed the TDT studies in 
trios involving the UK-based adults NAFLD patients and their parents but it is very 
difficult to find such trios due to the typical NAFLD patients being 50 to 60 years old. 
The selection of extreme phenotypes has shown to be a powerful study design for 
stronger association studies [Zhang et al., 2006]. The children selected for our study 
with fibrotic NAFLD might exhibit such extreme phenotype leading to the explanation 
of this association. However, recently the T-allele was found to be associated with 
NASH compared to simple steatosis in 131 patients from Brazil [Oliveira et al., 2010]. 
This association found in Brazil and not in Newcastle cohorts could be due to difference 
in region and sample size between the two studies and that a larger cohort is required for 
replication. The association found in the Brazil study is consistent with the T-allele 
being associated with lower promoter activity [Koide et al., 2003], but this still remains 
debatable [Butticaz et al., 2011]. No association was found between the GCLM C-588T 
promoter polymorphism and severity of NAFLD. The C-588T polymorphism was 
reported to be associated with increased risk of myocardial infarction which was 
consistent with the T-allele showing 40% to 50% lower promoter activity compared 
with the C-allele [Nakamura et al., 2002].  
Similarly to our other findings discussed above, we found no association between SNPs 
in the GSR, MAT1A, HMOX1 and UGT1A1 and severity of NAFLD. Our genotyping on 
the TA repeat variant of UGT1A1*28 was not found to be associated to NAFLD 
severity which was consistent with the study on 234 Taiwanese children with NAFLD 
[Lin et al., 2009]. Likewise, we did not find any association with genes encoding for 
transcription factors NRF1 and NRF2-KEAP1, although prior to Bonferroni correction 
two SNPs rs10245818 and rs7796553 which were found to be in LD (r
2
=0.86) in the 
NRF1 gene showed a borderline association with NAFLD severity. This was consistent 
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with [Gaulton et al., 2008] study, where rs7796553 was found to be associated with 
susceptibility to type 2 diabetes prior to Bonferroni correction.   
Though the various tag SNPs we selected did not show any association with severity of 
NAFLD, the common haplotypes they tag were the same common haplotypes identified 
by samples from HapMap CEU. There were no significant differences in frequencies of 
haplotypes between the Newcastle and HapMap CEU cohorts. Ideally, control cohorts 
from the UK should also have been used for comparison but it was not feasible to obtain 
a control population without NAFLD.  
Complex diseases involve multiple genes and their interactions. Epistasis is defined as 
one gene (epistatic gene) masking the effect of another (hypostatic gene) which may 
result in determining a specific phenotype [Van Steen, 2011;de Visser et al., 
2011;Cordell, 2002]. There are two types of epistasis; synergistic (increase activity) and 
antagonist (suppressing activity). There have been studies of epistasis in NAFLD 
related diseases such as diabetes and obesity [Neuman et al., 2010;Ochoa et al., 2004]. 
In type 2 diabetes patients gene-gene interaction resulted in higher risk of disease 
between four genes with prior evidence of association with diabetes [Neuman et al., 
2010]. Gene-gene interaction was observed between two genes influencing fat 
accumulation and found in the aetiology of obesity [Ochoa et al., 2004]. The interest in 
gene-gene interaction has increased in the past decade with the availability of large data 
sets and statistical software available to analyse such interaction [Cordell, 2009]. We 
have therefore examined the interactions between four common SNPs suggested to have 
a functional role in SOD2, GPX1, GCLC and GCLM. Between the six interactions 
studied only the combined SOD2 and GCLC, and SOD2 and GCLM showed an 
interaction. Our gene-gene results supports and is consistent with the biological 
mechanisms involving the enzymes SOD2, GPX1 and GCLC which are involved in O2
-
 
being dismutated by SOD2 into H2O2 and then detoxified by GPX1 and its co-factor 
GSH into H2O. Oestergaard and colleagues studied the interaction of 10 genes encoding 
proteins in the antioxidant defence system and breast cancer [Oestergaard et al., 2006]. 
SOD2 and GPX1 were among the genes studied for the gene-gene interaction on 2271 
cases and 2280 controls. However there was no evidence of interaction among the 10 
genes studied. The authors suggested that such lack of association may be due to the 
lack of statistical power. Since our study is considerably smaller than that from 
[Oestergaard et al., 2006], it is clear that our power to detect gene-gene interactions is 
also limited and our positive findings could be chance observations. Replication on a 
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larger sample size is required to confirm the interactions. However, our finding does 
appear biologically plausible and it seems more likely that oxidative stress genes could 
be important in overall susceptibility to advanced NAFLD compared with breast cancer. 
In summary, we failed to see any strong associations between NAFLD severity and the 
genotypes described in this Chapter. Lack of association may be due to the limited 
number of genes that had functional significant polymorphisms available to assess. The 
information available on the majority of genes selected for this study was limited and 
therefore lead to a tag SNP haplotype approach. However, we must not ignore the 
involvement of oxidative stress and its related genes in susceptibility to NAFLD. There 
are more polymorphisms to be investigated in oxidative stress related genes however 
due to financial restrictions it was not possible to study all. Therefore a larger scale 
study such as GWAS on NAFLD that includes oxidative stress genes is needed.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 5 
Investigation of the functional significance of the 
GCLC C-129T polymorphism
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5 Investigation of the functional significance of the GCLC C-129T 
polymorphism  
5.1 Introduction 
GSH, as explained previously (section 1.7.1.2), is protective during oxidative stress and 
works as a cofactor with GPx1 to detoxify H2O2 into H2O. GCL the rate limiting 
enzyme in synthesis of GSH is composed of two subunits encoded by GCLC and 
GCLM genes. Using deletion mutagenesis Mulcahy and colleagues demonstrated the 
promoter region sequences involved in the up and down regulation of GCLC gene 
activity [Mulcahy et al., 1997]. The 5‟-flanking region of GCLC (-3802 to +465) was 
cloned into pGL3-basic vector and the construct transfected into HepG2 cells. A series 
of deletions generated various reporter constructs which were transfected into the 
HepG2 cells and tested for reporter activity. The results showed that the region between 
-202 and +22 influenced the levels of expression and that deletion of this region resulted 
in a significant reduction in reporter gene activity and that further deletion (to +358) 
resulted in complete elimination of promoter activity. Results also showed other 
regulating elements such as ARE and AP-1 sequences and transcription binding 
sequences were found present in the -3802 to +465 sequence of GCLC (Figure 5.1). 
In 2003 Koide and colleagues identified two polymorphisms (A-3506G and C-129T) in 
the GCLC promoter region. The T allele of C-129T polymorphism was found to be 
associated with increased risk of myocardial infarction (p=0.03) and was also found to 
be associated with lower transcriptional activity using a reporter gene assay [Koide et al., 
2003]. Another polymorphism, a GAG trinucleotide repeat (TNR) polymorphism 
located downstream of the transcription start site in the 5`-untranslated region (5`-UTR) 
has been found to be associated with age of onset of type I diabetes and in LD with the 
C-129T polymorphism [Bekris et al., 2007]. The number of repeats varies from 4 to 10 
repeats and it is estimated that 90% of the general population have a 7 or 9 GAG repeat 
[Walsh et al., 2001]. Though not explicitly stated in any article, it seems likely that T-
129 variant is in linkage disequilibrium with the 7 GAG repeat allele, based on the 
report that 42% of a small group with a 7/7 repeat genotype were heterozygous for C-
129T [Bekris et al., 2007] [Butticaz et al., 2011]. The originally reported upstream 
sequence shows a C at position -129 combined with 7 TAG repeats [Mulcahy et al., 
1997]. GSH content has been suggested to be influenced by the number of GAG repeats, 
however not all results are consistent [Walsh et al., 2001;Gysin et al., 
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2007;Nichenametla et al., 2008]. Butticaz and colleagues recently examined the 
functional significance of the GAG TNR using a reporter gene assay by cloning the 
region including the repeats downstream of a SV40 promoter but upstream of a 
luciferase coding sequence. When a 7 repeat sequence was combined with T-129, lower 
luciferase activity was seen compared with all other combinations [Butticaz et al., 2011].  
A very recent study which considered the TNRs only also found higher luciferase 
activity associated with 8 and 9 repeats compared with 7 [Nichenametla et al., 2011].  
In view of the genotyping data presented in chapter 4 showing a significant association 
for the T-129 allele with NAFLD in the Italian families, though no significance in the 
adult cohort, we decided to further assess the functional significance of this SNP alone 
by studying the region upstream of the transcription start site by reporter gene assays. 
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Figure 5.1: 5’-flanking region of GCLC showing the transcription start site (+1), the C-129T polymorphism 
and the GAG repeat. 
 
 
 
 
 
 
101 
 
5.2 Methods 
5.2.1 Insert Design 
792 base pairs upstream of the transcription start site (where +1 is the transcription start 
site) was introduced to the pGL3 basic vector. The area contained a TATA box and the 
C-129T GCLC polymorphism. KpnI and SacI restriction enzymes determined the 
orientation of the insert into pGL3 vector by introducing restriction sites into the 
primers. The 792 base pairs were amplified using the primers: 5‟-
TTTCGGTACCAGATAAGGCCAACTCTAGGT-3‟ and 
5‟CTGGGAGCTCCCTGCGCTCCAGGTTTTATA-3‟. The bold type indicates the 
GCLC sequence. PCR was performed on two DNA samples, one with the -129TT and 
other -129CC genotypes which resulted in the two different constructs.  
5.2.2  Purification of PCR product for cloning 
DNA was amplified by PCR according to methods described in chapter 2. The 
annealing temperature used was 66
o
C. PCR products were run on a 2% agarose gel. A 
scalpel was used to remove the bands from the agarose gel on a UV transilluminator. A 
QIAGEN clean up kit was then used to purify the PCR products. The PCR product was 
ligated into a pGEM T-easy vector according to the manufacturer guidelines (Promega). 
5.2.3  Ligation and Transformation  
Ligation reaction was set up using 5 µl of 10x T4 ligation buffer, 1 µl of 50 ng T-easy 
vector, 1 µl T4 DNA ligase and 10 µl of PCR product. Reactions were incubated 
overnight at 4
o
C.  
Component JM109 E.coli cells (100 µl) were mixed with 10 µl of ligation reaction in a 
1.5 ml tube on ice for 20 minutes. The mixture was then heat shocked for 55 seconds in 
42
o
C in a water bath and placed on ice for 2 minutes. Sterile SOC medium (0.5% yeast 
extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgSO4, 10 mM MgCl2, 20 
mM glucose) was prepared and 900 µl was added to the tubes. Tubes were then 
incubated for 1.5 h with shaking at 37
o
C at 150 rpm.  
Transformed cells (100µl and 200µl) were then spread onto duplicate LB agar plates 
which had been overlaid previously with 100µl of 10µg/ml ampicillin and 20µl of 
0.03mg/ml X-gal and 0.3mM IPTG and then incubated overnight at 37
o
C. 
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5.2.4 Plasmid DNA extraction 
White colonies were picked by sterile pipette tips into 10 ml of LB medium containing 
100µg/ml ampicillin in universal tubes and incubated on an orbital shaker at 150 rpm at 
37
o
C overnight. The bacterial culture (1.5 ml) was then centrifuged at 13000 x rpm in 
1.5 ml eppendorf tube to pellet cells which were then used to extract plasmid DNA 
using a QIAGEN miniprep plasmid extraction kit.     
5.2.5 Preparation of GCLC promoter-pGL3 constructs 
Both the pGEM T-easy vector containing the insert and pGL3-vector were digested 
with both KpnI and SacI (2U in 10x buffer and 1% BSA for 3h) in separate tubes. 
Digests were then run on 2% agarose gels. Both inserts and pGL3 digested vector were 
extracted and ligation and transformation was performed as before. The pGL3-insert 
were then extracted and purified again. To confirm the presence of the pGL3 and insert 
we digested 5 µl of plasmid DNA with KpnI and SacI as above and ran the samples on a 
2% agarose gel (Figure 5.2). Plasmid DNA was then sent for sequencing (Eurofins 
MWG, UK) to confirm that the variation was only found at position -129 and not 
elsewhere. Primers for sequencing were supplied by Eurofins MWG and the plasmid 
DNA concentration was adjusted to 50-100 ng/µl.   
5.2.6 HepG2 and LS180 tissue culture 
HepG2 cells (hepatocellular carcinoma cell line) were supplied by Fiona Fenwick, 
Institute of Cellular Medicine, Newcastle University. LS180 (colon cancer cell line) 
were obtained from European collection of cell cultures (ECACC) (Porton Down, UK). 
Cells were cultured in 75cm
2
 filtered flasks with 90 ml sterile distilled H2O, 10 ml of 
10x Minimum Essential Medium – Eagles (EMEM) (Bio Whittaker) supplemented with 
10 ml of 10% heat-inactivated calf serum, 1 ml of 100U/mL penicillin and 100 µg/ml 
streptomycin, 1 ml of 200 mM L-Glutamine, 1 ml of non-essential amino acid and 5 ml 
of 4.4% gassed sodium bicarbonate containing 0.4% phenol red. Flasks were incubated 
at 37
o
C with 5% CO2. Confluent cells were split to 1:3 ratio every five days. Medium 
was removed and discarded. Cells were washed with PBS and 0.25% trypsin in Ca
2+
 
and Mg
2+
 free PBS with 0.02% EDTA at 37
o
C was used to detach cells from flasks.  
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Figure 5.2: 2% agarose gel of pGL3 GCLC promoter plasmid DNA digested with SacI and KpnI. The upper 
band shows the linearised vector and the lower band shows the -129 insert. 
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5.2.7 Seeding cells 
Cells were seeded into 24-well plates at a density between 4x10
-4
 cells/ml per well in 
complete medium to reach 50-80% confluence overnight. Medium was replaced with 
200 µl of full fresh EMEM per well. 
5.2.8 Cell Transfection and treatment 
GeneJuice (Merck, Nottingham, UK) was used with serum free medium for transfection. 
Serum free medium (100 µl) and 1.5 µl of GeneJuice was vortexed and incubated at 
room temperature for 5 minutes before adding 0.5 µg of the pGL3-promoter vector or 
pGL3-empty vector and 0.05 µg of Renilla control vector per well. This master mix was 
then left for 20 minutes at room temperature before adding 100 µl of master mix to the 
existing 200 µl fresh EMEM in the wells. Cells were then left overnight before 
replacing the transfection reagent with 1ml of fresh complete medium. Once cells were 
transfected they were left for 72 h before setting up luciferase reporter assay. One hour 
prior to performing the luciferase assay, cells were treated with 100 µM H2O2 for 1h. 
5.2.9 Luciferase reporter assay readings 
Medium was removed and surface of the wells were washed with sterile PBS before 
adding 100 µl of passive lysis buffer (PLB) (Promega). Wells were left with PLB for 
15-20 minutes at room temperature on a shaker to ensure even coverage of PLB and to 
disrupt the cells. Luciferase assay reagent II (LAR II) (100 µl) was added to 1.5 ml 
microcentrifuge tubes containing 20 µl of cell lysate. Cells were mixed thoroughly by 
pipetting before taking the initial reading (Firefly Luciferase). Stop and Glo reagent 
(100 µl) was then added and vortexed for the second reading (Renilla Luciferase).  The 
luminometer (Turner Biosystems) was set up to perform a 2 second delay followed by 
10 second measurement according to the Dual-Luciferase reporter assay protocol 
(Promega). 
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5.3 Results 
5.3.1 Sequencing  
The sequencing results showed that each construct only varied at the -129 position. All 
other SNPs in the region were found to be the same in each construct and all were wild-
type (Figure 5.3A and 5.3B).  
5.3.2 Luciferase reporter assay 
The first measurement taken was the Firefly luciferase activity. The second reading was 
Renilla luciferase activity which were then normalised by Firefly/Renilla. Normalised 
readings for each sample were expressed as a fold increase and compared to that of the 
pGL3-empty vector. Results of the control vector (pGL3-empty) transfected into the 
cells showed small or no sign of reporter activity. Average normalised reporter gene 
activity for pGL3-T was 51.3 ± 3 fold greater than pGL3-empty (Figure 5.4). For C, the 
average normalised reporter activity was 59 ± 4.2 fold greater than pGL3-empty (Figure 
5.4). To determine the difference between the pGL3-T and pGL3-C reporter gene 
activity a two-tailed t-test was performed. The slight difference was not found to be 
significant (p=0.3). 
HepG2 cells were also treated with H2O2 for an hour before measuring the reporter 
activity. Measurements and analysis were similarly done to that of the untreated cells. 
The average normalised reporter activity for pGL3-T-H2O2 was 45.8 ± 2.3 fold greater 
than the pGL3-empty-H2O2 (Figure 5.5). The average normalised reporter activity for 
pGL3-C-H2O2 was 51.5 ± 1.5 fold greater than the pGL3-empty-H2O2 (Figure 5.5). 
There was no significant difference between the pGL3-T-H2O2 and pGL3-C-H2O2 
reporter activity (p=0.3). 
Reporter activity was also tested on a different cell line (LS180). The results appeared 
to be similar to that of HepG2 cell line. The average normalised activity for pGL3-T-
LS180 was 16.5 ± 1.1 fold greater than pGL3-empty-LS180 (Figure 5.6). The average 
normalised reporter activity in pGL3-CC-LS180 was 16.1 ± 0.4 fold greater than pGL3-
empty-LS180 (Figure 5.6). There was no significant difference between pGL3-TT-
LS180 and pGL3-CC-LS180 reporter activity (p=0.7). 
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Figure 5.3: Sequencing results indicating GCLC sequence (in Black) and pGL3-vector sequence (in Blue) with 
variation only in -129. A) T-allele highlighted in red and 8 other SNPs in green. B) C-allele highlighted in red 
and other SNPs in green. No differences found between the other 8 SNPs in the two sequences. 
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Figure 5.4:  Luciferase reporter gene activity normalised to renilla activity, background and empty pGL3 
vector, between a -129 T promoter and a -129 C promoter. T-test (2 tailed) p-value= 0.3 (n=3) 
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Figure 5.5: Luciferase reporter gene activity normalised to renilla activity, background and empty pGL3 
vector, between a -129 T promoter and a -129 C promoter. T-test (2 tailed) p-value= 0.3 (n=3) 
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Figure 5.6: LS180 cells. Luciferase reporter gene activity normalised to renilla activity, background and empty 
pGL3 vector, between a -129 T promoter and a -129 C promoter. T-test (2 tailed) p-value = 0.7 (n=3) 
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5.4  Discussion 
Because of the involvement of GCLC in GSH synthesis described earlier (section 
1.7.1.2), it is important to understand the regulation of the GCLC gene. In this chapter 
we therefore described the reporter activity of the GCLC promoter region sequence that 
included the C-129T polymorphism. This appears to be the first study of the GCLC 
promoter region sequence that did not include transcription binding regulatory 
sequences further upstream and the 5`-UTR previously reported to be involved in gene 
expression as described in other studies [Koide et al., 2003;Butticaz et al., 2011]. The 
objective was to determine the effect of the C-129T SNP directly on gene transcription 
as effects from differences from the GAG repeats in the 5'-UTR may be at the level of 
mRNA stability or at the level of translation. Therefore for this purpose we designed a 
smaller construct (792bp) that only included the C-129T polymorphism compared with 
the larger construct (4267bp) previously studied which included upstream transcription 
binding regulatory sequences and the 5`-UTR that included a GAG TNR as shown in 
figure 5.7 [Koide et al., 2003]. 
Koide and colleagues suggested that the C-129T GCLC polymorphism showed 
functional significance with the luciferase activity for C significantly higher than for T 
[Koide et al., 2003]. However, our reporter gene assay results suggested the -129 
polymorphism had no functional significance. Also, treatment with H2O2 did not 
influence reporter activity between the two constructs in our study conflicting with the 
earlier findings [Koide et al., 2003]. This could be due to our chosen promoter sequence 
construct not including any ARE or AP-1 sequences that could bind nuclear protein 
factors and therefore treatment with H2O2 did not influence reporter activity. Using a 
different cell line did not change the outcome of the reporter activity and the results 
showed no difference between the two constructs.  
On the other hand our study was consistent with another study [Butticaz et al., 2011], 
where they found no differences between T-129 and C-129 constructs. However their 
constructs only had C-129 polymorphisms and therefore a point mutation by site-direct 
mutagenesis was introduced to construct T-129. The study demonstrated a decrease in 
activity only when both 7 GAG TNR and the T-129 were combined compared to the C-
129 constructs.  The GAG TNR is located in the 5`-UTR, a region which has been 
suggested by various studies to be involved in transcriptional mechanisms affecting 
gene expression [Mignone et al., 2002;Chen et al., 2008;Coppotelli et al., 2006]. The 
two very recent published studies involving reporter genes have investigated the activity  
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Figure 5.7: Schematic representation of the PGL3-basic vector constructs showing the location of the C-129T, 
GAG TNR and both ARE and AP sequences. A) Construct used in Koide et al. study included 5`-UTR and a 
large region of the promoter sequence. B&C) Constructs from Butticaz et al. study showing only the 5`-UTR in 
construct B and both 5`-UTR and the large region of the promoter sequence in C. D) Construct from our study 
showing only a smaller region of the promoter sequence.  
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of the GAG TNR without the GCLC promoter region sequence. There are discrepancies 
between them with one reporting no differences for luciferase with respect to the 
number of repeats alone but the other reporting higher luciferase for constructs with 8 or 
9 repeats compared with 7 [Butticaz et al., 2011;Nichenametla et al., 2011]. In addition, 
Butticaz and colleagues measured GCLC protein levels in skin fibroblasts from 
individuals who were homozygous for 7 GAG repeats but had either CC or CT 
genotypes for C-129T. In this case, they found a significantly lower GCLC protein 
content (1.45 fold lower) in cells from individuals with the CT genotype compared with 
the CC genotype using Western blot analysis. A smaller not significant effect was 
obtained for total GSH content though the levels in the CT cells were lower than the CC. 
The discrepancy between our findings and those of Koide et al. and Buttincaz et al. for 
C-129T might be due to factors involved in reporter gene assays. It has been previously 
reported that conflicting and inconsistent results in reporter gene activity in well-studied 
promoter SNPs may be due to the difference in reporter constructs, cell line used and 
transfection techniques reviewed by [Karimi et al., 2009].  
We cannot rule out the interaction between the two polymorphisms (C-129T and GAG 
repeats) recently suggested by [Butticaz et al., 2011]. Ideally it would have been useful 
to have included as controls sequences where differences between constructs would be 
expected and are well established but suitable sequences were not available to me. In 
addition, studies involving a range of different reporter constructs with varying lengths 
of the promoter region would have been helpful. 
My reporter gene assay results shows no evidence that the C-129T polymorphism 
directly influences reporter activity. This result is consistent with the case/control 
genotyping. The apparent preferential transmission of T over C in NAFLD families was 
only of borderline significance and may be a spurious finding. However, it is interesting 
that it is in line with suggestions in the literature that T-containing alleles are associated 
with lower GCLC levels than C-alleles.           
 
 
 
 
  
 
 
 
Chapter 6 
Patatin-like phospholipase-3 (PNPLA3) and 
Apolipoprotein-3 (APOC3) genotypes and their 
association with NAFLD severity 
 
112 
 
6 Patatin-like phospholipase-3 (PNPLA3) and Apolipoprotein-3 
(APOC3) genotypes and their association with NAFLD severity 
6.1 Introduction 
In 2008, a genome-wide association study (GWAS) on the association of genotype with 
hepatic fat content which involved nonsynonymous polymorphisms only found an 
association with a SNP (rs738409) that results in a cytosine to guanine substitution 
encoding for isoleucine to methionine substitution at residue 148 (I148M) in patatin-
like phospholipase-3 (PNPLA3) gene also known as adiponutrin [Romeo et al., 2008]. 
The limited GWAS involved 383 Hispanics, 1032 African-Americans and 696 
European-Americans and hepatic fat content was assessed by magnetic resonance 
imaging. The PNPLA3 G-allele was found to be associated with both  increased hepatic 
fat (p= 5.9 x10
-10
) and elevation of serum alanine aminotransferase (ALT) levels (p= 
1.3x10
-5
) [Romeo et al., 2008]. This was consistent with a separate population-based 
GWAS carried by Yuan and colleagues on plasma liver enzyme levels where variants in 
PNPLA3 predicted ALT levels [Yuan et al., 2008]. The association with liver fat was 
confirmed in two studies with smaller series of histological patients [Kotronen et al., 
2009a] [Sookoian et al., 2009]. Kotronen and colleagues genotyped the I148M variant 
in 291 Finish individuals with hepatic fat measured by proton magnetic resonance. The 
G-allele was found associated with increased liver fat (p=0.01) [Kotronen et al., 2009a]. 
Sookoian and colleagues on the other hand studied 103 biopsy-proven NAFLD and 
found the G-allele to be associated with severe steatosis (P<0.005) [Sookoian et al., 
2009]. The exact function of PNPLA3 is still controversial, however it is localised in 
adipose tissue and in liver and suggested to be functionally involved in both lipolysis 
and lipogenesis with the Met variant apparently associated with decreased catalytic 
activity [Romeo et al., 2010b] [Zimmermann et al., 2009] [He et al., 2010].  
Lipoproteins are complexes of lipids (TG, cholesterol and phospholipids) and proteins 
known as apolipoproteins (APOC) [Mahley et al., 1984].  The different classes of 
lipoproteins (Chylomicrons, Chylomicron remnants, VLDL, and HDL) are involved in 
transport and distribution of lipids in cells and tissues [Mahley et al., 1984]. The APOC 
family play an important role in regulating lipoprotein metabolism [Mahley et al., 1984]. 
APOC3 is synthesised in the liver and the intestine and its main function is to regulate 
lipolysis through inhibition of hydrolysis enzymes (Lipoprotein Lipase and hepatic 
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lipase) [Bruns et al., 1984;Karathanasis, 1985;Ooi et al., 2008]. Studies have found that 
insulin is involved in regulating APOC3 [Li et al., 1995a;Chen et al., 1994] which 
suggests the dysregulation of APOC3 during diseases linked with insulin resistance. 
Two common APOC3 polymorphisms T-455C and C-482T have been found to 
influence insulin resistance, lipid metabolism and susceptibility to NAFLD in a 
relatively small (n=95) study of Indian men [Petersen et al., 2010]. 
The aim of the work described in this chapter is to replicate the association of PNPLA3 
I148M variant with steatosis and to assess its relationship to severity of fibrosis. The 
effect of the APOC3 promoter region polymorphisms (T-455C and C-482T) on the 
severity of NAFLD in UK patients is also assessed.  
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6.2 Methods 
6.2.1 PNPLA3 and APOC3 SNP selection 
The non-synonymous PNPLA3 rs738409 polymorphism (I148M) was selected due to its 
association found in GWAS [Romeo et al., 2008]. Both APOC3 rs2854116 (T-455C) 
and rs2854117 (C-482T) were selected due to the association with NAFLD reported 
previously [Petersen et al., 2010]. 
6.2.2 PNPLA3 rs738409 genotyping assay 
PCR-RFLP was used to genotyped for rs738409. The forward and reverse primers were 
(5`-CTGCTCACTTGGAGAAAGCT-`3 and 5`-TGAAAGGCAGTGAGGCATGG-`3) . 
PCR amplification (35 cycles of denaturation at 95
o
C for 1 minute, annealing at 57
o
C 
for 1 minute and extension at 72
o
C for 1 minute) was then performed in a GeneAmp 
PCR system 9700 thermal cycler. PCR products were digested with BtsCI. The PCR 
digestion products were viewed on a 2% agarose gel. 
6.2.3 APOC3 rs2854116 and rs2854117 
APOC3 genotyping was initially performed by Julian Leathart using the CVD53 multi-
locus genotyping assay (Roche Molecular Diagnostic) published previously by [Cheng 
et al., 1998] and by PCR-RFLP previously published by [Hegele et al., 1997] which was 
performed as part of the present study. The forward and reverse primers (5'- 
TGTAACCAGGCCTTGTCGGA -3' and 5'-TTTCACACTGGAAATTTCAGG-3) were 
used to assess both SNPs. PCR amplification (35 cycles of denaturation at 95
o
C for 1 
minute, annealing at 57
o
C for 1 minute and extension at 72
o
C for 1 minute) was then 
performed in GeneAmp PCR system 9700 thermal cycler. PCR products were digested 
with MspI for C-482T and FokI for T-455C). PCR digestion products were viewed on a 
2% agarose gel. 
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6.3 Results 
6.3.1 PNPLA3 
The PNPLA3 rs738409 polymorphism was genotyped by PCR-RFLP with a typical 
result shown in Figure 6.1. Genotypes were in Hardy-Weinberg equilibrium (X
2
=0.36, 
p=0.54). The relationship between genotype and severity of steatosis was analysed 
(Table 6.1). Incidence with severe steatosis (Grade 2+3) was 59% in patients carrying 
the G-allele compared to 41% homozygous wild type (CC) with an odds ratio 1.87 
(95%CI 1.15 – 3.04; p=0.01). There was difference in genotype frequencies between 
mild fibrosis and severe fibrosis (Table 6.2). 28% of mild fibrosis patients carried the 
CC genotype in comparison with only 19% of severe fibrosis patients. However the GG 
genotype was found to be lower in mild fibrosis patients with only 20% compared with 
30% of severe fibrosis patients (chi-square for trend p=0.0007). Carrying the G-allele 
was found to be associated with development of severe fibrosis with an OR of 2.02 
(95% CI 1.29 – 3.1; p=0.002).  
The TDT on the Italian families showed 56 out of 71 families showed at least one 
parent to be heterozygous. In these families the G-allele was transmitted on 52/76 
(68%) occasions compared with the C-allele which was only transmitted on 24/76 
(32%) occasions from both or at least one heterozygous parents to the affected child 
(p=0.001) (Table 6.3).  
Multivariate analysis using logistic regression was performed on the Newcastle NAFLD 
samples to control for the effect of factors such as Genotype, age, sex, BMI, diabetes, 
steatosis and NASH that are relevant to disease severity (steatosis severity and fibrosis 
severity). The multivariate results demonstrated PNPLA3 genotype was a predictor for 
severe steatosis with an odds ratio 1.8 (95% CI 1.09-2.99; p=0.021) (Table 6.4A). The 
multivariate results demonstrated PNPLA3 genotype was a predictor for severe steatosis 
with an odds ratio 1.8 (95% CI 1.09-2.99; p=0.021) (Table 6.4A). PNPLA3 genotype 
did not reach significance for predicting of NASH and severity of fibrosis (p=0.05 and 
p=0.06 respectively) (Table 6.4B and C). 
6.3.2 Multivariate analysis combining PNPLA3, SOD2, KLF6 and ENPP1 
genotypes  
PNPLA3, SOD2 previously described (Chapter 3) and previously published significant 
findings of KLF6 [Miele et al., 2008] and ENPP1 [Dongiovanni et al., 2010] on the UK 
cohort were analysed to predict the factors involved in severe fibrosis (Table 6.5). 
116 
 
PNPLA3, SOD2 and KLF6 genotypes were found to be predictor factors for severity of 
fibrosis (p=0.03, p=0.001 and p=0.03 respectively) (Table 6.5). BMI, Diabetes and 
NASH were also found to be predictor factor for severity of fibrosis (Table 6.5). 
6.3.3 APOC3  
The promoter region polymorphisms of APOC3 rs2854116 (T-455C) and rs2854117 
(C-482T) were genotyped by CVD53 multi-locus and PCR-RFLP genotyping with a 
typical result for the latter shown in Figure 6.2A and B respectively. Genotypes were in 
Hardy-Weinberg equilibrium (X
2
=0.61, p=0.43 for T-455C and X
2
=0.008, p=0.92 for 
C-482T). The relation between genotype and severity of steatosis and fibrosis was 
analysed (Table 6.6 and Table 6.7 respectively). There was no difference in genotype 
frequency between mild steatosis and severe steatosis for both SNPs (p=0.9 and 0.6 
respectively). There was also no difference in genotype frequency between mild fibrosis 
and severe fibrosis for both SNPs (p=0.4 and 0.9 respectively). LD between the two 
SNPs was moderate (r
2
=0.5). The combined genotypes of both SNPs in relation to 
severity of steatosis and severity of fibrosis were analysed (Table 6.8 and 6.9 
respectively). There was no significant difference between the combined wild type 
genotypes (TT and CC) against the remaining combined genotypes in relation to 
steatosis and fibrosis (p=0.46 and p=0.75 respectively) (Table 6.8 and 6.9).  
The TDT showed 66 out 71 families to be at least heterozygous for one of the parents 
for T-455C polymorphism. In these families the T-allele was found to be transmitted on 
43/66 (69%) occasion compared with the C-allele which was transmitted only 23/66 
(31%) occasions, p=0.02 (Table 6.8). The TDT for C-482T polymorphism showed 61 
out of 71 families to be informative. The T-allele was transmitted on 25/61 (41%) 
occasions compared with the C allele 36/61 (59%) occasions p=0.2 (Table 6.10). 
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Figure 6.1: 2% agarose gel showing PNPLA3 rs738409 digested with BsaWI. Lane 1 shows homozygous 
mutant (GG), Lane 2 shows heterozygous (CG) and Lane 3 shows homozygous wild type (CC).  
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Table 6.1: PNPLA3 genotype distribution in Newcastle NAFLD patients in relation to steatosis severity 
Gene and SNP 
 
Genotype 
Steatosis 0+1 
(n=95) 
Steatosis 2+3 
(n=226) 
PNPLA3 
rs738409 
CC 53 (0.55) 91 (0.41) 
CG 34 (0.36) 104 (0.45) 
GG 8 (0.09) 31 (0.14) 
OR 1.87 (95% CI 1.15 – 3.04); p=0.01 
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Table 6.2: PNPLA3 genotype distribution in Newcastle NAFLD patients in relation to fibrosis severity 
Gene and SNP 
 
Genotype 
Fibrosis 0+1 
(n=188) 
Fibrosis 2-4 
(n=143) 
PNPLA3 
rs738409 
CC 98 (0.28) 50 (0.19) 
CG 74 (0.53) 69 (0.51) 
GG 16 (0.20) 24 (0.30) 
OR 2.02 (95% CI 1.29 – 3.16); p=0.002 
Chi-square for trend p=0.0007 
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Table 6.3: PNPLA3 transmission disequilibrium test, comparing the distribution on the transmitted and 
untransmitted allele from heterozygous parents to affected child  
Gene and SNP number Allele Transmitted Untransmitted p-value 
PNPLA3 rs738409 C 24 (32%) 52 (68%) 0.001 
G 52 (68%) 24 (32%)  
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Table 6.4:  Multivariate analysis of PNPLA3 using logistic regression for liver damage to control for predictor 
variables affecting severity of disease  
A. Steatosis 0+1 vs. 2+3 
Variables for OR (95% CI) p-value 
PNPLA3 1.80 (1.09-2.99)           0.021 
Age 0.97 (0.95-0.99)   0.025 
Sex 0.68 (0.39-1.19)     0.182 
BMI 1.04 (0.99-1.10)          0.080 
Diabetes 1.19 (0.70-2.06)       0.513 
PNPLA3 and Age found to be predictor factors  
B. NASH (0 vs 1)  
Variables for  OR (95% CI) p-value 
PNPLA3 1.62 (0.98-2.66)     0.05 
Age 1.0 2 (1.00-1.04)   0.04 
Sex 0.96 (0.55-1.69)          0.91 
BMI 1.04 (0.99-1.09)    0.08 
Diabetes 2.21 (1.30-3.81)       0.003 
Age and diabetes found to be predictor factors  
C. Fibrosis (0+1 vs 2-4) 
Variables for  OR (95% CI) p-value 
PNPLA3 1.79 (0.96-3.35)                   0.063 
Age 1.03 (1.01-1.06)   0.004 
Sex 1.37 (0.69-2.73)    0.358 
BMI 1.06 (1.00-1.13)  0.031 
Diabetes 2.13 (1.14-4.01)   0.017 
Age, BMI and diabetes found to be predictor factors  
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Table 6.5: Multivariate analysis combining PNPLA3, SOD2, KLF6 and ENPP1 in relation to severe fibrosis 
(0+1 vs. 2-4) and to control for predictor variables 
Variables for  OR (95% CI) p-value 
SOD2 2.3 (1.41 – 4.19) 0.001 
PNPLA3 2.2 (1.09 – 4.66) 0.03 
KLF6 0.28 (0.08 – 0.86)  0.03 
ENPP1 1.8 (0.85 – 4.22) 0.11 
Age 1.02 (099 – 1.05) 0.06 
Sex 1.6 (0.62 – 3.02) 0.43 
BMI 1.09 (1.02 – 1.18) 0.009 
Diabetes 2.5 (1.24 – 5.38) 0.011 
PNPLA3, SOD2 and KLF6 genotypes and both BMI and diabetes found to be predictor 
factors for severe fibrosis 
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Figure 6.2: A) 2% agarose gel showing digest of APOC3 T-455C with FokI. Lane 1 shows heterozygous (TC), 
Lane 2 shows homozygous mutant (CC) and Lane 3 shows homozygous wild type (TT). B) 2% agarose gel 
showing APOC3 C-482T digested with MspI. Lane 1 shows the heterozygous (CT), lane 2 shows the 
homozygous mutant (TT) and lane 3 showing homozygous wild type (CC) 
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Table 6.6: APOC3 genotype distribution in Newcastle NAFLD patients in relation to steatosis severity 
Gene and SNP 
 
Genotype Steatosis 0+1  Steatosis 2+3  
Odd ratio for 
carriage of 
minor allele 
(95% CI) 
P value 
for 
carriage of 
minor 
allele 
APOC3-455 
rs2854116 
TT 35 (0.41) 93 (0.41) 
0.9 (0.6 - 
1.6) 
0.9 TC 40 (0.45) 105 (0.46) 
CC 12 (0.14) 37 (0.13) 
APOC3-482 
rs2854117 
CC 51 (0.58) 125 (0.55) 
1.1 (0.7 – 
1.9) 
0.6 CT 32 (0.36) 85 (0.38) 
TT 5 (0.06) 15 (0.07) 
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Table 6.7: APOC3 genotype distribution in Newcastle NAFLD patients in relation to fibrosis severity 
Gene and SNP 
 
Genotype Fibrosis 0+1 Fibrosis 2-4 
Odd ratio for 
carriage of 
minor allele 
(95% CI) 
P value 
for 
carriage of 
minor 
allele 
APOC3-455 
rs2854116 
TT 78 (0.43) 54 (0.39) 
1.2 (0.76 – 
1.9) 
0.4 TC 79 (0.44) 71 (0.50) 
CC 24 (0.13) 15 (0.11) 
APOC3-482 
rs2854117 
CC 103 (0.57) 80 (0.57) 
0.9 (0.62 – 
1.5) 
0.9 CT 67 (0.37) 52 (0.37) 
TT 12 (0.07) 8 (0.06) 
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Table 6.8: Combination of APOC3 rs2854116 and rs3854117 wild type genotypes compared with all other 
genotypes in relation to steatosis scores 
APOC3 combined 
Genotypes 
Steatosis 0+1 (n=78) Steatosis 2+3 
(n=197) 
TT+CC 
All other 
33 (42%) 
45 (58%) 
93 (49%) 
104 (51%) 
OR 0.82 (95% CI 0.48-1.39); p=0.46 
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Table 6.9: Combination of APOC3 rs2854116 and rs3854117 wild type genotypes compared with all other 
genotypes in relation to fibrosis scores 
APOC3 combined 
Genotypes 
Fibrosis 0+1 (n=163) Fibrosis 2-4 (n=112) 
TT+CC 
All other 
74 (45%) 
89 (55%) 
53 (47%) 
59 (53%) 
OR 0.92 (95% CI 0.57-1.5); p=0.75 
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Table 6.10:  APOC3 transmission disequilibrium test comparing the transmitted and untransmitted allele from 
heterozygous parents to affect child 
Gene and SNP number Allele Transmitted Untransmitted p-value 
APOC3-455 rs2854116 T 43 (69%) 23 (31%) 0.02 
C 23 (31%) 43 (69%)  
APOC3-482 rs2854117 C 36 (59%) 25 (41%) 0.2 
T 25 (41%) 36 (59%)  
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6.4 Discussion 
We examined the association of the PNPLA3 I148M polymorphisms that has been 
identified in a GWAS to be associated with increased levels of fat [Romeo et al., 2008]. 
Our finding that carriage of the G-allele of the PNPLA3 polymorphism is associated 
with severity of steatosis (>1) is consistent with the GWAS finding [Romeo et al., 2008] 
and with a study on 103 biopsied NAFLD patients of European descent from Argentina 
[Sookoian et al., 2009] and a study on a Finnish population with 291 samples with liver 
fat measured by proton magnetic resonance [Kotronen et al., 2009a]. Our association on 
the association of the G allele with severe fibrosis in the adult Newcastle NAFLD 
samples is a novel finding. This was also replicated in a separate Italian cohort and both 
UK and Italian cohorts were combined and the results remained significant [Valenti et 
al., 2010a]. The PNPLA3 variant was found to be a predictor factor for both severe 
steatosis and severe fibrosis. The TDT on the Italian family trios with fibrotic NAFLD 
was consistent and confirmed the finding in the Newcastle samples. A study by Rotman 
and colleagues on Caucasians from the US reported an association of the G-allele with 
both steatosis and fibrosis in 894 biopsy-proven NAFLD samples with reported liver 
histological information [Rotman et al., 2010]. This was the first study to be consistent 
with our study on the association with fibrosis. A Japanese study (253 biopsy-proven 
NAFLD) reported the association of the G-allele with only fibrosis but not steatosis 
[Hotta et al., 2010] but this lack of association with steatosis may be due to differences 
in ethnicity. The I148M variant has also been found to be associated with severity of 
steatosis and fibrosis in children [Valenti et al., 2010b] which is consistent with our 
TDT results where 61 out the 71 children had fibrosis steatohepatitis (59 patients with 
stage 1 fibrosis and 2 patients with stage 2 fibrosis). To date there are 16 published 
studies on the influence of the I148M variant on the susceptibility and histological 
severity of NAFLD dating from 2008 to 2011, according to a meta-analysis study by 
[Sookoian and Pirola, 2011]. This combined study showed that the I148M variant 
influence liver fat accumulation with individuals with GG genotype having 73% higher 
fat compared to CC genotypes and also influences more aggressive disease where the 
GG genotype is 3.24 and 3.2-fold greater risk for developing NASH and fibrosis 
respectively compared with CC genotypes. The study also suggests the additive model 
(CG+GG vs. CC) best explains the effect of the I148M variant [Sookoian and Pirola, 
2011]. In a GWAS on NAFLD performed on females, the 15 SNPs in PNPLA3 that 
were studied did not show any significant association but rs734809 was not among the 
SNPs studied. A SNP in moderate LD (r
2
=0.65) (rs2076211) was included but did not 
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show genome-wide significance [Chalasani et al., 2010]. A recent GWAS however 
found the PNPLA3 rs738409 variant to be associated with increasing computed 
tomography (CT) hepatic steatosis (n=7167) and associated to NASH in subjects with 
biopsy proven NAFLD (n=592) [Speliotes et al., 2011].  
The exact function of PNPLA3 and the functional significance of its non-synonymous 
polymorphism (rs738409) that leads to a C to G substitution resulting in change of 
amino acid from isoleucine (ATC) to methionine (ATG) remain unclear. However it is 
suggested that substitution of methionine for isoleucine inhibits catalytic activity of the 
enzyme causing in appropriate access to substrate [He et al., 2010]. In vitro studies have 
shown that Met-PNPLA3 but not the wild-type Iso-PNPLA3 abolishes the activity of 
TG hydrolysis (lipolysis) resulting in accumulation of hepatic TG content and therefore 
suggesting a loss of PNPLA3 function [He et al., 2010]. However Chen and colleagues 
creation of a Pnpla3 gene-deleted mouse produced by gene targeting resulted in Pnpla3
-
/-
 mouse failure to cause increase in hepatic TG content [Chen et al., 2010] adding 
further mystery to the function of Pnpla3. The human PNPLA3 gene consists of four 
haplotype blocks and is 23kb long. It is possible that there are other genetic variants 
highly linked to rs738409.  
Since PNPLA3 genotype appeared to predict severity of fibrosis and SOD2 is also a 
predictor of fibrosis severity (Chapter 3) and genotype for KLF6 has also been shown to 
predict severity in a separate study using these NAFLD DNA samples [Miele et al., 
2008], the overall contribution of PNPLA3 to severity alongside both SOD2 and KLF6 
genotypes was also assessed. The overall effects of both SOD2 and PNPLA3 are 
broadly similar in terms of odds ratio (approx. 2) though the p value seen for SOD2 is 
lower, possibly because the variant genotype associated with increased risk is more 
common. The effect of the KLF6 variant genotype is different since it decreases fibrosis 
risk but this had a slightly larger effect (approx 3 fold decrease in risk).  
On the other hand, data on APOC3 C-482T and T-455C did not show any significant 
association with severity of steatosis and fibrosis in the Newcastle cohort. However 
borderline significance for transmission of the -455 T-allele was found in the family 
study. Although Petersen and colleagues reported the T-allele to protect against 
steatosis in 95 male Asians from India with no liver histology available [Petersen et al., 
2010], our result would indicate the opposite effect. The significance in our TDT may 
be a chance observation. Our finding for the adult Newcastle cohort was also replicated 
131 
 
in a separate Italian cohort. Both UK and Italian cohorts were also combined to increase 
the numbers and the results remained non-significant [Valenti et al 2011]. The data 
therefore suggests APOC3 SNPs do not influence severity of NAFLD in Europeans. 
Our finding has been the first to report the lack of association of APOC3 genotype with 
NAFLD severity. However, the same US cohort used to originally identify the PNPLA3 
variant association with hepatic fat was recently assessed for the APOC3 variants and 
the results showed no significant association with hepatic fat content [Kozlitina et al., 
2010].   
In conclusion, the PNPLA3 I148M is associated with risk of developing both steatosis 
and fibrosis severity in NAFLD patients suggests a link between lipid metabolism and 
fibrogenesis. The PNPLA3 rs734809 is the strongest variant to be reported to date in 
susceptibility to NAFLD. Multivariate analysis showed that PNPLA3, SOD2 and KLF6 
genotypes are independent risk factors for fibrosis. The APOC3 promoter region 
variants do not affect severity of NAFLD in UK and Italian patients.     
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7 Chapter 7 Claudin-10 (CLDN10) – a candidate gene for NAFLD 
progression 
7.1  Introduction 
There has been accumulating evidence supporting the liver-gut axis in the pathogenesis 
of NAFLD and therefore investigating the mechanisms involved in gut permeability is 
of interest [Dumas et al., 2006] [Solga and Diehl, 2003] [Farhadi et al., 2008]. In 
addition, there is evidence that intestinal tight junctions in NAFLD patients are 
disrupted, increasing gut permeability though it is possible that this could be due to 
small intestinal bacterial overgrowth rather than an abnormality within the tight 
junctions [Miele et al., 2009]. Increased gut permeability could result in increased fat 
deposition in the liver. A study by Beale and colleagues on liver tissue by expression 
microarray analysis suggested up-regulation of CLDN10 gene (which encodes for 
CLDN-10 which is involved in paracellular permeability) is associated with advanced 
fibrosis [Beale et al., 2009].  
Tight junctions are related to the cell-cell membrane contact of polarised cells 
(endothelia and epithelia). They form tissue barriers and pores that act as fences and 
gates. Tight junctions are involved in localizing membrane proteins (for example they 
occur at the boundary between the sinuosoidal and canalicular regions of the hepatocyte 
cell membrane) and  regulating movement of solutes and electrolytes by  the 
paracellular pathway [Berry and Boulpaep, 1975;Diamond, 1978] [Krause et al., 2008] 
[Amasheh et al., 2011]. Electrical resistance and preference for cations or anions are the 
characteristics of tight junctions permeability [Powell, 1981]. In transmission electron 
microscopy, tight junctions display a network of strands and groves [Staehelin, 1974]. 
Several transmembrane proteins such as occludin, claudins, tricellulin and marvelD3 
have been identified in these tight junction strands suggesting their roles in barrier 
formation [Furuse et al., 1993] [Furuse et al., 1998] [Ikenouchi et al., 2005] [Steed et al., 
2009].  
Claudins are proteins with four transmembrane segments and two extracellular domains 
[Van Itallie et al., 2006]. The claudin family consists of 24 members, some of which are 
involved in forming paracellular channels and others play a role in tightening epithelia 
[Amasheh et al., 2011]. Claudins can therefore be divided into three functional groups, 
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barrier builders, pore formers and claudins of ambiguous function according to 
Amasheh and colleagues for review [Amasheh et al., 2011].  
Claudin-10, a member of the claudin family is involved in mediating paracellular 
permeability and is encoded by CLDN10 gene. It is mainly expressed in kidney and at 
low levels in the liver of mouse tissues [Van Itallie et al., 2006] [Gunzel et al., 2009]. 
Van Itallie and colleagues showed weak claudin-10 immunoreactivity in tight junctions 
of hepatocytes [Van Itallie et al., 2006]. The study also found two isoforms of claudin-
10, claudin-10a and claudin-10b. The study reported that the two isoforms in both 
mouse and human differed in their first exon with claudin-10b having two extra amino 
acids (214bp in 10a and 220bp in 10b) and revealed that claudin-10a creates pore 
permeable for anions and claudin-10b for cations [Van Itallie et al., 2006]. On the other 
hand Gunzel and colleagues' study on mouse found six spliced isoforms in claudin-10, 
claudin-10a (expressed in kidney and uterus) and claudin-10b (expressed ubiquitously) 
being the main isoforms [Van Itallie et al., 2006] [Gunzel et al., 2009]. Gunzel and 
colleagues' study was consistent with claudin-10a and claudin-10b being the common 
isoforms, but also found another isoform of claudin-10a (claudin-10a_v1) that lacked 19 
amino acids in the first exon. Claudin-10a_v1 variant has no direct effect on the ion 
selectivity as does the two common (10a and 10b) isoforms, however it does modulate 
claudin-10a's effect on organic anion permeability. The study also found three other 
variants of claudin-10 that lacked exon four which is predicted to contain the fourth 
transmembrane region. The remaining variants that lack exon four were not found in the 
tight junctions [Gunzel et al., 2009]. No studies to date have performed experiments on 
cldn10-deficient mice, however claudin-2 which is highly expressed with claudin-10 in 
the kidney has been studied in cldn2-deficient mice [Muto et al., 2010]. The cldn2-
deficient mice show a loss of cation selectivity suggesting a role for the protein in cation 
permeability [Muto et al., 2010].  
Down-regulation of CLDN-10 expression appears to be associated with prolonged 
disease free-survival in hepatocellular carcinoma (HCC) [Ip et al., 2007]. Though 
claudins are generally localized along the plasma membrane, immunostaining on HCC 
found CLDN-10 localised strongly around the nuclei [Inai et al., 2005] [Sanada et al., 
2007]. Liver tissue microarray analysis showed the up-regulation of CLDN10 is 
associated with advanced fibrosis [Beale et al., 2009]. Since hepatic claudin-10 
expression in fibrosis cases is increased, it is possible that a similar effect could be 
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present in intestinal epithelial cells of NAFLD patients which could explain the 
increased gut permeability. 
To date no polymorphisms have been investigated in CLDN10 gene and therefore it 
would be of interest to study its variations, especially since studies in mice show the 
existence of six splice variant isoforms which could be due to splice site SNPs. A 
similar situation could occur in humans. 
The aim of this chapter is to determine whether common haplotypes in CLDN10 predict 
progression of NAFLD and also to perform immunohistochemistry (IHC) for claudin-
10 in liver tissues of NAFLD patients to assess its expression in liver and possible 
functional significance of polymorphisms in CLDN10. 
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7.2 Materials and Methods 
7.2.1 Immunhistochemistry (IHC) 
Formalin-fixed and paraffin-embedded tissues were prepared by Helen Reeves' group, 
Newcastle University. Section (5-µm thick) slides were dewaxed in xylene for 5 
minutes and rehydrated in alcohol gradient (100% to 75%). Slides were then incubated 
in 180ml of water with 3ml of 30% hydrogen peroxide for 10 minutes at room 
temperature to inactivate endogenous peroxidase. Slides were then incubated in 0.01M 
citrate buffer (pH 6.0) and microwaved for 10 minutes for antigen retrieval. Slides were 
then incubated with tris buffered saline (TBS, pH 7.6, 0.14 M NaCl, 5 mM Tris-HCl pH 
7.6) for 5 minutes. Sections were then incubated overnight at 4
o
C with appropriate 
primary antibodies with optimized dilutions (Table 7.1). Sections were then rinsed with 
TBS two times for 5 minutes. For the secondary antibody Menapath Kit was used 
(Table 7.1). The secondary antibody is a new horseradish-peroxidase (HRP) 
polymerization technology and was applied for 20 minutes at room temperature 
according to the manufacturer‟s guidelines, followed by a rinse in water for 20 minutes. 
Sections were then incubated with 3,3‟-diaminobenzidine (DAB) substrate kit for 1 
minute, producing a brown colour. Slides were then rinsed with water and then 
counterstained with Mayer‟s haematoxylin, followed by further rinse in water and brief 
dehydration in graded ethanol (75% to 100%) and xylene. Sections were mounted with 
DPX mounting medium.  
7.2.2 Visualization 
Slides were visualized using the ScanScope digital scanner. Slides were then viewed on 
Aperios Imagescope viewer software from www.aperio.com.  
7.2.3 Evaluation of Immunohistochemical finding  
The slides were analysed using a scoring system that incorporates both staining 
intensity (0 absent, 1 weak, 2 moderate or 3 strong) which was multiplied to overall 
percentage (from 0 to 100%) of staining resulting in score ranging from 0 to 300 
(expression score) [Stefano et al., 2011].  
7.2.4  CLDN10 genotyping  
Tag SNP selection was carried out by Gary Beale, Newcastle University. All SNPs 
selected were genotyped via K-bioscience fluorescent allele-specific PCR system as 
mentioned previously in section 2.1.6 for the Newcastle NAFLD samples. For the 
Italian „trio‟ families, only rs4143093 was genotyped due to financial restrictions.  
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7.2.5 Statistical analysis 
Genotyping analysis were carried out as discussed in section 2.4 
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 Table 7.1: Summary of antibodies used for immunohistochemistry 
Primary Antibodies Source Optimal dilution 
Rabbit anti-claudin-10 
(polyclonal) 
Abcam Ab66053 1:200 
Mouse anti-claudin-10 
(monoclonal) 
Invitrogen 415100 1:100 
Secondary Antibody   
X-cell plus Universal polymer 
HRP detection kit 
MenaPath MP-XCP-U6 One drop/section  
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7.3 Results 
7.3.1 CLDN10 candidate gene association study  
A tag SNP approach was adopted for CLDN10 due to the limited information on the 
existence of functionally significant polymorphisms in the CLDN10 gene. Eight 
CLDN10 polymorphisms were selected for genotyping. Five tag SNPs (rs4143093, 
rs1000600, rs2031540, rs12855856 and rs1000601) were originally selected by Gary 
Beale. In addition, I selected three promoter region SNPs (rs12870505, rs9584304 and 
rs3751334) which were not found to be in LD with the tag SNPs selected in HapMap 
CEU data (Figure 7.1). HapMap data on CLDN10 consisted of information on two 
isoforms (claudin-10a and claudin-10b). Using Haploview, Claudin-10a consisted of 
eight haplotype blocks whereas claudin-10b consisted of one haplotype block which 
was the only block shared between the two isoforms (Figure 7.1). Five tag SNPs 
(rs4143093, rs1000600, rs2031540, rs12855856 and rs1000601) from the shared 
haplotype were selected, these tag SNPs were in LD (r
2 
> 0.8) with 12 other SNPs found 
across the haplotype blocks that were able to determine the common haplotypes (Figure 
7.1). These selected SNPs were genotyped by allelic discrimination and the relationship 
between genotype and severity of steatosis (summarised in table 7.2), presence of 
NASH (summarised table 7.3) and severity of fibrosis (summarised in table 7.4) were 
analysed. For the eight SNPs selected all were in Hardy-Weinberg equilibrium (P>0.05). 
There was a significant difference between the  mild steatosis (0+1) group compared to 
the severe steatosis (2+3) group in carriage of the A-allele of rs4143093 with OR 2.82 
(95% CI (1.5-5.3), p=0.0009) (Table 7.2). There was no significant difference between 
mild steatosis and severe steatosis in the remaining SNPs (Table 7.2). There were no 
significant differences in carriage of the variant alleles between presence and absence of 
NASH (Table 7.3) or between mild fibrosis and severe fibrosis groups (Table 7.4). The 
polymorphism rs4143093 was genotyped in the Italian family trio samples but there was 
no preferential transmission of any allele to the affected children (p=0.88) (Table 7.5). 
Multivariate analysis using logistic regression analysis was performed to evaluate the 
factors associated with severe steatosis. CLDN10 genotype for rs4143093 was the only 
significant predictor factors for severe steatosis with OR 2.66 (95% CI (1.42-5.25); 
p=0.003) for CLDN10 (Table 7.6A). The common PNPLA3 rs738409 variant 
previously described (Chapter 6) was added to the multivariate analysis and both 
genotype factors were found to be predictor factors for steatosis (Table 7.6B). 
Frequencies of common haplotypes were generated using the five tag SNPs (Table 7.7). 
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There was no difference between frequencies of haplotypes generated compared against 
frequencies from HapMap CEU (p=0.73) (Table 7.7).  
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Figure 7.1: Five polymorphisms were selected and their position in the CLDN10 gene is illustrated. One 
common haplotype block was identified between the two isoforms using Haploview. The haplotype block 
covers a region of the CLDN10 gene represented by dotted lines. Five tag SNPs illustrated with red arrows 
were selected to identify all the haplotypes. Three promoter region polymorphisms from isoform one were 
selected.   
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Table 7.2: CLDN10 genotype distribution in Newcastle NAFLD patients in relation to steatosis severity 
CLDN10 
 
Genotype Steatosis 0+1 Steatosis 2+3 
Odd ratio for 
carriage of 
minor allele 
(95% CI) 
P value 
for 
carriage of 
minor 
allele 
rs4143093 
GG 59 (0.8) 121 (0.58) 
2.82 (1.5-
5.3) 
0.0009 GA 13 (0.18) 79 (0.38) 
AA 2 (0.02) 8 (0.04) 
rs1000600 
CC 54 (0.73) 122 (0.59) 
0.94 (0.58 – 
1.52) 
 0.08 CG 19 (0.26) 79 (0.38) 
GG 1 (0.01) 7 (0.03) 
rs2031540 
GG 30 (0.41) 90 (0.44) 
0.87 (0.51 - 
1.5) 
0.63 GA 36 (0.49) 99 (0.48) 
AA 8 (0.1) 17 (0.08) 
rs1000601 
AA 27 (0.36) 85 (0.41) 
0.81 (0.46 – 
1.4) 
0.45 AG 34 (0.46) 94 (0.46) 
GG 13 (0.18) 26 (0.13) 
rs12855856 
AA 71 (0.97) 198 (0.95) 
1.97 (0.42 – 
9.1) 
0.37 AG 2 (0.03) 11 (0.05) 
GG 0 0 
rs12870505 AA 59 (0.65) 153 (0.67) 
0.91 (0.54 – 0.73 
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AC 27 (0.3) 70 (0.31) 1.52) 
CC 5 (0.05) 6 (0.02) 
rs3751334 
AA 66 (0.72) 171 (0.75) 
0.84 (0.49 – 
1.45) 
0.54 AG 22 (0.24) 54 (0.24) 
GG 4 (0.04) 3 (0.01) 
rs9584304 
CC 38 (0.43) 106 (0.46) 
0.86 (0.52 – 
1.41) 
0.56 CT 38 (0.43) 102 (0.45 
TT 13 (0.14) 21 (0.09) 
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Table 7.3: CLDN10 genotype distribution in Newcastle NAFLD patients in relation to presence of NASH 
CLDN10 
 
Genotype NASH (No) NASH (Yes) 
Odd ratio for 
carriage of 
minor allele 
(95% CI) 
P value 
for 
carriage of 
minor 
allele 
rs4143093 
GG 80 (0.68) 103 (0.61) 
1.3 (0.8 - 
2.1) 
0.26 GA 33 (0.28) 60 (0.36) 
AA 5 (0.04) 5 (0.03) 
rs1000600 
CC 77 (0.65) 102 (0.60) 
1.2 (0.7 – 1.9 0.43 CG 37 (0.31) 62 (0.37) 
GG 4 (0.04) 4 (0.03) 
rs2031540 
GG 45 (0.41) 79 (0.44) 
0.69 (0.43 – 
1.12) 
0.13 GA 60 (0.49) 75 (0.48) 
AA 12 (0.1) 13 (0.08) 
rs1000601 
AA 48 (0.36) 64 (0.41) 
1.1 (0.68 – 
1.7) 
0.67 AG 57 (0.46) 73 (0.46) 
GG 12 (0.18) 29 (0.13) 
rs12855856 
AA 111 (0.97) 162 (0.95) 
0.79 (0.26 – 
2.44) 
0.69 AG 6 (0.03) 7 (0.05) 
GG 0 0 
rs12870505 AA 97 (0.65) 118 (0.67) 
1.1 (0.74 – 0.45 
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AC 36 (0.3) 61 (0.31) 1.9) 
CC 8 (0.05) 3 (0.02) 
rs3751334 
AA 99 (0.72) 140 (0.75) 
0.77 (0.47 – 
1.28) 
0.32 AG 36 (0.24) 41 (0.24) 
GG 4 (0.04) 3 (0.01) 
rs9584304 
CC 61 (0.43) 85 (0.46) 
0.85 (0.54 – 
1.32) 
0.47 CT 64 (0.43) 77 (0.45 
TT 16 (0.14) 18 (0.09) 
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Table 7.4: CLDN10 genotype distribution in Newcastle NAFLD patients in relation to fibrosis severity 
CLDN10 
 
Genotype Fibrosis 0+1 Fibrosis 2-4 
Odd ratio for 
carriage of 
minor allele 
(95% CI) 
P value 
for 
carriage of 
minor 
allele 
rs4143093 
GG 103 (0.65) 84 (0.64) 
1.05 (0.64-
1.7) 
0.83 GA 50 (0.31) 44 (0.33) 
AA 6 (0.04) 4 (0.03) 
rs1000600 
CC 99 (0.62) 84 (0.64) 
0.94 (0.58 – 
1.52) 
 0.8 CG 55 (0.35) 45 (0.34) 
GG 5 (0.03) 3 (0.02) 
rs2031540 
GG 70 (0.44) 56 (0.43) 
1.06 (0.66 - 
1.7) 
0.79 GA 75 (0.47) 62 (0.47) 
AA 13 (0.09) 13 (0.1) 
rs1000601 
AA 60 (0.38) 53 (0.41) 
0.88 (0.55 – 
1.4) 
0.62 AG 76 (0.48) 57 (0.44) 
GG 22 (0.14) 20 (0.15) 
rs12855856 
AA 153 (0.96) 124 (0.94) 
1.64 (0.55 – 
4.86) 
0.41 AG 6 (0.04) 8 (0.06) 
GG 0 0 
rs12870505 AA 129 (0.69) 89 (0.63) 
1.29 (0.81 – 0.26 
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AC 51 (0.27) 48 (0.34) 2.06) 
CC 7  (0.04) 4 (0.03) 
rs3751334 
AA 132 (0.71) 112 (0.78) 
0.67 (0.4 – 
1.12) 
0.13 AG 50 (0.27) 28 (0.19) 
GG 4 (0.02) 3 (0.03) 
rs9584304 
CC 84 (0.45) 65 (0.46) 
0.94 (0.6 – 
1.46) 
0.78 CT 83 (0.44) 61 (0.44) 
TT 20 (0.1) 14 (0.1) 
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Table 7.5: CLDN10 Transmission disequilibrium test, comparing the transmitted and untransmitted allele 
from heterozygous parents to affected child   
Gene and SNP number Allele Transmitted Untransmitted p-value 
CLDN10 rs4143093 G 25 (52%) 23 (48%) 0.88 
A 23 (48%) 25 (52%)  
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Table 7.6:  Multivariate analysis of CLDN10  rs4143093 for severity steatosis (0+1 vs. 2+3), controlling for 
predictor variables 
A. Steatosis 0+1 vs. 2+3 
Variables for OR (95% CI) p-value 
CLDN10 2.66 (1.42-5.25)           0.003 
Age 0.98 (0.96-1.00)   0.21 
Sex 0.66 (0.35-1.23)     0.192 
BMI 1.04 (0.98-1.10)          0.125 
Diabetes 1.37 (0.76-2.51)       0.291 
CLDN10 appeared to be the only predictor factor for severe steatosis 
B. Steatosis 0+1 vs. 2+3 
Variables for  OR (95% CI) p-value 
PNPLA3 1.8 (1.0 – 3.2) 0.04 
CLDN 2.7 (1.4 – 5.5) 0.003 
Age 0.9 (0.9 – 1.0) 0.23 
Sex 0.6 (0.3 – 1.1) 0.15 
BMI 1.03 (0.9 – 1.1) 0.18 
Diabetes  1.1 (0.6 – 2.2) 0.57 
MVA showing PNPLA3 and CLDN to be predictor variables for severe steatosis  
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Table 7.7: CLDN10 Haplotype frequencies compression in both Newcastle and HapMap populations  
 
 
 
 
 
 
 
 
Chi-square test analysing the differences between frequencies of the Newcastle and 
HapMap populations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Newcastle 
frequency 
CEU 
samples 
from 
HapMap 
frequency 
P-value 
CLDN10    
GGGAC 0.373 0.400 
0.73 
AGAAC 0.305 0.289 
GAAAG 0.184 0.142 
GGAAC 0.086 0.067 
AGAGC 0.024 0.061 
GGAAG 0.014 0.017 
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7.3.2 Claudin-10 immunohistochemical analysis 
Two claudin-10 antibodies, a rabbit polyclonal and a mouse monoclonal antibody were 
used for immunostaining. Claudin-10 expression was found in three cell types, 
hepatocytes, bile ducts and inflammatory cells but mainly in bile ducts (Figure 7.2). 
Intensity and localisation of expression correlated with severity of disease (Figure 7.2 
A-F). Expression of claudin-10 in bile ducts and hepatocytes was seen in both 
polyclonal and monoclonal antibodies (Figure 7.2 C-D). Expression of claudin-10 in 
inflammatory cells was only positive in the polyclonal antibodies compared to the 
monoclonal antibody (Figure 7.2 C and D).  
The relationship between IHC expression and rs4143093 genotype was analysed to 
assess the possible functional significance of this SNP (Table 7.8). Only 7 NAFLD 
patients were analysed by IHC and all had rs4143093 genotypes available. One subject 
was heterozygous (GA) and the remaining six were homozygous wild-types (GG). The 
patient with the GA genotype had both severe fibrosis and severe steatosis (Table 7.8). 
The GA patient appeared to have the highest expression score of claudin-10 compared 
to the GG patients. However due to the small number of samples genotyped this needs 
to be further assessed on a larger number of samples.     
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Figure 7.2: Immunohistochemistry using polyclonal antibodies (A, C and E x20) and monoclonal antibodies (B, 
D and F x20) A&B) represents mild steatosis, absence of NASH and fibrosis, no expression is seen in both 
antibodies C&D) represents severe steatosis, presence of NASH, and absence of fibrosis, expression seen in bile 
ducts (black arrow) for both antibodies, expression in inflammatory cells (green arrow) only positive in 
polyclonal antibody and in hepatocytes (red arrow). E&F) represents severe steatosis and presence of fibrosis, 
expression found in both bile ducts (black arrow) and hepatocytes (red arrow). 
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Table 7.8: Histology, claudin-10 expression and rs4143093 genotype  
Case 
No.  
Steatosis Nicro-
inflamation 
Fibrosis Abcam (polyclonal) 
Cell type (Intensity, over all %) 
(expression score) 
Invitrogen (monoclonal) 
Cell type (Intensity, over all %) 
(expression score) 
Genotype 
1 1 0 0 HEP (1, 10%) (10) 
BD (1, 20%) (20) 
HEP (1, 5%) (5) 
BD (2, 25%) (50)  
GG 
2 1 0 0 HEP (1, 5%) (5) 
BD (1, 5%) (5) 
HEP (1, 5%) (5) 
BD (0, 100%) (0) 
GG 
3  3 0 1 HEP (1, 90%) (90) 
BD-nucleus (1, 20%) (20) 
HEP (0, 100%) (0) 
BD-membrane (2, 25%) (50) 
GG 
4  2 0 0 HEP (2, 45%) (90) 
BD (3, 90%) (270) 
INF (3, 90%) (270) 
HEP (0, 100%) (0) 
BD (2, 80%) (160)  
GG 
5  2 1 0 HEP (1, 90%) (90) 
BD (3, 90%) (270) 
HEP (1, 100%) (100) 
BD (1, 35%) (35) 
GG 
6  3 0 0 HEP (1, 5%) (5) 
BD (1, 10%) (10) 
Other  
HEP (0, 100%) (0) 
BD (1, 25%) (25) 
GG 
7  3 1 2 HEP (3, 90%) (270) 
BD (3, 90%) (270) 
HEP (1, 90%) (90) 
BD (3, 90%) (270) 
GA 
 
HEP: Hepatocytes; BD: bile ducts; INF: inflammatory cells 
Group1 Mild Steatosis (0+1) and Mild Fibrosis (0+1) 
Group2 Severe Steatosis (2+3) and Mild Fibrosis (0+1) 
Group3 Severe Steatosis (2+3) and Severe Fibrosis (2-4) 
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7.4 Discussion 
The finding of increased gut permeability in NAFLD subjects and its correlation with 
severity of steatosis suggests the disruption of tight junctions [Miele et al., 2009]. The 
possibility of up-regulation of CLDN10 in advanced fibrosis [Beale et al., 2009] 
suggests the involvement of claudin-10 in NAFLD. We have therefore investigated 
variants in the CLDN10 gene that encodes for claudin-10 which is involved in 
mediating paracellular permeability. We have shown an association between an intronic 
polymorphism (rs4143093) and severity of steatosis which is consistent with  a role for 
tight junctions in NAFLD [Miele et al., 2009]. The polymorphism rs4143093 is found 
31 nucleotides downstream of exon 3 and might be involved in splicing due to its 
location. Using exon sequence enhancer (ESE) finder [Cartegni et al., 2003], the A-
allele is suggested to destroy an SC35 splicing factor recognition site and create novel 
binding sites for both SRp40 and SRp55 (Helen Reeves, Newcastle University, 
unpublished observations) but this requires further assessment. The two common 
isoforms of claudin-10 (claudin-10a and claudin-10b) show a difference in exon one. It 
is therefore less likely that the sequence in the area of rs4143093 is involved in creating 
these two variants. The possibility that other SNPs could affect the relative levels of the 
two isoforms requires further investigation. Gunzel and colleagues work on mice found 
three isoforms of claudin-10 that lacked exon 4 [Gunzel et al., 2009]. However, it is not 
clear that this can be applied to humans and that rs4143093 could create a novel isoform 
that lacks an exon, though addressing this hypothesis requires further work.  
The current study demonstrates the immunoexpression of claudin-10 in the spectrum of 
NAFLD and confirms the expression of claudin-10 in human liver tissues as was 
previously shown in mouse liver [Gunzel et al., 2009]. The increase in expression of 
claudin-10 in severe disease is consistent with the earlier finding that CLDN10 gene 
expression was increased in severe NAFLD (severe fibrosis) [Beale et al., 2009]. The 
discrepancy between the expression of claudin-10 in inflammatory cells between the 
polyclonal and monoclonal antibodies is consistent with the differences in immunogen 
of the antibodies used where the monoclonal antibody is a mixture of two peptides from 
the middle and C-terminal regions of claudin-10 compared with only the C-terminal of 
the polyclonal antibody which makes the monoclonal more specific and may suggest 
the existence of two different isoforms. 
Although results from IHC found expression of claudin-10 in liver tissues of NAFLD 
subjects with varying severity of disease, the study still has its limitations. The scoring 
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method used for IHC relies on a trained pathologist, which involves two characteristics; 
stain intensity and overall percentage. The errors in assessing for positive staining could 
lead to false results specially by not having control samples to eliminate any negative 
staining. Setting for a positive threshold should give better measurements. Computer 
imaging systems such as Aperio supplemented by a pathologist is able to set a positive 
threshold for staining that should result in accurate measurements [Nassar et al., 2011].          
The relationship between IHC expression scores and genotype show increased 
expression scores of claudin-10 in GA subjects with severe NAFLD compared with GG 
genotype with mild NAFLD which may suggest the polymorphism to be associated 
with higher expression of claudin-10. However due to the small number of subject 
available for both IHC and genotyping these results need to be validated on a larger 
scale. Claudin-10 expression in hepatocytes, bile ducts and inflammatory cells suggests 
it could be of direct relevance to NAFLD. Tight junction function within hepatocytes 
could be a contributory factor to disease in addition to the previous suggestion that tight 
junction function in the intestine is important [Miele et al., 2009].    
In conclusion, the finding from the association study suggests claudin-10 genotype is a 
contributor to severe steatosis in NAFLD. The findings from IHC confirm that the gene 
is expressed in the liver, and the overall expression of claudin-10 is increased in severe 
NAFLD. It remains unclear whether there is any relationship between this finding and 
the increased frequency of rs4143093 in severe steatosis with further IHC or RNA 
expression studies needed on more diseased samples of known genotype. 
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8 General discussion 
8.1 General discussion  
Non-alcoholic fatty liver disease is a complex disorder influenced by both genetic and 
environmental factors. NAFLD encompasses a spectrum of liver diseases ranging from 
steatosis to its more severe forms NASH/advanced fibrosis and cirrhosis. However not 
all individuals with steatosis will progress to the more severe forms. Although it is yet 
unclear what triggers such progression, it is suggested that knowledge of genetic 
variation in genes related to the mechanisms in the pathogenesis of NAFLD could 
enable us to determine those that are at high risk in developing severe NAFLD. 
Therefore those at high risk could be considered for preventive treatments. 
This study was designed to compare unrelated patients of adults with NAFLD of 
varying severity assessed using the gold standard method liver biopsy. Because of the 
invasive nature of liver-biopsy, normal control samples were not studied. This therefore 
lead to the comparison of mild NAFLD patients against severe NAFLD patients. A 
second group of children with fibrotic NAFLD and their two parents in whom we have 
performed the transmission disequilibrium test was used to test for association and to 
confirm effects seen for the adult NAFLD group. It would have been ideal to use a 
normal control group free of NAFLD but the lack of non-invasive methods to establish 
absence of NAFLD was not feasible. There has been progress in assessing NAFLD 
severity using non-invasive methods that are based on a number of laboratory 
measurements in combination with clinical parameters such as BARD score, NAFLD 
fibrosis score, FIB-4 test, AST/ALT ratio and FibroMeter reviewed by [Dowman et al., 
2011]. Other tests use the combination of fibrosis biomarkers such as the FibroTest 
[Poynard et al., 2007]. Radiological assessments such as ultrasound, computed 
tomography (CT) and magnetic resonance imaging (MRI) have been used to distinguish 
between NAFLD stage however not all studies have been reliable, as reviewed recently 
[Dowman et al., 2011]. This recent article suggests that SteatoTest and NASHTest can 
be used for steatosis and NASH assessments, combining 10 and 13 available blood tests 
respectively with age, gender and BMI [Dowman et al., 2011].  The ELF test   also 
involves enzyme measurements and has recently been used as a measure of fibrosis in 
patients with hepatitis C [Trepo et al., 2011]. Despite the availability currently of these 
improved tests, they were not available when the current study was initiated. In addition, 
the cost of performing these on healthy controls is likely to be quite high and there are 
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potential ethical problems if normal controls were to be diagnosed with liver fibrosis. In 
view of all these limitations, the design used in the current study seemed the best 
approach when the study began and continues to have value except that genetic factors 
involved in susceptibility to simple steatosis would not be detected unless a control 
group without steatosis was included. 
Using candidate gene association studies, our work has found significant associations in 
SOD2 with severity of fibrosis, PNPLA3 with severity of both steatosis and fibrosis and 
CLDN10 with severity of steatosis (Table 8.1). Due to the correlation between NASH 
and fibrosis, assessing severity of fibrosis was sufficient to predict severe NAFLD.  
Assessing these SNPs alone would not be sufficient to predict severity of NAFLD but 
they are factors contributing to disease initiation and progression that could be targeted 
in the design of novel treatments. When we extend the findings described in the current 
thesis to other genetic studies performed on the same sample cohort where significant 
associations with disease severity have been detected, we should consider studies on 
KLF6  [Miele et al., 2008], ENPP1 and IRS-1 [Dongiovanni et al., 2010]. All three have 
been demonstrated to affect risk of fibrosis though not steatosis. However, in 
multivariate analysis on fibrosis severity, it was decided only to add both KLF6 and 
ENPP1 as additional genetic risk factors because IRS1 was found to be a significant risk 
factor for fibrosis severity only when additional cases from Italy were included as well 
as the Newcastle cohort [Dongiovanni et al., 2010]. Although the four genes were 
included in the multivariate analysis to predict severity of fibrosis, only SOD2, 
PNPLA3 and KLF6 were found to be significant predictor factors.  It appears that 
genetic risk varies over an almost 15 fold range with those positive for the KLF6 variant 
but wild-type for SOD2 and PNPLA3 showing a 3 fold lower risk of severe fibrosis 
compared with those wild-type for all 3 but an individual positive for the "at risk" 
SOD2 and PNPLA3 genotypes and wild-type for KLF6 would show a 4 fold increase in 
risk compared with homozygous wild-types for the 3 genes. The risk of severe steatosis 
in individuals positive for the risk alleles of CLDN10 and PNPLA3 are approximately 4-
fold higher compared to those negative for the risk alleles.  
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Table 8.1: Summary of significant findings on NAFLD severity genes on the Newcastle NAFLD cohort results 
Gene and rs. Number Steatosis Fibrosis 
CDN10 rs4143093  2.66 (1.42 - 5.25); p=0.003 NS 
PNPLA3 rs738409  1.8 (1.09 - 2.99); p=0.02 2.2 (1.09 – 4.66); p=0.03 
SOD2 rs4880 NA 2.3 (1.41 – 4.19); p=0.001 
KLF6 NA 0.28 (0.08 – 0.86); p=0.03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
158 
 
Unlike the other genes studied, the selection of claudin-10 as a candidate gene for this 
study was due to the microarray expression analysis resulting in up-regulation of 
CLDN10 in association with advanced fibrosis [Beale et al., 2009]. The positive 
association of CLDN10 polymorphism with severity of steatosis has added mechanisms 
involving tight junctions to possible mechanisms involved in NAFLD. This finding 
supports use of expression microarray studies to identify candidate genes. Therefore in 
the future the choices of candidate genes can be selected from genome and proteome 
expression studies in liver tissues with different stages of disease, quantitative trait locus 
mapping in animal models and mouse mutagenesis studies [Day, 2010].  
Our association findings are consistent with the involvement of lipid metabolism and 
oxidative stress in the pathogenesis of NAFLD as previously described in the literature. 
However the association with claudin-10 has opened a new venue towards identifying 
tight junctions as a new mechanism involved in the pathogenesis of NAFLD and 
therefore more consideration should be given to this newly involved mechanism. The 
SOD2 supports the current use of antioxidants in patients with NAFLD [Foster et al., 
2011] which may open up new venues that lead to designing new drugs or using current 
drugs for directing lifestyle advice. 
A mechanistic explanation for the current findings can be proposed. Subjects having the 
risk allele of PNPLA3 will have excess fat in the liver due to either the variant allele 
abolishing hydrolysis (breakdown of TG) and therefore causing accumulation of hepatic 
TG or increasing lipogenesis (increase in FA synthesis and subsequently TG synthesis). 
Carrying the CLDN10 risk allele may also result in increased liver fat deposition from 
dietary fat due to increased gut-liver permeability. This excess fat results in lipid 
peroxidation (due to an increase in free radical production). Having the SOD2 risk allele 
(lower enzyme activity) will result in less antioxidant activity. An imbalance between 
formation of free radicals and antioxidant activity will result in oxidative stress leading 
to the increased level of liver fibrosis seen in fibrosis stages 2 to 4. The reason for 
PNPLA3 contributing to risk of fibrosis in addition to steatosis (unlike CLDN10) may 
be due to its lipogenesis role whereas CLDN10 will simply allow more dietary fat to 
accumulate in the liver.  Clearly both this study and the recent findings from others 
[Speliotes et al., 2010] suggest that PNPLA3 genotype is a important risk factor for 
NAFLD progression and measures to correct this deficiency (e.g. by drug treatment) 
might be of value in limiting disease severity.  
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The work done by our group has shed further light on the aetiology of NAFLD. The 
previous „two-hit‟ hypothesis by [Day and James, 1998] suggested a set of factors to be 
involved in the initiation of NAFLD (first hit) where as a different set is involved in the 
progression of NAFLD (second hit). Although Day suggested the „two-hit‟ theory, Day 
also suggested the involvement of insulin resistance in both initiation and progression of 
NAFLD. Other authors on the other hand suggested the interaction of factors 
[Malaguarnera et al., 2009]. Our findings of CLDN10 and SOD2 being associated with 
only severity of steatosis and severity of fibrosis respectively and PNPLA3 being 
associated with both severe steatosis and severe fibrosis supports the observations that a 
group of factors may be only involved in initiation or progression whereas other factors 
may be involved in both initiation and progression together. This observation supports 
the complex nature of NAFLD. 
Although the studies conducted in our lab did not find any association with the other 
oxidative stress related genes besides SOD2 despite studying a number of SNPs in a 
range of candidate genes, these findings cannot be used to eliminate the role of 
oxidative stress in disease progression. This observation highlights the limited number 
of genes that had functionally significant polymorphisms available to assess and that 
information available on the majority of genes selected for this study was limited.  It is 
therefore clear from our study that future studies examining susceptibility of NAFLD 
need to have a considerably larger number of samples than those performed so far and 
to be able to increase the coverage of functional and rare variants (rare variants < 5%) 
being studied. This can be achieved by collaborations and the establishment of consortia 
as well as use of the more contemporary approaches such as GWAS and whole-genome 
sequencing discussed below. 
Today it is clear the main issue underlining NAFLD genetic association studies is the 
lack of consistency in selection of methods for liver assessment and the number of 
sample size between different studies. This inconsistency starts with the different non-
invasive and invasive techniques being used for histological determination, a well-
phenotyped cases and controls would be hard to achieve and also with the lack of 
collaboration the low number of samples used will result in non-robust findings that 
usually lead to most studies not being replicated by others. Another challenge today is 
identifying the actual functional disease variant when the surrounding variants are in 
strong LD which will result in similar association strength. Re-sequencing the genomic 
region is usually necessary to identify novel and uncommon variants. Functional studies 
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are necessary however they are only feasible for well-characterized genes and therefore 
challenging for SNPs located in unknown genes or non-coding regions and gene deserts.  
GWAS studies have been a major tool in identifying novel variants that lead to increase 
understanding of disease biology. Their advantage is that no prior knowledge of disease 
aetiology is needed. In GWAS, 500,000 to 1,000,000 SNPs are analysed at once, to 
avoid detecting incorrect associations due to type 1 error, a stringent p-value for 
significance is needed. Because of this requirement, some true associations may not 
reach significance unless a very large sample size is used and such a large sample size 
may not be available in many cases. GWAS will not be able to identify all disease genes 
due to rare variants not being covered, resulting in missed variants [Goldstein, 2009]. 
However, work on improving the genotyping platforms (Illumina and Affymetrix) that 
have poor coverage for rare variants which are currently biased towards only common 
alleles is in progress. The study design of GWAS is hypothesis-generating rather than 
hypothesis testing, and therefore independent replication studies are required are also 
needed further increasing the sample size required [Seng and Seng, 2008]. However, for 
NAFLD, the PNPLA3 association which was originally detected by a limited genome-
wide association study has already been widely replicated in independent studies and 
this should also be possible in other cases. 
To date there have been three GWAS on NAFLD which have been limited in the 
number of  SNPs being assessed (only non-synonymous) [Romeo et al., 2008] or on 
small cohorts of 236 female NAFLD patients [Chalasani et al., 2010]. However, 
recently a GWAS (n=7176) by Speliotes and colleagues combined four cohorts from 
four different studies where NAFLD was not the primary diagnosed disease, the Old 
Order Amish, Age Gene/Environemt Susceptibility-Reykjavik study (AGES-Reykjavik), 
Family Heart, and Framingham Heart Studies [Speliotes et al., 2011]. Computed 
tomography (CT) was used for liver attenuation measuring hepatic steatosis. Although it 
is a non-invasive method, it is limited in assessing NASH/Fibrosis histology. However 
the study did replicate its findings in an independent cohort of 592 samples with biopsy-
proven NAFLD from the NASH CRN samples from the US compared with 1405 
control samples from iCONT. Our group are currently in process of a GWAS on 
biopsy-proven NAFLD samples from Northern Europe which is the first study to be 
conducted on only NAFLD samples assessed using the golden standard method. The 
study aims to reach 1000 samples for GWAS and an independent cohort will be 
available for replication to confirm the findings from the GWAS.    
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The value of the GWAS approach is well illustrated by recent progress on type 2 
diabetes genetics. To date 44 different polymorphisms mostly in separate genes in type 
2 diabetes have been discovered [Wheeler and Barroso, 2011]. Most of the associations 
have been well replicated. Although only 10% of the risk for type 2 diabetes is 
explained when combining all these loci [Wheeler and Barroso, 2011], knowledge of 
the risk factors can be used as targets for potential therapeutic drugs. There is strong 
evidence to date of the use of these discovered genes as drug targets, for example 
PPARG and thiazolidinediones and KCNJ11 and sulfonylureas [Hakonarson and Grant, 
2011].  Type 2 diabetes clearly overlaps with NAFLD and there is no reason why 
further GWAS studies on NAFLD should not quickly advance knowledge of genetics of 
this disease to the level now seen for type 2 diabetes. Nevertheless, it is desirable that if 
GWAS on NAFLD leads to the discovery of a relatively large number of genes 
affecting severity that more than 10% of risk will be explained.   
SNPs alone cannot explain the genetic susceptibility of complex disease and therefore 
copy number variations (CNV) which are currently provided by GWAS platforms can 
be utilized to increase our understanding of the genetics of complex diseases. Other 
factors should be taken into consideration such as the involvement of microRNAs in 
posttranscriptional regulation of gene expression [Kerr et al., 2011] and DNA 
methylation and histone modification (the area of epigenetics) [Cooney, 2007] which 
deserve recognition as the understanding of these areas increases. 
The newest approach for detecting disease-associated variants involves either whole 
genome sequencing covering the entire genome which is still costly or exome 
sequencing which is an approach for analysing polymorphisms in exons only. Although 
exome sequencing targeting only the coding regions is relatively simple using modern 
next generation sequencing methods, this does not detect other variations in the 
promoter and intronic regions that may also be functionally significant. The ongoing 
1000 genome project is a large scale human genome sequencing programme divided 
into three projects; low-coverage genome sequencing, high coverage-genome 
sequencing and exon-targeted sequencing [Durbin et al., 2010]. Up to the present, the 
number of disease associated variants detected by these approaches is limited but very 
recently a number of new variants associated with rare diseases have been detected by 
exome sequencing.  For example exome sequencing in Parkinson‟s disease (PD) has 
identified a missense mutation in the VPS35 gene (component of the retromer cargo-
recognition complex) suggested to cause late-onset disease [Zimprich et al., 2011]. 
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Other diseases such as gray platelet syndrome has identified NBEAL2 (Neurobeachin-
like 2) as a causative gene [Albers et al., 2011]. Although there are an increasing 
number of published studies using exome sequencing, the majority of these are on 
Mendelian disorders rather than complex genetic disorders. It is possible that whole 
genome sequencing not exome sequencing may be needed to progress on identifying 
rarer variants important in complex diseases such as NAFLD. 
Finally, though they suffer from a number of limitations, candidate gene association 
studies have resulted in improved understanding of NAFLD risk though currently the 
genes detected account for only a small proportion of the overall disease risk. With 
improved technology such as GWAS and genome sequencing and also the increased 
incidence of NAFLD due to the rise in obesity which makes finding cases relatively 
easy, it seems likely that additional genes will be identified in the near future. 
Knowledge of genetic factors will be useful for improving the understanding of disease 
biology which may lead to the development of new strategies such as directing lifestyle 
advice and development of new drugs for NAFLD. 
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Homozygosity for the Patatin-Like Phospholipase-3/
Adiponutrin I148M Polymorphism Influences
Liver Fibrosis in Patients with Nonalcoholic
Fatty Liver Disease
Luca Valenti,1 Ahmad Al-Serri,3 Ann K. Daly,3 Enrico Galmozzi,1 Raffaela Rametta,1
Paola Dongiovanni,1 Valerio Nobili,4 Enrico Mozzi,2 Giancarlo Roviaro,2 Ester Vanni,5 Elisabetta Bugianesi,5
Marco Maggioni,6 Anna Ludovica Fracanzani,1 Silvia Fargion,1 and Christopher P. Day3
Inherited factors play a major role in the predisposition to nonalcoholic fatty liver disease
(NAFLD), and the rs738409 CfiG polymorphism of PNPLA3/adiponutrin, encoding for
the isoleucine-to-methionine substitution at residue 148 (I148M) protein variant, has
recently been recognized as a major determinant of liver fat content. However, the effect of
the rs738409 polymorphism on the severity of liver fibrosis in patients with NAFLD is still
unknown. In this study, we considered 253 Italian patients, 179 healthy controls, and 71
family trios with an affected child with NAFLD. Analyses were replicated in 321 patients
from the United Kingdom. The rs738409 polymorphism was determined by TaqMan
assays. Liver histology was scored according to Kleiner et al. Hepatic expression of genes
regulating liver damage was assessed by real-time polymerase chain reaction in 52 patients.
The rs738409 GG genotype was more prevalent in patients than in controls (14% versus
3%, adjusted odds ratio [OR] 5 3.29, 95% confidence interval [CI] 5 1.8-6.9), and in the
family study, the G allele was overtransmitted to affected children (P 5 0.001). In Italian
and United Kingdom patients, adiponutrin genotype influenced alanine aminotransferase
levels and the severity of steatosis. Adiponutrin genotype was associated with the expres-
sion of genes involved in the steatosis-related liver damage, including the proapoptotic
molecule Fas ligand. In the whole series combined, adiponutrin genotype was associated
with steatosis grade >1 (OR 5 1.35, 95% CI 5 1.04-1.76), nonalcoholic steatohepatitis
(OR 5 1.5, 95% CI 5 1.12-2.04), and fibrosis stage >1 (OR 5 1.5, 95% CI 5 1.09-2.12),
independent of age, body mass index, and diabetes. Adiponutrin genotype demonstrated a
dose effect with heterozygote risk intermediate between CC and GG homozygotes. Conclu-
sion: In patients with NAFLD, adiponutrin rs738409 CfiG genotype, encoding for
I148M, is associated with the severity of steatosis and fibrosis and the presence of nonalco-
holic steatohepatitis. (HEPATOLOGY 2010;51:1209-1217)
Abbreviations: ALT, alanine aminotransferase; FASL, Fas ligand; FFA, free fatty acid; HDL, high-density lipoprotein; INSR, insulin receptor; LDL, low-density
lipoprotein; mRNA, messenger RNA; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PNPLA3, patatin-like phospholipase-3; PPAR-
a, peroxisome proliferator-activated receptor-a; qRT-PCR, quantitative real-time polymerase chain reaction; a-SMA, a-smooth muscle actin; SNP, single-nucleotide
polymorphism; SREBP1c, steroid regulatory element binding protein 1c.
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onalcoholic fatty liver disease (NAFLD),
affecting 20%-34% of the U.S. and Euro-
pean populations,1,2 is currently considered a
hepatic manifestation of the metabolic syndrome3 and
is associated with increased mortality due to cardiovas-
cular and liver diseases.4,5
Hepatocellular fat accumulation and insulin resist-
ance are the key factors in NAFLD pathophysiology
and are deeply entangled with the progression of liver
disease. Insulin resistance in the adipose tissue results
in an excess of free fatty acid (FFA) supply to the liver,
which may induce lipotoxicity, oxidative stress, and ap-
optosis, thus leading to nonalcoholic steatohepatitis
(NASH).6 NASH is considered the progressive form
of NAFLD and is characterized by necroinflammatory
changes, ballooning degeneration, and/or fibrosis. Insu-
lin resistance per se may be involved in the onset of
liver damage, and the presence of the metabolic syn-
drome predicts the severity of liver disease.4,7
Inherited factors play a major role in susceptibility to
the metabolic syndrome and NASH. Predisposition to
NASH appears to cluster with the heritability of meta-
bolic risk factors within families, and ethnic differences
have been reported.8 Single-nucleotide polymorphisms
(SNPs) in genes involved in inflammation, oxidative
stress, and fibrogenesis have been associated with the se-
verity of liver damage in NAFLD,9-11 but data are contra-
dicting and explain only a minority of fibrosis variations.
Recently, genomewide association studies identified
an SNP in adiponutrin/patatin-like phospholipase-3
(PNPLA3), rs738409 C!G, encoding the I148M
(isoleucine-to-methionine substitution at residue 148)
protein variant, as the strongest genetic determinant of
liver fat and alanine aminotransferase (ALT) levels.12-14
The 148M variant was more common in Hispanics,
who are known to be at increased risk for NASH and
cryptogenic cirrhosis.12 Importantly, the I148M SNP
influenced liver fat independently of body mass, dys-
lipidemia, and insulin resistance. In addition, PNPLA3
variants have also been associated with alcoholic liver
disease and alcohol-related cirrhosis.15
Adiponutrin/PNPLA3, which belongs to the patatin-
like phospholipase family, is expressed in the liver and
adipose tissue and possesses acyl hydrolase activity.16
Adiponutrin expression is increased by carbohydrate
feeding and a Western-type diet,17,18 and has lipase ac-
tivity against triglycerides and acylglycerol transacylase
activity, thus being likely involved in energy mobiliza-
tion and storage in lipid droplets.19 Recently, it was
reported that the 148M adiponutrin allele is a loss-of-
function variant that predisposes an individual to steato-
sis by decreasing triglyceride hydrolysis in hepatocytes.20
However, although the adiponutrin genotype has previ-
ously been reported to be associated with steatosis sever-
ity and NASH in a very small series of biopsied
patients,21,22 the relationship between adiponutrin
expression and liver damage, as well as the effect of the
I148M SNP on liver fibrosis, have not been evaluated in
adequately powered samples.
Because the degree of steatosis has previously been
reported to influence the severity of liver damage in
NAFLD,23 the aim of this study was to evaluate the
relationship between the adiponutrin I148M polymor-
phism and the severity of liver fibrosis.
Patients and Methods
Patients. We analyzed DNA from 574 unrelated
patients with biopsy-proven NAFLD diagnosed
between January 1999 and January 2008. These
included 190 Italian patients who underwent liver bi-
opsy because of persistently abnormal liver enzymes/se-
rum ferritin or a long-lasting history of steatosis associ-
ated with severe metabolic abnormalities, 63 Italian
severely obese patients who were found to be affected
by NAFLD at routine percutaneous liver biopsy per-
formed during bariatric surgery, and 321 adult patients
from Newcastle, UK. Other causes of liver disease
were excluded, including increased alcohol intake
(>30/>20 g/day for males/females, respectively), as
confirmed by at least one family member or friend
and carboxydesialylated transferrin determination, viral
and autoimmune hepatitis, hereditary hemochromato-
sis, and alpha1-antitrypsin deficiency. Part of this
group had previously been described.9 The available
demographic and clinical features are shown in Table 1.
All patients included in the study had a fatty liver
index >50.24
In addition, we tested 71 Italian family trios with
both parents alive and an index child with biopsy-proven
fibrotic NAFLD. We used transmission disequilibrium
testing to look for preferential transmission of rs738409
C/G alleles to the affected children. This approach is not
subject to the potential confounding effects inherent in
case-control studies and is significantly more powerful at
detecting true associations.10,25
Published online in Wiley InterScience (www.interscience.wiley.com).
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Controls. The Italian control group included 179
geographically-matched, age-matched, and sex-matched
Italian subjects out of a larger series of 482 blood
donors from Northern Italy who were selected because
of the lack of clinical and biochemical evidence of liver
and metabolic disease and no alcohol abuse (<30/20
g/day in males/females). We excluded subjects with
ALT >35/30 IU/mL in males/females, gamma-glu-
tamyl transferase >35 IU/mL, body mass index (BMI)
>28, abdominal circumference >100 cm, glucose lev-
els 100 mg/dL, triglycerides 150 mg/dL, high-den-
sity lipoprotein (HDL) 45/55 in males/females or a
fatty liver index >35, a value with high specificity to
rule out NAFLD in the general population.24
The study protocol was approved by the Institu-
tional Review Board of the Ospedale Policlinico
MaRE IRCCS, Milan, Italy, and by Local Research
Ethics Committee in Newcastle, UK. Informed written
consent was obtained from each patient and control
subject, and the study conforms to the ethical guide-
lines of the 1975 Declaration of Helsinki.
Histological Assessment. Tissue sections were
stained with hematoxylin and eosin, impregnated with
silver for visualizing reticulin framework, and stained
with trichrome for visualizing collagen. One expert pa-
thologist unaware of clinical and genetic data reviewed
all biopsies for fibrosis stage at each clinical center.
The severity of steatosis, features of NASH, and fibro-
sis was assessed according to Kleiner et al.26 NASH
was considered to be present when steatosis, balloon-
ing, and lobular inflammation were present. The mini-
mum biopsy size was 1.7 cm and the number of portal
areas was 10.
Genetic Analysis. DNA was extracted from periph-
eral blood collected at the time of liver biopsy by the
phenol-chloroform method. Success rate in extracting
DNA was 100% for each study group. The adiponutrin/
PNPLA3 rs738409 C!G SNP, encoding I148M, was
genotyped by a TaqMan assay (assay on demand for
rs738409; Applied Biosystems, Foster City, CA) by per-
sonnel unaware of clinical status of patients and controls.
Post–polymerase chain reaction (PCR) allelic discrimi-
nation was carried out measuring allele-specific fluores-
cence on the Opticon2 detection system (MJ Research,
Waltham, MA). Random samples were confirmed by
direct genotyping that provided concordant results in all
cases. Samples from both patients with NAFLD and
controls were included in all batches analyzed, and qual-
ity controls were performed to verify the reproducibility
of the results. Valid genotypic data were obtained for
more than 99% of subjects analyzed.
Determination of Messenger RNA Levels of Adipo-
nutrin and Genes Regulating Liver Metabolism and
Damage. In 52 patients who underwent bariatric sur-
gery for whom adequate liver biopsy samples collected
at the time of surgery were available (comprising 42
subjects with NAFLD included in the genotype fre-
quency study, and 10 subjects with steatosis <5% and
no histological abnormalities), RNA was isolated by
the Trizol reagent (Invitrogen, Carlsbad, CA), digested
with deoxyribonuclease I, and quality evaluated by
measuring the absorbance ratio at 260/280 nm (1.8)
and by electrophoresis. First-strand complementary
DNA was synthesized using equal amounts (0.5 lg) of
total RNA, with the SuperScript VILO complementary
DNA synthesis kit (Invitrogen, Carlsbad, CA). The
Table 1. Demographic and Clinical Features of Patients with 179 Italian Healthy Control Subjects with Normal Liver Enzymes
and Metabolic Parameters and 253 Patients with NAFLD, Including 190 Patients Who Underwent Liver Biopsy Because of
Persistently Abnormal Liver Enzymes and/or Metabolic Abnormalities, and 63 Patients Found to Have NAFLD at Routine
Liver Biopsy During Bariatric Surgery
Feature Italian Controls Italian NAFLD Patients UK NAFLD Patients
Number 179 253 321
Female sex 38 (21) 76 (30) 123 (38)
Age (years) 48.4 6 13 46.4 6 11 49.5 6 12
BMI (kg/m2) 25.1 6 2.7 30.5 6 7.8 34.0 6 5.3
LDL cholesterol (mg/dL) 118.7 6 29 132.5 6 43 127.0 6 43
HDL cholesterol (mg/dL) 55.2 6 13 44.9 6 12 47.0 6 13
Triglycerides (mg/dL) 90.1 6 44 155.2 6 84 248.3 6 178
Glucose (mg/dL) 89.0 6 10 98.3 6 27 121.4 6 54
HOMA-IR 2.7 6 1.6 4.3 6 3.4 6.4 6 6.2
IGT-IFG or diabetes 0 63 (25) 120 (37)
ALT (IU/mL) 21.8 6 7 55.5 6 41 80.8 6 64
GGT (IU/mL) 23.7 6 16 86.2 6 108 130.0 6 184
NASH (%) 0 124 (49) 184 (57)
Fibrosis stage F0/F1/F2/F3/F4 n (%) – 123/85/25/10/10 (49/33/10/4/4) 124/58/53/51/35 (39/18/16/16/11)
Values in parentheses are % values. IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NASH, nonalcoholic steatohepatitis.
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messenger RNA (mRNA) levels were analyzed by
quantitative real-time PCR (qRT-PCR) with SYBR
Green chemistry (Fluocycle II SYBR green mix; Euro-
clone, Pero, Italy). All the reactions were performed in
triplicate with the Opticon2 qRT-PCR system (MJ
Research, Waltham, MA). In patients with and with-
out NAFLD, we evaluated the PNPLA3/adiponutrin
mRNA levels, and we correlated the PNPLA3 I148M
genotype with the expression of insulin receptor
(INSR), which regulates insulin signaling and is down-
regulated in the metabolic syndrome,27 steroid regula-
tory element binding protein 1c (SREBP1c), which
regulates lipogenesis,28 peroxisome proliferator-acti-
vated receptor-a (PPAR-a), which regulates lipolysis
and is decreased in NASH,29 and Fas ligand (FASL),
which is a proapoptotic molecule induced by insulin
resistance.30,31 Primers are shown in Table 2. Results
were normalized for b-actin and 18S RNA, which
were chosen as a control because of stable expression
among different samples.
Statistical Analysis. Results are expressed as means
6 standard deviation. Mean values were compared by
analysis of variance (ANOVA) and post-hoc analysis or
Wilcoxon test, when appropriate, and frequencies by
Fisher’s exact test, and chi-squared test for trend, when
appropriate. Variables were correlated by the Spear-
man’s rho test.
The association between the I148M variant and the
presence of metabolic abnormalities, NASH, and fibro-
sis was evaluated by multivariate logistic regression
analysis. In analyzing the association between I148M
and steatosis and fibrosis, we compared allele and ge-
notype frequencies in those with none or mild steato-
sis/fibrosis (0 and 1/3 for steatosis; 0 and 1/4 for fibro-
sis) versus those with moderate/severe steatosis/fibrosis
(2 and 3/3 for steatosis; 2, 3, and 4/4 for fibrosis).
Analyses were carried out with JMP 6.0 statistical anal-
ysis software (SAS Institute Inc, Cary, NC).
Results
Adiponutrin Genotype Influences the Risk of
NAFLD. The frequency distribution of the rs738409
C!G adiponutrin genotype, which was in Hardy-
Weinberg equilibrium in Italian and UK patients and
in controls, is shown in Table 3. The frequency distri-
bution of the mutant G allele was significantly higher
in Italian patients with NAFLD than in geographi-
cally-matched, age-matched, and sex-matched healthy
controls with normal liver enzymes and metabolic pa-
rameters and a normal fatty liver index (P < 0.0001;
Table 2). In Italian adult subjects, the adiponutrin GG
genotype was associated with an increased risk of
NAFLD compared to the CC genotype independently
of age, sex, and BMI (odds ratio ¼ 3.29, 95% confi-
dence interval ¼ 1.8-6.9; Table 3).
The frequency distribution of the rs738409 C!G
adiponutrin genotype, as well as the prevalence of the
GG genotype, was very similar between Italian and
UK patients with NAFLD (P ¼ nonsignificant;
Table 3).
In the family study conducted in 71 Italian trios, 56
families were ‘‘informative’’ in that one or both parents
were heterozygous for the SNP (a total of 76 parents
were heterozygous for the rs738409 C!G SNP). In
these families, the variant allele was transmitted on 52
of 76 (68%) possible occasions, whereas the wild-type
C allele was transmitted on only 24 of 76 (32%) occa-
sions (P ¼ 0.001).
Table 2. Primers Used for Evaluation of Hepatic Gene
Expression Analysis
Gene Primers
Adiponutrin (PNPLA3) Fw 50-TTTACAGTGGCCTTATCCCT-30
Rv 50-GAAAGTTCGTGGACTTGACT-30
b-actin Fw 50-GGCATCCTCACCCTGAAGTA-30
Rv 50-GGGGTGTTGAAGGTCTCAAA-30
FASL Fw 50-GCACTTTGGGATTCTTTCCA-30
Rv 50-CCTCCATTTGTCTGGCTCAT-30
INSR Fw 50-TCAACGGGCAGTTTGTCGAA-30
Rv 50-GCTGAAGTTCACACAGCGCC-30
PPAR-a Fw 50-ATGGCATCCAGAACAAGGAG-30
Rv 50-TCCCGTCTTTGTTCATCACA-30
FASL, Fas ligand; Fw, forward primer; INSR, insulin receptor; PPAR-a, peroxi-
some proliferator-activated receptor-a; Rv, reverse primer; SREBP1c, steroid reg-
ulatory element binding protein 1c.
Table 3. Frequency Distribution of the rs738409 CfiG
adiponutrin/PNPLA3 Genotype, Encoding for the I148M
Protein Variant, in 253 Italian Patients with NAFLD and 197
Italian Healthy Subjects with Normal Liver Enzymes and
Metabolic Parameters (P < 0.0001 for the Frequency
Distribution of the G Allele Between Italian Patients and
Controls), and in 321 NAFLD Patients from the
United Kingdom
PNPLA3 rs738409 CfiG genotype (encoding for I148M)
CC (148I/I) CG (148I/M) GG (148M/M)
Italian patients 103 (40.7) 114 (45.1) 36 (14.2)
Italian controls 118 (65.9) 56 (31.3) 5 (2.8)
Adjusted OR* Reference 0.80 3.29
95% CI – 0.5-1.2 1.8-6.9
UK patients 142 (44.2) 140 (43.6) 39 (12.1)
*For Italian patients versus Italian controls. Adjusted for age, sex, and BMI.
CI, confidence interval; OR, odds ratio.
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Influence of Adiponutrin Genotype on Metabolic
and Biochemical Parameters. The effect of the
rs738409 C!G adiponutrin genotype, encoding for
the I148M protein variant, on clinical features and
metabolic and biochemical parameters in Italian
patients is shown in Table 4. In patients with NAFLD,
the GG genotype was associated with higher LDL, and
both the CG and GG genotypes were associated with
lower HDL cholesterol, although it was not associated
with age, sex distribution, and BMI. The GG geno-
type was associated with significantly higher fasting in-
sulin levels and homeostasis model assessment of insu-
lin resistance (HOMA-IR) score, but not with
hyperglycemia or type 2 diabetes. In addition, the G
allele (148M variant) was associated with higher ALT
in a dose-dependent manner (P ¼ 0.0007).
Broadly similar data were obtained in the UK
cohort (Supporting Information Table 1). Patients car-
rying the GG genotype had significantly higher ALT
levels compared to those carrying the CC or GG geno-
types (76.0 6 54 IU/L CC, 74.5 6 56 CG, 123.0 6
103 GG; P < 0.0001 at ANOVA, P < 0.05 for GG
versus either CC or CG genotypes). In contrast to the
data in Italian patients, the rs738409 genotype was
not associated with abnormal HDL or LDL levels.
Association Between Adiponutrin Genotype and
Liver Damage. At histology, and as expected from
previous studies, using an additive model for adiponu-
trin genotype, carriage of the G allele was an inde-
pendent predictor for the presence of grade 2/3 steato-
sis together with BMI, sex, and diabetes in the
combined cohort. In the UK patients alone, both ge-
notype and age were predictors (Table 5A). More
importantly, the adiponutrin genotype was strongly
associated with the presence of NASH (Table 5B; P ¼
0.007 in the combined cohort, P ¼ 0.03 in the UK
cohort, and P ¼ 0.07 in the Italian cohort) and stage
>1 fibrosis (Table 5C; P ¼ 0.01 in the combined
cohort, P ¼ 0.06 in the UK cohort, and P ¼ 0.04 in
the Italian cohort) independent of BMI, diabetes and
steatosis (for NASH), and age, BMI, diabetes, steatosis,
and NASH (for fibrosis). Furthermore, there was a dose
effect of adiponutrin genotype, in that CG heterozygotes
had a prevalence of NASH and fibrosis intermediate
between CC and GG homozygotes (Fig. 1A,B).
Correlation Between Adiponutrin Expression,
Metabolic Features, and Liver Damage. Hepatic adi-
ponutrin mRNA levels, measured in 52 obese patients,
were not significantly affected by the presence of the
I148M variant (Fig. 2). Adiponutrin mRNA levels
were significantly higher in females than in males
(0.95 6 0.39 versus 0.66 6 0.24 arbitrary units, P ¼
0.002), and lower in patients with fibrosis >1 (0.64 6
0.2 versus 0.94 6 0.4 arbitrary units, P ¼ 0.01). Adi-
ponutrin mRNA levels correlated with serum triglycer-
ides (rho ¼ 0.63, P < 0.0001), but were not signifi-
cantly associated with age, BMI, diabetes and insulin
resistance, steatosis percentage, and the severity of
necroinflammation.
Association Between Adiponutrin Genotype and
Expression of Genes Associated with Steatosis-Related
Liver Damage. Expression of INSR, SREBP1c, PPAR-
Table 4. Association of the rs738409 CfiG adiponutrin/PNPLA3 SNP, Encoding for the I148M Protein Variant, with
Metabolic Features and Liver Damage in 253 Italian Patients with NAFLD
Characteristic
I148M PNPLA3 genotype
PyCC (148I/I) CG (148I/M) GG (148M/M)
Number 103 114 36
Age (years) 47 6 11 46 6 12 46 6 10 0.59
Sex (F) 32 (31) 33 (28.9) 11 (30.6) 0.93
BMI (kg/m2) 30.7 6 8 30.7 6 8 29.8 6 7 0.10
LDL (mg/dL) 129 6 41 129 6 46 152 6 35*,‡ 0.02
HDL (mg/dL) 48 6 13 42 6 12* 43 6 8* 0.004
Triglycerides (mg/dL) 145.6 6 74 163.5 6 94 158.5 6 78 0.30
Glucose (mg/dL) 96 6 19 99.9 6 35 98 6 15 0.71
Fasting insulin (IU/mL) 15.7 6 9 16.7 6 10 23.1 6 18*,‡ 0.01
HOMA-IR 3.9 6 3.5 4 6 2.7 5.2 6 4.7*,‡ 0.07
IFG-IGT / diabetes n (%) 16 (15)/9(8) 11 (10)/17(15) 7 (19)/3(8) 0.31
Hypertension 43 (41.7) 49 (43.0) 17 (47.2) 0.81
ALT (IU/mL) 47 6 30 56 6 44* 77 6 56*,‡ 0.0007
GGT (IU/mL) 91 6 107 83 6 119 73 6 76 0.68
Values in parentheses are % values. M, male; F, female; NAS, nonalcoholic steatohepatitis activity score.
†P at ANOVA,
*P < 0.05 versus the I/I PNAPLA3 genotype,
‡P < 0.05 versus the I/M genotype.
HEPATOLOGY, Vol. 51, No. 4, 2010 VALENTI ET AL. 1213
a, and FASL was significantly different among adipo-
nutrin genotypes (P < 0.05; Fig. 2). Homozygosity
for the 148M variant was associated with higher
expression of the proapoptotic molecule FASL, and
lower mRNA levels of INSR, SREBP1c, and PPAR-a
compared to the I/I 148 variant (P < 0.05; Fig. 2).
The expression of INSR and PPAR-a were negatively
correlated with percentage of steatosis and NAFLD
activity score (NAS) (rho ¼ 0.38, P ¼ 0.02 and rho
¼ 0.33, P ¼ 0.03, respectively for the correlation
of INSR with steatosis percentage and NAS; rho ¼
0.61, P ¼ 0.005 and rho ¼ 0.41, P ¼ 0.01,
respectively, for the correlation of PPAR-a with steato-
sis and NAS). SREBP1c was positively associated
with steatosis percentage (rho ¼ 0.38, P ¼ 0.02).
FASL expression correlated with fibrosis stage (rho ¼
0.36, P ¼ 0.02).
Discussion
The Adiponutrin/PNPLA3 genotype has recently
been identified by genomewide association studies as a
major inherited determinant of liver triglyceride accu-
mulation and ALT levels at the population level, and
the I148M variant as the most prevalent SNP predis-
posing to steatosis in Caucasians.12,13 These results
confirm that the frequency of the 148M variant is sig-
nificantly higher in patients with NAFLD compared
to controls with normal liver enzymes and metabolic
parameters.32 The risk of NAFLD was about 3.3-fold
higher in subjects carrying the rs738409 GG genotype,
and was detected in about 3% of healthy subjects but
in 14% of patients, compared to the CC genotype.
Because blood donors are often a healthy subset of the
population, and we carefully further excluded subjects
with any metabolic and liver enzyme abnormality, we
cannot exclude that the prevalence of the G allele is
higher in the general population, 20%-30% of whom
have NAFLD, than in our controls.
In line with previous data,12 the rs738409 SNP was
not associated with BMI and serum triglycerides, but
the 148M allele was associated with ALT levels in a
dose-dependent manner. The altered HDL cholesterol
levels observed in patients carrying the minor allele are
consistent with recent data indicating that adiponutrin
genotype influences lipoprotein metabolism.33 How-
ever, because this association has not been observed in
other populations12 and was not confirmed in patients
from the UK, additional studies are required to define
whether an interaction exists between liver steatosis
and the rs738409 SNP in determining lipoprotein
metabolism.
Table 5. Association of the adiponutrin/PNPLA3 rs738409 Genotype (Encoding for the 148 I/M Protein Variants) and Liver
Damage, as Evaluated by Multivariate Logistic Regression Analysis, in 574 Adult Italian and UK Patients with NAFLD
Variables
UK (n 5 321) Italy (n 5 253) Combined (n 5 574)
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
A. Steatosis (0þ1 versus 2þ3)
Genotype* 1.6 (1.10-2.37) 0.01 1.3 (0.88-1.9) 0.1 1.35 (1.04-1.76) 0.02
Age (years) 0.97 (0.95-0.99) 0.02 0.99 (0.97-1.02) 0.9 0.99 (0.97-1.1) 0.3
Sex 0.65 (0.37-1.14) 0.1 0.51 (0.24-2.02) 0.06 0.59 (0.38-90.89) 0.01
BMI (kg/m2) 1.04 (0.99-1.1) 0.07 1.1 (1.05-1.15) 0.00001 1.1 (1.07-1.14) 5.03  1010
Diabetes 0.82 (0.47-1.39) 0.47 2.79 (1.45-5.55) 0.002 1.82 (1.2-2.78) 0.005
B. NASH (presence versus absence)
Genotype* 1.5 (1.04-2.2) 0.03 1.7 (0.95-3.14) 0.07 1.5 (1.12-2.04) 0.007
Age (years) 1.0 (1.0-1.02) 0.02 1.0 (0.96-1.05) 0.2 1.01 (1.00-1.02) 0.006
Sex 0.76 (0.37-1.5) 0.4 0.44 (0.13-1.33) 0.09 0.68 (0.4-1.17) 0.1
BMI (kg/m2) 1.04 (0.99-1.09) 0.08 1.04 (0.98-1.12) 0.2 1.03 (1.00-1.07) 0.02
Diabetes 2.38 (1.43-4.17) 0.001 4.54 (1.82-12.5) 0.001 2.78 (1.79-4.55) 0.000009
Steatosis 2.56 (1.8-3.72) 0.0000003 32.1 (13.2-95.2) 1.4  1012 4.01 (3.02-5.42) 2  1016
C. Fibrosis (0-1 versus 2-4)
Genotype* 1.54 (0.98-2.45) 0.06 1.7 (1.02-3.1) 0.04 1.5 (1.09-2.12) 0.01
Age (years) 1.04 (1.01-1.06) 0.003 1.02 (0.98-1.06) 0.1 1.04 (1.02-1.06) 0.0001
Sex 1.28 (0.6-2.4) 0.48 0.57 (0.2-1.54) 0.2 1.1 (0.65-1.8) 0.7
BMI (kg/m2) 1.07 (1.00-1.14) 0.02 0.99 (0.93-1.04) 0.8 1.03 (0.99-1.07) 0.08
Diabetes 2.22 (1.19-4.35) 0.01 4.2 (1.85-9.9) 0.0007 2.56 (1.59-4.17) 0.0001
Steatosis 1.13 (0.71-1.8) 0.59 0.68 (0.39-1.17) 0.16 0.99 (0.71-1.37) 0.9
NASH 22.7 (11.0-51.5) 1.03  1015 15.4 (4.8-60.4) 0.00001 16.4 (8.96-32.1) 2  1016
CI, confidence interval; OR, odds ratio; NS, not significant.
*Based on an additive model for rs738409 genotype.
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In this study, we have confirmed in a large series of
biopsied patients that the adiponutrin rs738409 geno-
type influences both the presence of NASH and the se-
verity of fibrosis in patients with NAFLD independent
of the degree of obesity, the presence of diabetes, and
the previously demonstrated effect of genotype on stea-
tosis. This effect was observed in two independent
cohorts and confirmed in transmission disequilibrium
testing of family trios with fibrotic NAFLD. The asso-
ciation between adiponutrin genotype, steatosis, ALT
levels, and NASH is not a novel finding, although his-
tological damage has been evaluated so far only in
small series of patients.21,22,34 In contrast, the associa-
tion with fibrosis severity is completely novel. The ob-
servation that the association between genotype and
NASH/fibrosis is independent of steatosis provides fur-
ther evidence that steatosis may not be an a priori
‘‘first hit’’ in the development of progressive damage35
and suggests that adiponutrin, possibly by regulating
FFA fluxes, may be involved in pathogenic mecha-
nisms of NASH and fibrosis that are independent of
its effects on the amount of hepatic triglyceride accu-
mulation. An effect of adiponutrin genotype on FFA
flux, endoplasmic reticulum, and oxidative- or cyto-
kine-mediated stress would independently influence
both steatosis, necroinflammation, and fibrosis, and
would reconcile the clinical observation that steatohe-
patitis and fibrosis severity correlate with the degree of
steatosis.19 However, we cannot exclude that the loss
of liver fat, the presence of which is known to be asso-
ciated with the development of severe fibrosis, may
have negatively affected the association among adipo-
nutrin genotype, steatosis, and fibrosis severity in this
cross-sectional study.
Whether patients with the CG/GG genotype have
different response to therapy and outcome, or may
benefit from a tailored follow-up, needs to be eval-
uated in further studies.
In line with a functional effect of the I148M poly-
morphism on adiponutrin activity leading to steato-
sis,20 the rs738409 GG genotype, coding for the
148M/M variant, did not affect hepatic adiponutrin
mRNA, but influenced the expression of molecules
associated with steatosis-related liver damage, such as
INSR, PPAR-a, and the membrane receptor FASL. In
particular, FASL sensitizes hepatocytes to apoptosis
and has been implicated in the pathogenesis of
NASH,36 and indeed FASL expression was correlated
with fibrosis stage in the patients evaluated. Decreased
adiponutrin mRNA expression in patients with more
severe liver fibrosis suggests also that decreased activity
of the enzyme may predispose individuals to progres-
sive liver disease. However, because reduced mRNA
levels do not always translate to reduced protein levels,
Fig. 1. Prevalence of (A) NASH and (B) fibrosis in 591 biopsied
patients with NAFLD subdivided according to the adiponutrin
rs738409 C!G genotype (encoding for I148M) and the referral cen-
ter. (A) P ¼ 0.0002 at chi-squared for trend for the prevalence of
NASH across the adiponutrin genotypes in the combined series. (B) P
< 0.0001 at chi-squared test for trend for the prevalence of fibrosis
>1 across the adiponutrin genotypes in the combined series. *P <
0.05, **P < 0.005, ***P < 0.0001 versus CC genotype.
Fig. 2. Expression of adiponutrin and genes involved in insulin sig-
naling, lipogenesis, apoptosis, and fibrogenesis according to the adi-
ponutrin I148M genotype in 52 obese patients with NAFLD. Data are
shown as mean 6 standard error. FASL, Fas ligand; INSR, insulin re-
ceptor; PPAR-alpha, peroxisome proliferator-activated receptor-a;
SREBP1c, steroid regulatory element binding protein 1c. P < 0.05 for
the expression of INSR, SREBP1c, PPAR-alpha and FASL across adipo-
nutrin genotypes. *P < 0.05 versus I/I genotype.
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and gene expression analysis was restricted to a subset
of patients subjected to bariatric surgery, these data
should be interpreted with caution. Additional mecha-
nistic studies are required to clarify these issues.
The rationale for evaluating gene expression in bari-
atric patients was related to the availability at our center
of larger samples of hepatic tissue from needle biopsies
performed at the time of surgery, and of the full spec-
trum of liver pathology samples ranging from normal
liver without steatosis to fibrotic steatohepatitis. More-
over, even if the high BMI of the evaluated subject may
limit generalizability of the results, this population has
the advantage of eliminating the confounding effect of
peripheral adiposity (which was present in all subjects)
on liver fat and gene expression.
A limitation of this study is the lack of ultrasono-
graphic exclusion of liver steatosis in control subjects.
However, these subjects were carefully selected among
a much larger pool of healthy blood donors because of
normal metabolic parameters, liver enzymes, and a
very low fatty liver index.24 Another limitation is
related to the relatively small number of patients, all
affected by severe obesity, who were subjected to gene
expression evaluation. However, the strengths of this
study are: (1) it is by some considerable margin the
largest association study examining the influence of the
adiponutrin I148M genotype on NAFLD histological
severity; (2) the associations were present in two inde-
pendent cohorts of patients and confirmed in a family
study; and (3) this is the largest association study for
which hepatic gene expression data in relation to the
adiponutrin genotype are available.
In conclusion, the adiponutrin I148M genotype is
associated with the risk of developing NAFLD and its
progression to necroinflammation and fibrosis. Further
studies on the function of adiponutrin are awaited
with interest, but these data suggest that this is
unlikely to be restricted to a role in the accumulation
of hepatic triglyceride.
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76a complex disease trait where genetic variations and environ-
ment interact to determine disease progression. The association
of PNPLA3 with advanced disease has been consistently demon-
strated but many other modifier genes remain unidentified. In
NAFLD, increased fatty acid oxidation produces high levels of
reactive oxygen species. Manganese-dependent superoxide dis-
mutase (MnSOD), encoded by the SOD2 gene, plays an important
role in protecting cells from oxidative stress. A common non-syn-
onymous polymorphism in SOD2 (C47T; rs4880) is associated
with decreased MnSOD mitochondrial targeting and activity
making it a good candidate modifier of NAFLD severity.
Methods: The relevance of the SOD2 C47T polymorphism to
fibrotic NAFLD was assessed by two complementary approaches:
we sought preferential transmission of alleles from parents to
affected children in 71 family trios and adopted a case-control
approach to compare genotype frequencies in a cohort of 502
European NAFLD patients.
Results: In the family study, 55 families were informative. The T
allele was transmitted on 47/76 (62%) possible occasions whereas
the C allele was transmitted on only 29/76 (38%) occasions,
p = 0.038. In the case control study, the presence of advanced
fibrosis (stage >1) increased with the number of T alleles,
p = 0.008 for trend. Multivariate analysis showed susceptibility
to advanced fibrotic disease was determined by SOD2 genotype
(OR 1.56 (95% CI 1.09–2.25), p = 0.014), PNPLA3 genotype
(p = 0.041), type 2 diabetes mellitus (p = 0.009) and histological
severity of NASH (p = 2.0  1016).
Conclusions: Carriage of the SOD2 C47T polymorphism is associ-
ated with more advanced fibrosis in NASH.
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familial allele association studies. J Hepatol (2011), doi:10.1016/j.jhep.2011.05.029Non-alcoholic fatty liver disease (NAFLD), widely considered to
be the hepatic manifestation of the metabolic syndrome, encom-
passes a spectrum of liver disease from simple steatosis (fatty
liver) through non-alcoholic steatohepatitis (NASH) to fibrosis
and ultimately cirrhosis in the absence of alcohol abuse [1]. The
prevalence of NAFLD is rapidly increasing and it is now the most
common cause of chronic liver disease in Western countries [2].
Despite its high prevalence, only a minority of patients with ste-
atosis progress to develop inflammation and less than a quarter
of subjects with NAFLD ever progress beyond steatosis to signif-
icant fibrosis and cirrhosis [3,4].
NAFLD is best considered a complex disease trait where subtle
inter-patient variations including host genetic factors and environ-
ment interact to produce disease phenotype and determine disease
progression [5–7]. Basic science is helping to elucidate the mecha-
nisms perpetuating liver cell injury and fibrosis in NAFLD through
in vitro and in vivo studies. Attention is currently focused on the role
of increased free fatty acid (FFA) flux on a background of insulin
resistance as key drivers of pathogenesis through hepatocellular
oxidative stress secondary to reactive oxygen species (ROS) produc-
tion during b- and x-FFA oxidation, direct lipotoxicity, cytokine
releaseandendoplasmic reticulumstress. Consequentcellulardam-
age triggers a mixture of immune mediated hepatocellular injury
and both necrotic and apoptotic cell death pathways [8–11]. Persis-
tence of these processes culminates in hepatic fibrosis [12].
Whilst the reasons for the apparent variation in individual
susceptibility to progressive disease are incompletely under-
stood, family/ethnic studies suggest that genetic factors play a
significant role [13,14]. Accordingly, genes encoding proteins
influencing the magnitude of these different forms of cellular
stress are obvious candidates as genetic factors contributing to
susceptibility to progressive NAFLD [5]. Single nucleotide poly-
morphisms (SNPs) in several candidate genes involved in inflam-
mation, oxidative stress and fibrogenesis have been associated
with the severity of liver damage in NAFLD (reviewed [5]). As
yet, only the association of PNPLA3with advanced NASH has been
consistently replicated in large studies [5].11 vol. xxx j xxx–xxx
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18 October 2011The mitochondrial enzyme manganese-dependent superoxide
dismutase (MnSOD), encoded by the nuclear SOD2 gene, plays an
important role in protecting cells from superoxide radicals [15].
SOD2 is subject to a common polymorphism (C47T, rs4880)
which results in an amino acid substitution in the signal
sequence targeting the enzyme to the mitochondrion (Ala16Val)
and may induce a conformational change in the protein tertiary
structure [16]. The presence of alanine at position 9 in this
sequence (C47 allele) has been demonstrated to be associated
with more efficient protein import than valine (T47 allele) by
in vitro expression studies and is predicted to result in higher
enzyme activity [17,18]. This SOD2 polymorphism (rs4880) has
been investigated as a possible susceptibility factor in NASH
and several other diseases where oxidative stress is considered
to play a role in pathogenesis including hereditary hemochroma-
tosis [19] and drug induced liver injury [20]. A small study in 63
Japanese patients found a significantly increased prevalence of
the lower activity homozygous T genotype among cases [21].
More recently, the homozygous T genotype was reported to be
associated with an increased incidence of diabetic nephropathy
in large studies of type 1 diabetics from Sweden [22] and Den-
mark [23] and with susceptibility to pancreatic cancer in a US-
based study [24]. SOD2 has also been investigated in relation to
susceptibility to alcoholic liver disease but the results have been
inconsistent and inconclusive [25,26].
To further examine this biologically plausible association
between SOD2 genotype and susceptibility to fibrosing steato-
hepatitis, we have used two complementary approaches. Firstly,
we have carried out a family study analyzing trios consisting of
children with fibrotic NAFLD and their two parents in which we
have performed transmission disequilibrium test (TDT) analysis
to determine whether there is preferential transmission of a par-
ticular parental allele to the affected children [27]. Secondly, we
performed a classical case-control allelic association study in
unrelated patients with NAFLD of varying severity including five
times more patients than that reported previously [21].180
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207Materials and methods
Patients
A large patient cohort was recruited across centers in UK and Italy. The study had
all necessary ethical approvals in both countries and all participants (or their par-
ents) gave informed consent.
The Italian family study, collected DNA from 71 Italian family ‘trios’ in Rome
(210 individuals) each comprising two living parents and an index child with
biopsy-proven fibrotic NAFLD. Other causes of liver disease were excluded,
including increased alcohol intake, chronic viral hepatitis, autoimmune hepatitis,
hereditary hemochromatosis, a1-antitrypsin deficiency, Wilson’s disease, and
drug induced liver disease. Detailed clinical data concerning these children has
been presented previously [28].
For the case-control study, 502 European Caucasian patients with biopsy-
proven NAFLD of different stages of disease were enrolled (338 patients from
Newcastle upon Tyne, UK and a further 164 patients from Milan, Italy). Baseline
characteristics of the cohort are shown in Table 1. These were unrelated
patients with NAFLD, derived from a patient population originally identified
as having ultrasonographically detected bright liver and abnormal biochemical
tests (ALT and GGT) between January 1999 and 2007 [29]. Alternate diagnoses
were excluded, including increased alcohol intake (males and females consum-
ing greater than 21/14 U of alcohol per week [>30/20 g/day ethanol] respec-
tively were excluded), as were any individuals with chronic viral hepatitis
(hepatitis B and hepatitis C), autoimmune liver diseases, hereditary hemochro-
matosis, a1-antitrypsin deficiency, Wilson’s disease, and drug induced liver
disease.Please cite this article in press as: Al-Serri A et al. The SOD2 C47T polymorphis
familial allele association studies. J Hepatol (2011), doi:10.1016/j.jhep.2011.05.029
2 Journal of Hepatology 201Clinical and laboratory data were collected on the date a diagnostic liver
biopsy was performed. Body mass index (BMI) was calculated using the formula:
weight (kilograms)/height (m2). The presence of diabetes mellitus (fasting glu-
coseP7.1 mmol/L mg/dl or treatment with anti-diabetic drugs) and hypertension
(blood pressureP130/85 or on treatment for previously diagnosed hypertension)
was recorded. Laboratory evaluation included routine liver biochemistry (alanine
and aspartate aminotransferase, total bilirubin, albumin, alkaline phosphatase
and gamma glutamyl transpeptidase); complete blood count; total- and HDL-cho-
lesterol and total triglycerides; fasting glucose; fasting insulin; viral serology for
hepatitis B and C infection, and autoantibodies.
Liver biopsy
Ultrasound guided liver biopsy was performed in all patients. Specimens (at least
1.6 cm length and 5 lm thick) were fixed in formalin for evaluation. Tissue sec-
tions were stained with hematoxylin and eosin, impregnated with silver for visu-
alizing reticulin framework, and stained with trichrome for visualizing collagen.
Liver biopsies were reviewed by a single expert liver pathologist at each partici-
pating center, unaware of clinical or genetic data. The severity of steatosis, necr-
oinflammatory grade and stage of fibrosis were scored according to modified
Brunt criteria [30]. For fibrosis, stage 0 = no fibrosis; stage 1 = isolated perisinu-
soidal or portal fibrosis; stage 2 = perisinusoidal and portal/periportal fibrosis;
stage 3 = septal or bridging fibrosis; and stage 4 = cirrhosis. As the main aim of
this study was to evaluate the possible role of the polymorphism of SOD2 in pre-
dicting patients with progressive NAFLD, a priori we considered the presence of
stage 2 fibrosis in adults to be indicative of a more progressive disease phenotype.
Given the younger age and therefore limited duration of disease exposure of pedi-
atric patients, the presence of fibrosis stage 1 or greater was considered indicative
of a progressive disease phenotype in the family study.
DNA preparation
Venous blood was collected at the time of liver biopsy and DNA was prepared
from peripheral blood lymphocytes as described previously [31]. Genotyping
was performed by personnel unaware of clinical status or histology of patients.SOD2 rs4880 genotyping
SOD2 genotype was determined by PCR-RFLP analysis using a minor modification
of our previously described method [26]. The final volume (20 ll) of the PCR reac-
tion contained 0.5–1 lg genomic DNA, 0.625 U Taq DNA polymerase, 1 Taq DNA
polymerase reaction buffer (50 mM potassium chloride, 10 mM Tris–HCl pH 9.0,
0.1% (v/v) Triton X-100, 1.5 mMMgCl2), 0.1 mM dNTPs and 0.25 lM both forward
and reverse primers (50-CAGCCCAGCCTGCGTAGACGG-30 and 50-GCGCGTTGATG
TGAGGTTCCAG-30). Amplification (35 cycles of denaturation at 95 C for 1 min,
annealing at 63 C for 1 min and extension at 72 C for 1 min) was then per-
formed in a GeneAmp PCR system 9700 thermal cycler. After successful amplifi-
cation, PCR products (6 ll) were diluted with the appropriate restriction enzyme
buffer to a final volume of 20 ll and 5 U BsaWI added. The digestion was then
incubated at 60 C for 3 h. The presence of a T at the polymorphic site results
in the creation of a restriction site for BsaWI. Digests were analyzed by polyacryl-
amide gel electrophoresis on 10% polyacrylamide gels in 1 TBE buffer and visu-
alized by staining with ethidium bromide.Statistical analysis
Statistical analyses were performed using various packages including ‘genetics’,
‘combinat’ and ‘dgc.genetics’ running in the R software environment (R version
2.7.1) [32]. Transmission disequilibrium tests (TDT) were performed to determine
preferential transmission of alleles and statistical significance in the family study.
This approach is not subject to many of the potential confounding effects inherent
in case control studies and is significantly more powerful at detecting true asso-
ciations [27]. In the cohort study, we evaluated by univariate and multivariate
analysis the capability of SOD2 to predict progressive NAFLD (fibrosis 2–4). Para-
metric and non-parametric data were presented as means ± standard deviation
and percentage when appropriate. The statistical analysis was performed using
ANOVA, Student t test, Pearson Chi-square test and Chi-square test for trend,
when appropriate. Significance was taken as p <0.05. Hardy–Weinberg equilib-
rium was determined for each study population using the web-based calculator
available at www.tufts.edu/ which confirmed that UK and Italian study popula-
tions were in equilibrium. The multivariate analysis was performed by logisticm influences NAFLD fibrosis severity: Evidence from case-control and intra-
1 vol. xxx j xxx–xxx
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
Table 1. Cohort characteristics.
All UK Italy p value*
Number 502 338 164 -
Country/Ethnicity Caucasian UK Caucasian Italy Caucasian -
Sex (Male) 339 (67.5%) 210 (62.1%) 129 (78.6%)
SOD2 rs4880 C-Allele frequency 0.491 0.494 0.484
Age, years 49.1 ± 12.3 49.7 ± 12.7 47.9 ± 11.4 0.1
BMI, kg/m2 31.8 ± 5.7 34.05 ± 5.3 27.4 ± 3.8 4.5x10-45
DM 166 (33.5%) 127 (38.3%) 39 (23.7%) 0.001
HOMA-IR 5.5 ± 5.3 6.3 ± 6.2 4.3 ± 3.5 0.0003
ALT, IU/L 75.1 ± 59.2 80.6 ± 64.05 63.7± 46.1 0.001
Total cholesterol 5.44 ± 1.5 5.6 ± 1.3 5.09 ± 1.7 0.0007
TG 2.42 ± 1.8 2.81 ± 2.0 1.64 ± 1.0 2x10-16
Steatosis score
1 198 (40%) 96 (29%) 102 (62%) <0.0001
2 178 (36%) 145 (44%) 33 (20%) <0.0001
3 115 (24%) 86 (27%) 29 (18%) 0.03
NASH (yes) 263 (53%) 184 (55%) 79 (48%) 0.18
Fibrosis score
0 215 (43%) 129 (38%) 86 (52.4%) 0.002
1 108 (22%) 62 (18%) 46 (28.1%) 0.01
2 76 (15%) 56 (17%) 20 (12.1%) 0.23
3 62 (12%) 55 (16%) 7 (4.3%) 0.00008
4 41 (8%) 36 (11%) 5 (3.1%) 0.004
⁄Statistical analysis of UK vs. Italian recruitment centers.
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18 October 2011regression analysis to evaluate the factors associated with progressive NAFLD
(fibrosis stageP2). The results of the multivariate analysis are expressed as odds
ratio (OR) with 95% confidence intervals (CI).235
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251Results
The SOD2 C47T allele is preferentially transmitted to children with
fibrosing steatohepatitis
In the Italian family study, 61 out of the 71 children had fibrosing
steatohepatitis (59 patients exhibited stage 1 fibrosis and 2
patients had stage 2 disease). Transmission disequilibrium test-
ing (TDT) [27] was used to seek preferential transmission of
either SOD2 allele to affected children in the family study. For
SOD2 rs4880, 55 out of the 71 families were informative in that
one or both parents were heterozygous for this SNP. In these fam-
ilies, the T allele was transmitted on 47/76 (62%) possible occa-
sions whereas the C allele was transmitted on only 29/76 (38%)
occasions, p = 0.038.252
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259Carriage of the C47T SOD2 genotype is associated with advanced
fibrosis
To determine whether carriage of the SOD2 rs4880 SNP
influenced susceptibility to fibrosing steatohepatitis in an adult
population, we examined whether it was associated with histo-
logical disease progression in a large cohort of NAFLD patients.
The total study population of 502 patients with biopsy-proven
NAFLD was genotyped for SOD2 rs4880. Clinical details arePlease cite this article in press as: Al-Serri A et al. The SOD2 C47T polymorphis
familial allele association studies. J Hepatol (2011), doi:10.1016/j.jhep.2011.05.029
Journal of Hepatology 201reported in Table 1. Broadly, the UK study population exhibited
a more severe metabolic syndrome and NASH phenotype than
the Italian population. SOD2 genotypes were in Hardy–Weinberg
equilibrium. Similar SOD2 allele frequencies were observed at
both the UK (C47: 49.4%) and Italian (C47: 48.4%) centers which
were consistent with those observed in a cohort of North-Wes-
tern European descent by the International HapMap project
(www.ncbi.nlm.nih.gov/projects/SNP; rs4880).
Table 2 summarizes the relationship between SOD2 genotype
and a number of patient-specific and clinical parameters relevant
to the disease. Both age and a fibrosis score >1 were significantly
associated with SOD2 genotype. In particular, a gene-dosage
effect was observed with the incidence of advanced fibrosis
(stage >1) increasing with the number of T (Val) alleles
(p = 0.008, v for trend) (Fig. 1). 72.2% of CC individuals had a
fibrosis score of 0 or 1 compared with 56.2% of homozygous T
patients. Homozygosity for the T allele vs. C was associated with
an odds ratio of 2.02 (95% CI 1.19–3.45; p = 0.008) for the devel-
opment of fibrosis of grade 2 or above. There was no significant
difference for steatosis score or other clinical parameters, includ-
ing the presence of diabetes, between SOD2 genotype groups.
Multivariate analysis and relevance of PNPLA3 genotype
Given the previous reports demonstrating a role for PNPLA3
I148M [33,34] as a modifier of disease progression in NAFLD,
the cohort was also genotyped for this polymorphism. A multi-
variate logistic analysis was performed to control for the effect
of PNPLA3 together with other factors relevant to disease severity.
In line with our previous findings [34], a dominant effect for them influences NAFLD fibrosis severity: Evidence from case-control and intra-
1 vol. xxx j xxx–xxx 3
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Table 2. Comparison of selected patient characteristics according to SOD2
genotype.
Phenotype Combined Cohort
CC
(n = 119)
CT
(n = 255)
TT
(n = 128)
p value
Age (yrs) 49.6 ± 12.6 47.9 ± 12.1 51.3 ± 12.1 0.036
BMI (kg/m2) 31.9 ± 5.9 32.1 ± 6.1 30.9 ± 5.1 0.1
Gender
Male 76 (0.64) 173 (0.68) 90 (0.70) 0.2
Female 43 (0.36) 82 (0.32) 38 (0.30)
Diabetes
Yes 32 (0.27) 87 (0.35) 47 (0.38) 0.07
No 87 (0.73) 164 (0.65) 78 (0.62)
Fibrosis >1
Yes 33 (0.19) 90 (0.50) 56 (0.31) 0.008
No 86 (0.27) 165 (0.51) 72 (0.22)
NASH
Yes 59 (0.22) 131 (0.5) 73 (0.27) 0.1
No 60 (0.26) 121 (0.52) 51 (0.22)
Steatosis >1
Yes 66 (0.23) 146 (0.5) 81 (0.27) 0.11
No 52 (0.26) 104 (0.53) 42 (0.21)
Hypertension
Yes 58 (0.23) 118 (0.47) 74 (0.3) 0.1
No 53 (0.24) 124 (0.56) 44 (0.2)
ALT (IU/L) 70.4 ± 49.7 77.1 ± 62.2 75.5 ± 61.4 0.6
Glucose 35.4 ± 41.7 37.8 ± 49.2 40 ± 47 0.7
Insulin 21 ± 18.8 20.3 ± 17.8 19.2 ± 14.6 0.8
HOMA-IR 5.6 ± 6.2 5.6 ± 5.2 5.1 ± 4.5 0.8
Total cholesterol 
(mmol/L)
5.3 ± 1.4 5.5 ± 1.4 5.2 ± 1.6 0.08
TG (mmol/L) 2.3 ± 1.5 2.5 ± 2.1 2.2 ± 1.3 0.1
Population Hardy–Weinberg calculation (UK: v2 ¼ 0:58, p = 0.44; Italy: v2 ¼ 0:21,
p = 0.65; combined: v2 ¼ 0:13, p = 0.72) i.e. in equilibrium. Advanced fibrosis
with TT genotype vs. CC 2.02 (95% CI 1.19–3.45), p = 0.008; CC vs. CT 1.4 (0.88–
2.28), p = 0.14.
Table 3. Multivariate analysis by disease element. (A) Steatosis 0 + 1 vs. 2 + 3.
(B) NASH 0 vs. 1. (C) Fibrosis 0 + 1 vs. 2 + 3 + 4.
A
Variables OR (95% CI) p value
SOD2 1.35 (1.01-1.80) 0.039
PNPLA3 1.64 (1.09-2.46) 0.016
Age 0.98 (0.96-0.99) 0.040
Sex 0.74 (0.46-1.19) 0.222
BMI 1.06 (1.02-1.11) 0.003
Diabetes 1.46 (0.94-2.27) 0.09
Recruitment Centre 0.33 (0.20-0.54) 1.2x10-5
B
Variables OR (95% CI) p value
SOD2 1.09 (0.81-1.48) 0.538
PNPLA3 1.44 (0.94-2.21) 0.091
Age 1.02 (1.00-1.04) 0.024
Sex 0.74 (0.44-1.22) 0.244
BMI 1.06 (1.01-1.11) 0.008
Diabetes 2.97 (1.86-4.78) 5.3 x10-6
Steatosis 3.91 (2.86-5.45) 2x10-16
Recruitment Centre 2.21 (1.27-3.91) 0.005
C
Variables OR (95% CI) p value
SOD2 1.56 (1.09-2.25) 0.014
PNPLA3 1.69 (1.02-2.84) 0.041
Age 1.02 (0.99-1.04) 0.056
Sex 1.41 (0.81-2.5) 0.231
BMI 1.03 (0.97-1.08) 0.261
Diabetes 1.94 (1.17-3.21) 0.009
Steatosis 0.81 (0.56-1.16) 0.273
NASH 21.9 (1.16-44.3) 2x10-16
Recruitment Centre 0.33 (0.17-0.62) 0.0006
Calculations assume a co-dominant model for SOD2 and a dominant model for
PNPLA3 variants.
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18 October 2011PNPLA3 variant allele was assumed. Recruitment center (UK vs.
Italy) was included within the analysis to ensure that variations
in environmental influences were controlled. In multivariate
analysis, degree of steatosis was found to be significantly
associated with BMI and SOD2 genotype (odds ratio 1.35 (95%
CI 1.01–1.80), p = 0.039) as well as, in agreement with our273
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Fig. 1. Gene dosage effect of SOD2 C47T SNP on NASH associated fibrosis.
Prevalence of advanced fibrosis in 502 patients with biopsy proven NASH
subdivided according to SOD2 C47T genotype. Chi-squared for trend p = 0.008. CC
vs. CT + TT: OR 1.6 (1.02–2.5) p = 0.038.
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4 Journal of Hepatology 201previous findings, PNPLA3 genotype (Table 3A). Steatohepatitis
was independently associated with a greater degree of steatosis,
age, BMI and the presence of diabetes (Table 3B). Consistent with
its metabolic function and supporting the view that SOD2 geno-
type exerts its modifier effect through direct modulation of fibr-
ogenic response to oxidative stress rather than initiation of
steatohepatitic injury, carriage of neither SOD2 allele predicted
severity of steatohepatitis (Table 3B). The analysis confirmed that
carriage of the SOD2 rs4880 polymorphism was an independent
risk factor for advanced fibrosis (OR 1.56 (95% CI 1.09–2.25),
p = 0.014) (Table 3C). The effect of SOD2 on fibrosis was compara-
ble to that of PNPLA3 (rs738409; I148M) (OR 1.69, p = 0.041). His-
tological steatohepatitis grade also remained a strong predictor of
fibrosis stage (OR 21.9 (95% CI 1.16–44.3), p = 2.0  1016).280
281
282Discussion
Using both case-control and intra-familial association methodol-
ogies, we have shown a consistent association between am influences NAFLD fibrosis severity: Evidence from case-control and intra-
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18 October 2011functional SNP in the mitochondrial targeting sequence of SOD2
and fibrosis severity in NAFLD. These results provide persuasive
genetic evidence that mitochondria-derived oxidative stress is
important in the pathogenesis of advanced NAFLD. In particular,
use of TDT analysis in a young NAFLD population is a novel fea-
ture. In addition, we have also demonstrated a strong association
with SOD2 genotype in a European case-control study population
(p = 0.008, v for trend). The central role of MnSOD in cellular pro-
tection against oxidative stress has been well demonstrated by
the finding that deficiency of this enzyme is lethal in mice [35].
Homozygous knockout mice typically die within the first 10 days
post-natally, with impairment of function of several organs, par-
ticularly the heart [36]. Hepatic steatosis is also observed in this
model, reflecting the interaction between ROS production and
exacerbation of hepatic insulin resistance and lipid accumulation.
An effect that was also observed in the current study where
increased steatosis with SOD2 genotype was found (p = 0.039),
possibly reflecting oxidative stress mediated Apolipoprotein B
degradation and impaired VLDL excretion [37]. Heterozygous ani-
mals have a normal lifespan but evidence for increased hydroper-
oxide accumulation in hepatocyte mitochondria followed by
apoptosis has been reported [36]. More recently, conditional
knockouts with deficiency of MnSOD only in hepatocytes have
been generated. These animals show a number of signs of liver
failure as well as loss of metabolic zonation [38].
The presence of alanine at position-9 in the SOD2 sequence
(C47 allele) has been demonstrated to be associated with more
efficient protein import than valine (T47 allele) by in vitro expres-
sion studies and is predicted to result in greater SOD2 enzyme
activity[17,18]. Expression of the SOD2 gene is inducible by a
variety of modulators ranging from cytokines to UV irradiation
[15] but it is likely that even when induced, the difference
between the two allelic variants will be maintained. Our associa-
tion of T allele carriage with greater NAFLD severity is consistent
with the previous small study in a Japanese population [21] and
also with studies on other diseases where oxidative stress is
likely to be relevant to disease pathogenesis including diabetic
nephropathy [22], pancreatic adenocarcinoma [24], exocrine pan-
creatic insufficiency in chronic alcoholic pancreatitis [39] and
diabetic retinopathy [40]. SOD2 is a relatively small gene of
14 kb and consists of a single haplotype block. SNPs other than
rs4880 have been described but most of those studied previously,
for example rs2855116 [41], are in strong linkage disequilibrium
with the rs4880 SNP, which is the only common non-synony-
mous polymorphism described in SOD2.
In the mammalian liver, fatty acid oxidation occurs in three
organelles; b-oxidation takes place in the mitochondria and
peroxisomes and cytochrome P4504A mediated x-oxidation
takes place in the microsomes [42,43]. The synthesis of reactive
oxygen species by fatty acid metabolism and the mitochondrial
respiratory chain is increased in patients with NAFLD [44]. ROS
are able to induce lipid peroxidation of the expanded lipid stores,
compromise mitochondrial integrity and promote apoptotic cell
death [44]. There is increasing evidence from studies in both
humans and rodents that fibrotic NAFLD is associated with
increased levels of ROS and mitochondrial abnormalities [45].
Superoxide-generated lipid hydroperoxides degrade to several
hydroxy-alkenals including 4-hydroxynonenal. Studies in both
humans and animals suggest that 4-HNE induces and/or activates
uncoupling protein 2 (UCP2) [46]. Though this process results in
uncoupling of substrate oxidation from ATP synthesis and shouldPlease cite this article in press as: Al-Serri A et al. The SOD2 C47T polymorphis
familial allele association studies. J Hepatol (2011), doi:10.1016/j.jhep.2011.05.029
Journal of Hepatology 201avoid a further increase in mitochondrial hydrogen peroxide pro-
duction, ATP depletion makes cells more vulnerable to damage if
exposed to further insults. The high activity (C47) form of MnSOD
is likely to protect mitochondria from superoxide exposure better
than the T47 form, thus avoiding the need to uncouple the elec-
tron transfer process.
As with many other complex genetic diseases, susceptibility
to fibrotic NAFLD is likely to be determined by epistatic interac-
tion of a number of different genes and environmental influences,
indeed several genetic modifiers have been reported across a
range of progressive liver diseases [5,34,47–53]. In clinical stud-
ies, it is difficult or impossible to control for all subtle inter-
patient variations, whether genetic or environmental, that inter-
act to determine disease phenotype and progression [7] and so
there remains a need for validation in independent patient
cohorts, either through further candidate gene studies or large-
scale genome-wide association studies. However, SOD2 repre-
sents a good example of a biologically plausible candidate gene
with a common, well-established, functionally significant poly-
morphism. This study clearly demonstrates the predicted associ-
ation with disease susceptibility for fibrosing steatohepatitis and
has several key methodological strengths: (i) it is the largest
association study examining the influence of SOD2 on NASH asso-
ciated fibrosis; (ii) the cohort studied comprised patients with
biopsy proven NASH; and (iii) the association was further demon-
strated in a family study where preferential transmission of the
low activity (T47) allele was seen in offspring with biopsy proven
NASH. Much focus is given to changes in gene expression that
increase ROS in NASH pathogenesis whilst the role of modifiers
of host defense is too often ignored. The current study highlights
the importance of this aspect of disease pathogenesis. Although
results of some therapeutic trials of anti-oxidants in NASH have
been inconclusive [54–59], other large studies have been sup-
portive [60]. Taken together with the data presented here, these
provide a strong rationale for further investigation of the utility
of anti-oxidants to ameliorate fibrosis progression in
steatohepatitis.Conflict of interest
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are not associated with the severity of liver damage independently of
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Milan, ItalyBackground & Aims: The T-455C and C-482T APOC3 promoter fibrosis) in Italian as well as in UK patients, and in the whole
region polymorphisms (SNPs) have recently been reported to pre-
dispose to dyslipidemia, insulin resistance, and nonalcoholic fatty
liver disease (NAFLD) in Indian subjects, but the association with
liver damage has not been evaluated so far. The aim was to assess
the association between APOC3 SNPs and liver damage in Cauca-
sian patients.
Methods:We considered 437 Italian patients with histological
diagnosis of NAFLD (including 137 children, 120 morbid obese)
and 316 healthy controls, 71 Italian family trios, and 321 patients
from the UK. APOC3 SNPs were determined by sequencing, allele-
specific oligonucleotide probes and PCR–restriction fragment
length polymorphism analysis, hepatic APOC3 mRNA levels by
real-time PCR.
Results:APOC3 SNPs were not associated with NAFLD in Italian
subjects, although a borderline significance for the transmission
of the 455T allele was observed in the family study. Homozy-
gosity for the APOC3wild-type genotype (APOC3 WT) was associ-
ated with a more favorable lipid profile in control subjects, and
consistently with lower hepatic APOC3 mRNA levels in obese
patients without diabetes. However, APOC3 SNPs, alone or in
combination, were not associated with insulin resistance, altered
lipid levels, liver enzymes, and with liver damage (severity of ste-
atosis, nonalcoholic steatohepatitis, and moderate/severeJournal of Hepatology 20
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Nonalcoholic fatty liver disease (NAFLD), affecting 20–34% of the
population in Western countries [1,2], is the hepatic manifesta-
tion of the metabolic syndrome [3], and is associated with
increased mortality due to liver disease [4,5].
Insulin resistance (IR) is a key factor in NAFLD pathophysiol-
ogy and is deeply entangled with the progression of liver disease.
Adipose tissue IR results in an excess of fatty acids supply to the
liver [6], which induces lipotoxicity, oxidative stress, and apopto-
sis thus leading to steatohepatitis (NASH) [7]. NASH is considered
the progressive form of NAFLD and is characterized by necroin-
flammatory changes and hepatocellular damage (ballooning),
with potential evolution to fibrosis. IR predicts the severity of
liver disease and is directly involved in the pathogenesis of liver
damage [4,8,9].
Inherited factors play a major role in the susceptibility to
NASH [10–13], and recently the rs738409 C >G single nucleotide
polymorphism (SNP) of patatin-like phospholipase domain con-
taining-3 (PNPLA3), encoding the I148M protein variant, was
identified by a genomewide approach as a strong genetic
determinant of liver fat content independently of body mass,
dyslipidemia, and insulin resistance [14], and associated with
NASH and progressive fibrosis in patients with steatosis
[15–17]. In a large series of Caucasian patients with histological
evaluation of liver damage, we have previously shown that also
some genetic variants influencing insulin signaling and oxidative
stress predispose to NASH and fibrosis in patients with steatosis
[9,18,19].11 vol. xxx j xxx–xxx
promoter region polymorphisms are not associated with the severity of liver
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Interestingly, Petersen et al. have recently reported that the
two common Apoliporotein C3 (APOC3) T-455C and C-482T pro-
moter SNPs that hamper the regulation of the apolipoprotein
C3 expression by insulin signaling via FOXO1 phosphorylation
[20], predispose to liver fat accumulation in Indian men by
altering lipid metabolism and IR [21]. However, the relationship
with altered liver enzymes and liver damage was not assessed.
The aim of this study was to evaluate whether the T-455C and
C-482T APOC3 promoter SNPs influence the severity of liver
damage (i.e. the presence of NASH and moderate/severe fibrosis)
in Caucasian patients with NAFLD.Patients and methods
Patients
We analyzed DNA from 758 unrelated patients with biopsy proven NAFLD diag-
nosed between January 1999 and January 2008. These included 163 Italian
patients who underwent liver biopsy because of persistently abnormal liver
enzymes/serum ferritin or a long lasting history of steatosis associated with
severe metabolic abnormalities (82% overweight, 26% obese), 137 Italian severely
obese patients who underwent percutaneous liver biopsy performed during bari-
atric surgery, 137 Italian children (100% obese after age correction), and 321 adult
patients from Newcastle, UK, who were biopsied because of persistently abnor-
mal liver enzymes (98% overweight, 84% obese, and 44% severely obese). Other
causes of liver disease were excluded, including increased alcohol intake (>30/
20 g/day for M/F), as confirmed by at least one family member or friend and carb-
oxydesialylated transferrin determination, viral and autoimmune hepatitis,
hereditary hemochromatosis, and alpha1-antitrypsin deficiency. We included
bariatric patients because of the high, but not universal, risk of NAFLD and in par-
ticular of progressive NASH in severely obese patients [22], despite their over-
whelming increase in body mass. In addition, PNPLA3 genotype, a major
determinant of liver fat in the general population, has been shown to predispose
to liver damage in particular in morbidly obese subjects [23]. This makes these
subjects an ideal group to test the effect of genetic factors specifically influencing
liver steatosis and NASH progression independently of body mass [9,15,24]. Part
of this group had previously been described [25]. The available demographic and
clinical features are shown in Table 1. All patients included in the study had a
fatty liver index >50 [26].Table 1. Demographic and clinical features of patients with NAFLD and controls.
Italian controls
Italian adults
Number 316 180
Sex F 54 (18) 34 (19)
Age years 48 ± 12 48 ± 12
BMI Kg/m2 25.2 ± 3 27.1 ± 4
LDL cholesterol mg/dl 117 ± 30 135 ± 45
HDL cholesterol mg/dl 56 ± 13 44 ± 12
Triglycerides mg/dl 90 ± 45 155 ± 86
Glucose mg/dl 89 ± 10 98 ± 26
Diabetes/IGT 0 43 (24)
HOMA-IR 2.9 ± 1.5 4.2 ± 3.2
ALT UI/ml 23 ± 8 63 ± 43
GGT UI/ml 23 ± 16 89 ± 98
NASH - 84 (47)
Fibrosis stage F2-F4 - 36 (20)
( ): % values, Na: not available, IGT: impaired glucose tolerance, NASH: nonalcoholic ste
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index child with biopsy-proven fibrotic NAFLD. We used transmission disequilib-
rium testing to look for preferential transmission of risk alleles to the affected
children. This approach is not subjected to the potential confounding effects
inherent in case–control studies and is significantly more powerful at detecting
true associations [9,15,27,28].
Controls
The Italian control group included 316 geographically, age, and sex matched Ital-
ian subjects who were selected because of the lack of clinical and biochemical
evidence of liver and metabolic disease and no alcohol abuse (<30/20 g/day in
males/females). We excluded subjects with ALT >35/30 IU/ml in males/females,
GGT >35 IU/ml, BMI >28, abdominal circumference >100 cm, glucose lev-
elsP100 mg/dl, triglyceridesP150 mg/dl, HDL 645/55 in M/F, or a fatty liver
index >35, a value with high specificity to rule out NAFLD in the general popula-
tion [26].
The study protocol was approved by the Institutional Review Board of the
Ospedale Maggiore ‘‘Ca’ Granda’’ Policlinico IRCCS, Milan, Italy and by Local
Research Ethics Committee in Newcastle. Informed written consent was obtained
from each patient and control subject, and the study conforms to the ethical
guidelines of the 1975 declaration of Helsinki.
Histological assessment
Tissue sections were stained with hematoxylin and eosin, impregnated with sil-
ver for reticulin framework, and stained with trichrome for collagen. One expert
pathologist unaware of clinical and genetic data reviewed all biopsies for fibrosis
stage at each clinical center. The severity of steatosis, features of NASH and fibro-
sis were assessed according to Kleiner et al. [29] NASH was considered to be pres-
ent when steatosis, ballooning and lobular inflammation were present. The
minimum biopsy size was 1.7 cm and the number of portal areas 10.
Genetic analysis
For the adult Italian samples, DNA was extracted from peripheral blood collected
at the time of liver biopsy by the phenol–chloroform method. Success rate in
extracting DNA was 100% for each study group. The APOC3 T-455C (rs2854116)
and C-482T (rs2854117) promoter SNPs were assessed by direct sequencing (for-
ward primer: 50-GAAACCCAGAGATGGAGGTG-30; reverse primer: 50-
TCTCAGCCTTTCACACTGGA-30) by personnel unaware of patients and controls
clinical status. For the Italian families and UK cases, DNA was prepared fromNAFLD patients
UK adults Italian
children
Italian
obese
321 137 120
123 (38) 51 (37) 93 (78)
50 ± 13 10 ± 3 43 ± 11
34.1 ± 5 25.7 ± 5 41.5 ± 8
123 ± 44 NA 131 ± 39
47 ± 13 NA 54 ± 14
245 ± 174 113 ± 69 129 ± 61
121 ± 59 82 ± 13 104 ± 33
117 (36) 68 (50) 33 (28)
6.8 ± 6.6 2.7 ± 1.4 NA
81 ± 64 89 ± 61 30 ± 33
128 ± 183 32 ± 19 26 ± 22
180 (56) 103 (75) 65 (54)
140 (44) 15 (11) 16 (13)
atohepatitis.
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Fig. 1. Prevalence of homozygosity for the wild-type allele of the APOC3 C-
428T and T-455C SNPs (APOC3 WT) in 437 Italian patients with NAFLD and 316
Italian controls (p = n.s.). The prevalence of APOC3 WT in 321 UK patients is also
shown.
JOURNAL OF HEPATOLOGYperipheral blood lymphocytes as described previously [30]. Genotyping used
either the CVD35 multi-locus genotyping assay (Roche Molecular Diagnostics)
[31] or by restriction fragment length polymorphism–PCR [32].
Valid genotypic data were obtained for over 99% of subjects analyzed.
PNPLA3 genotype, determined as previously described [15], was available in
731/758 patients (96%).
Gene expression analysis
In 60 patients submitted to bariatric surgery for whom adequate samples were
available, RNA was isolated by the Trizol reagent (Lifetech, Carlsbad, CA), digested
with DNaseI, and quality evaluated by measuring the 260/280 nm absorbance
ratio (P1.8) and by electrophoresis. First-strand cDNA was synthesized using
equal amounts (0.5 lg) of total RNA, with the SuperScript VILO cDNA synthesis
kit (Invitrogen, Carlsbad, CA). The APOC3 mRNA levels were analyzed by qRT-
PCR with SYBR Green chemistry (Fluocycle II SYBR green mix, Euroclone, Pero,
Italy). All the reactions were performed in triplicate with the ABI 7500fast quan-
titative real time (qRT)-PCR system (Lifetech, Carlsbad, CA). Primers are available
upon request. Results were normalized for b-actin and 18S, which were chosen as
a control because of stable expression among different samples.Table 2. Effect of APOC3 WT on clinical and metabolic parameters in 316 Italian hea
Italian controls
APOC3 p A
WT
(n = 114)
POL
(n = 202)
WT
(n = 145)
Age years 48 ± 13 48 ± 13 0.78 34 ± 19
Gender F 13 (11) 41 (20) 0.05 57 (39)
BMI Kg/m2 25.1 ± 3 25.2 ± 3 0.75 30.8 ± 8
LDL mg/dl 115 ± 30 123 ± 23 0.03 138 ± 46
HDL mg/dl 58 ± 14 55 ± 12 0.03 48 ± 14
Triglycerides mg/dl 88 ± 44 94 ± 50 0.36 135 ± 71
Glucose mg/dl 88 ± 9 89 ± 11 0.43 96 ± 22
HOMA-IR 2.0 ± 1.8 1.8 ± 0.9 0.20 2.8 ± 1
Diabetes 0 0 1 51 (35)
Hypertension 0 0 1 47 (32)
ALT IU/ml 24 ± 8 22 ± 8 0.28 68 ± 58
GGT IU/ml 23 ± 16 24 ± 15 0.80 66 ± 73
APOC3 WT/POL: absence or presence of polymorphic allele at position 455 and 482
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Results are expressed as means ± standard deviation and considered significant
when p <0.05 (two-tailed). Transmission Disequilibrium Tests (TDT) were per-
formed using the TDTHAP package (http://www-gene.cimr.cam.ac.uk/clayton/
software) running in the R software environment (R version 2.7.1). The R package
was used to determine preferential transmission of alleles and statistical signifi-
cance. Mean values were compared by t-test and frequencies by Fisher’s exact
test, and gene expression was correlated by Spearman’s rho test. The association
between the APOC3 SNPs and the presence of NASH and moderate/severe fibrosis
(stage >1) was evaluated by logistic regression analysis adjusted for confounders
(age, BMI, ALT, glucose and ferritin levels, considered as continuous variables).
Given a prevalence of homozygosity for the wild-type alleles of 35%, a prevalence
of NASH of 50% and of fibrosis >1 of 30%, our sample had a 99% and 95% power of
detecting an OR of 1.5 for NASH and fibrosis >1, respectively, with a significance
of 5%. Analyses were carried out with JMP 6.0 statistical analysis software (SAS
Institute Inc, Cary, NC).Results
The frequency distribution of the APOC3 T-455C and C-482T SNPs
was in Hardy–Weinberg equilibrium in all groups tested. The
prevalence of homozygosity for the wild-type alleles at both loci
(henceforth APOC3 WT), previously associated with lower ApoC3
levels, faster lipid clearance, insulin sensitivity, and protection
from steatosis in Indians [21], was not significantly different
between Italian patients and controls (Fig. 1). We also did not
detect any significant difference in the frequency distribution of
the two SNPs analyzed separately between Italian patients and
controls (not shown in details). We did not find any protective
effect of APOC3WT on the risk of NAFLD either in men or women,
or in subjects who were not overweight compared with those
with BMI >25 (p >0.3 for all comparisons).
In contrast, the prevalence of homozygosity for the PNPLA3
148M allele, previously associated with NASH [14,15], was signif-
icantly higher in Italian patients than in controls (59/437, 13.5%
vs. 12/316, 3.8%; p <0.0001). Stratification for PNPLA3 genotype
did affect the lack of significant association between APOC3 WT
and the presence of NAFLD in Italian subjects (not shown).lthy controls, 437 Italian, and 321 UK patients with NAFLD.
Italian patients UK patients
POC3 p APOC3 p
POL
(n = 292)
WT
(n = 127)
POL
(n = 194)
35 ± 19 0.51 51 ± 13 49 ± 13 0.17
121 (41) 0.69 77 (40) 46 (36) 0.53
30.8 ± 9 0.98 34.4 ± 6 33.8 ± 5 0.36
131 ± 40 0.20 123 ± 43 123 ± 45 1
47 ± 13 0.32 46 ± 14 48 ± 13 0.30
135 ± 80 0.98 268 ± 212 229 ± 142 0.07
95 ± 30 0.60 125 ± 59 118 ± 59 0.30
3.0 ± 2 0.18 2.8 ± 1 3.0 ± 2 0.18
93 (32) 0.32 54 (44) 63 (33) 0.056
94 (32) 0.96 47 (32) 94 (32) 0.96
60 ± 51 0.21 75 ± 58 85 ± 68 0.15
59 ± 79 0.49 139 ± 191 122 ± 178 0.43
of the APOC3 gene, respectively.
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Fig. 2. Effect of APOC3 WT genotype on APOC3 expression (hepatic mRNA
levels) in Italian obese patients with NAFLD, but without diabetes. APOC3 WT/
POL: absence or presence of polymorphic allele at position 455 and 482 of the
APOC3 gene, respectively.
Research ArticleInterestingly, the prevalence of the putative protective APOC3
WT genotype was higher in UK than in Italian patients (Fig. 1),
despite higher severity of liver disease in UK patients (Table 1).
In the family study conducted in the 71 Italian trios, the 455
wild type T allele, previously reported to protect from NAFLD
[21], showed borderline significance at the TDT with the trans-
mission of NAFLD (informative families: 66; transmitted in 43/
66 cases, 65%; p = 0.02), whereas the wild-type 482 T allele
was not significantly associated with NAFLD transmission (infor-
mative families: 61; transmitted in 25/61 cases, 41%; p = 0.2). In
the same family study, PNPLA3 genotype has been previously
shown to predispose to NAFLD [15].Table 3. Prevalence of steatosis >1, NASH, and fibrosis stage >1 in Italian and UK pa
Italian patients
APOC3 p
Overall series
(n = 758)
WT
(n = 145)
POL
(n = 292)
Steatosis >1 69 (48) 137 (47) 0.89
NASH 60 (41) 121 (41) 0.99
Fibrosis >1 21 (14) 46 (16) 0.72
PNPLA3 148 I/I
(n = 313)
WT
(n = 60)
POL
(n = 114)
Steatosis >1 21 (35) 33 (29) 0.49
NASH 16 (27) 30 (26) 0.99
Fibrosis >1 8 (13) 8 (7) 0.18
PNPLA3 148 I/M
(n =323)
WT
(n = 57)
POL
(n = 133)
Steatosis >1 32 (56) 78 (59) 0.75
NASH 25 (45) 58 (44) 0.97
Fibrosis >1 7 (12) 27 (20) 0.17
PNPLA3 148 M/M
(n = 94)
WT
(n = 25)
POL
(n = 33)
Steatosis >1 15 (60) 25 (72) 0.39
NASH 19 (76) 28 (85) 0.50
Fibrosis >1 6 (24) 8 (24) 1
( ): % values, Na: not available, APOC3WT/POL: absence or presence of polymorphic allele
could not be assessed in six UK patients with advanced fibrosis (burn-out NASH). PNPLA3
NASH and fibrosis >1 across PNPLA3 genotypes in both Italian and UK patients.
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enced insulin resistance (Table 2). We did not find any significant
association between APOC3 genotype and metabolic data in Ital-
ian patients, whereas APOC3 WT was not significantly associated
with higher triglycerides and prevalence of diabetes in UK
patients. In control subjects, APOC3 WT was associated with
higher HDL (58 ± 14 vs. 55 ± 12; p = 0.03) and lower LDL choles-
terol levels (115 ± 30 vs. 123 ± 33; p = 0.03). No significant associ-
ation was found between the two single SNPs and the metabolic
and clinical parameters were evaluated.
In obese patients with NAFLD, hepatic APOC3 mRNA levels
were not significantly associated with age, sex, BMI, ALT, GGT,
and triglyceride levels, the presence of severe steatosis, NASH,
and fibrosis >1, but were significantly correlated with total cho-
lesterol and HDL levels (rho = 0.34, p = 0.019 and rho = 0.30,
p = 0.034, respectively). In addition, hepatic APOC3 mRNA levels
were significantly downregulated in patients with type 2 diabetes
(0.39 ± 0.14, n = 9 vs. 0.58 ± 0.25, n = 51; p = 0.006; Fig. 2). The
APOC3 WT genotype was significantly associated with reduced
hepatic APOC3 mRNA levels in patients without type 2 diabetes
(0.48 ± 0.16, n = 12 vs. 0.64 ± 0.27, n = 39; p = 0.02; Fig. 2).
The main aim of the study was to assess whether the T-455C
and C-482T promoter SNPs influence the severity of histologically
determined liver damage in patients with NAFLD. There was no
significant association between APOC3WT genotype and steatosis
severity, the presence of NASH, and the presence and severity of
liver fibrosis in Italian and UK patients (Table 3, Fig. 3, and not
shown). The associations tested were not significant in any sub-
group of patients evaluated (adult patients, severely obese, and
children). In contrast, PNPLA3 genotype was strongly associated
with NASH and the severity of liver damage (stage >1) in thetients with NAFLD according to the APOC3 and PNPLA3 genotypes.
UK patients Overall series
APOC3 p APOC3 p
WT
(n = 127)
POL
(n = 194)
WT
(n = 272)
POL
(n = 486)
NA NA NA NA NA NA
65 (52) 115 (60) 0.17 125 (46) 236 (49) 0.53
53 (42) 87 (45) 0.64 74 (27) 133 (27) 0.96
WT
(n = 59)
POL
(n = 80)
WT
(n = 119)
POL
(n = 194)
NA NA NA NA NA NA
23 (40) 42 (53) 0.12 39 (33) 72 (37) 0.47
20 (34) 28 (35) 1 28 (24) 36 (19) 0.31
WT
(n = 58)
POL
(n = 75)
WT
(n = 115)
POL
(n = 208)
NA NA NA NA NA NA
34 (61) 44 (60) 0.96 59 (52) 102 (50) 0.72
27 (47) 37 (49) 0.86 34 (30) 64 (31) 0.82
WT
(n = 8)
POL
(n = 28)
WT
(n = 277)
POL
(n = 498)
NA NA NA NA NA NA
6 (75) 22 (78) 0.83 25 (76) 50 (82) 0.59
4 (50) 18 (64) 0.46 10 (30) 26 (43) 0.27
at position 455 and 482 of the APOC3 gene, respectively. The presence of NASH
genotype was available in 731/758 patients (96%). p 60.001 for the prevalence of
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Fig. 3. Effect of homozygosity for the wild-type allele of the APOC3 C-428T
and T-455C SNPs (APOC3 WT) on histologically evaluated liver damage in 775
Italian and UK patients with NAFLD. Yes: APOC3 WT genotype, NO: presence of
APOC3 SNPs.
JOURNAL OF HEPATOLOGYsame patients (Table 3; p <0.0001 and p = 0.001, respectively). In
particular, PNPLA3 genotype was associated with NASH and fibro-
sis >1 in Italian patients (p = 0.05 and p = 0.02, respectively), UK
patients (p = 0.003 and p = 0.01, respectively), Italian children
(p <0.0001 and p = n.s., likely due to their young age [16], respec-
tively), and morbid obese patients (p = 0.01 and p = 0.1, respec-
tively). Furthermore, no significant association was found
between the two single APOC3 SNPs evaluated and the histologi-
cal parameters evaluated in both the populations and the sub-
groups studied.
Stratification for the PNPLA3 genotype did not reveal any asso-
ciation between APOC3 genotype and liver damage in any of the
categories evaluated inboth Italian andUKpatients (Table 3). Since
the presence of diabetes was associated with reduced APOC3
expression independently of APOC3 WT genotype, we also
explored whether the presence of diabetes might influence the
association between APOC3 WT and liver damage. Although the
results of this analysis should be interpretedwith caution, we only
observed a nominally significant lower prevalence of fibrosis >1 in
PNPLA3 148M/M patients with APOC3 WT genotype than in those
carrying APOC3 promoter SNPs (3/22, 14% vs. 16/44, 36%; p = 0.05).Discussion
In this study, we evaluated whether APOC3 promoter region SNPs
previously reported to influence lipid metabolism, insulin resis-
tance, and NAFLD susceptibility [21], affect the histological sever-
ity of liver damage in a large series of Caucasian patients with
biopsy-proven NAFLD. Our data indicate that APOC3 SNPs do
not influence the severity of liver damage in NAFLD patients of
European descent.
Furthermore, we did not detect any association between
APOC3 SNPs and the presence of NAFLD in Italian subjects,
whereas PNPLA3 genotype, a strong genetic determinant of stea-
tosis [14,15], was strongly associated with NAFLD in the same
case–control series. Although a borderline significance for the
transmission of the 455T allele was observed in the family
study, since the same allele was previously reported to protect
from steatosis [21], and the effect was not consistent for the
two genetic variants studied, we believe that this formal associa-
tion is likely due to chance. These results are in line with veryPlease cite this article in press as: Valenti L et al. The APOC3 T-455C and C-482T
damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fa
Journal of Hepatology 201recent findings obtained in the US general population, where
APOC3 genotype was not found associated with liver fat content
or with insulin resistance (HOMA-IR) [33].
APOC3 SNPs were also not associated with higher insulin
resistance and dyslipidemia in Italian patients with NAFLD,
although an association was detected between the ‘‘protective’’
APOC3 WT genotype, previously associated with lower APOC3
levels and faster lipid clearance [21], and less atherogenic lipid
profile (lower LDL and higher HDL cholesterol) in Italian control
subjects without steatosis, as well as in the US general population
[33]. This phenotype is consistent with the protective effect of
null APOC3 mutations on atherosclerosis due to lower LDL and
triglycerides and higher HDL levels [34]. However, possibly due
to the confounding effect of unhealthy lifestyle and other genetic
factors, the association was lost in patients with NAFLD. Indeed, it
has been reported that APOC3 genotype interacts with dietary
factors in the regulation of lipid metabolism [35]. Thus, further
studies are required to evaluate the relevance of the association
between APOC3 promoter SNPs, dyslipidemia, and atherogenesis.
Importantly, although the results of this exploratory analysis
should be interpreted with caution, we were able to confirm in
a subset of obese patients with NAFLD included in this study that
the APOC3 WT genotype influenced APOC3 hepatic expression,
associated with cholesterol levels, suggesting that the lack of
association between APOC3 WT and the metabolic phenotype
was not explained by a lack of biological activity of the genetic
variants under study. Interestingly, the effect was only evident
in patients without diabetes, which per se was associated with
a strong downregulation of APOC3, possibly explained by hyper-
insulinemia [20] and/or pharmacological therapy with insulin,
insulin sensitizing, and lipid lowering drugs.
The main result of this study is that APOC3 genotype was not
associated with liver enzymes, and with the histological severity
of liver damage (severity of steatosis, presence of NASH, and of
fibrosis of moderate/severe degree) in Italian as well as in UK
patients, and in thewhole cohort.Wealsodid notdetect any signif-
icant influence on the specific components of the NAFLD activity
score [29] and fibrosis stage evaluated as ordinal variables (not
shown in details). Stratification for the I148M PNPLA3 mutation,
associated with the susceptibility to NASH [15–17,36], did not
reveal any PNPLA3 genotype-specific association between APOC3
genotype and liver damage, and NAFLD susceptibility as well.
A major strength of this study is the large number of patients
evaluated with available liver histology, which still represents
the gold standard for evaluation of liver damage, the complete
clinical characterization, the evaluation of the biological activity
of APOC3 genotype on gene expression in a subset of patients,
and the availability of PNPLA3 genotype as a positive control
and for the stratification of patients. The study was well powered
to detect an effect of APOC3WT genotype on the risk of NASH and
moderate/severe fibrosis. To our knowledge, this is the first
report of an evaluation of the association between APOC3 geno-
type and histologically determined liver damage.
Limitations of this study include the lack of evaluation ofAPOC3
SNP prevalence in UK control subjects. In addition, we could not
assess the effect of APOC3 genotype on ApoC3 serum levels, and
we also cannot exclude that APOC3 genotype influences liver dam-
age in Indian (Asian) patientswithNAFLD, inwhomitwas reported
as a strong effect on lipid metabolism and insulin resistance [21],
as the effect of the genetic variantmay be ethnic specific requiring
additional genetic factors for phenotypic expression. Furthermore,promoter region polymorphisms are not associated with the severity of liver
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our data suggest that diabetes or insulin sensitizing/lipid lowering
drugs may affect the expression of APOC3 genotype in European
patients with metabolic diseases.
In conclusion, our data suggest that APOC3 SNPs do not predis-
pose to progressive liver damage in Caucasian patients with
NAFLD.
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